

Access DB# 76027**SEARCH REQUEST FORM**

Scientific and Technical Information Center

Requester's Full Name: _____ Examiner #: _____ Date: _____
Art Unit: _____ Phone Number 30 _____ Serial Number: _____
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

STAFF USE ONLY**Type of Search****Vendors and cost where applicable**

Searcher: <u>Jan</u>	NA Sequence (#) _____	STN _____
Searcher Phone #: <u>4498</u>	AA Sequence (#) <input checked="" type="checkbox"/> _____	Dialog <u>_____</u>
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>9/18/02</u>	Bibliographic _____	Dr. Link _____
Date Completed: <u>9/18/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems <input checked="" type="checkbox"/> _____
Clerical Prep Time: <u>10</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>10</u>	Other _____	Other (specify) _____

This Page Blank (uspto)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:12:57 ; Search time 75.12 Seconds
(without alignments)
294.245 Million cell updates/sec

Title: US-09-383-551B-2

Perfect score: 1082

Sequence: 1 MKSLGWFFFLCLRIKVLGTG.....YMFMRVNTAKKSRLTDVTL 199

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_032802.*

```

1: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA2001.DAT.*

```

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1082	100.0	199	19 AAW75956	Human cell surface
2	1082	100.0	199	19 AAW75957	Human cell surface
3	1082	100.0	199	20 AAY08026	Human activated T-
4	1082	100.0	199	21 AAB08731	Amino acid sequenc
5	1082	100.0	199	22 AAE03428	Human gene 2 encod
6	1082	100.0	199	22 AAE03460	Human gene 2 encod
7	1082	100.0	199	22 AAE03525	Human secreted pro
8	1066.5	98.6	198	21 AAY92213	Human Th2-specific
9	737.5	68.2	200	21 AAY92212	Murine Th2-specific
10	734	67.8	200	21 AAB08723	Amino acid sequenc
11	722.5	66.8	200	19 AAW75958	Mouse cell surface

12	701	64.8	200	19 AAW71874	Rat cell surface p
13	696	64.3	216	19 AAW71875	Rat cell surface p
14	658	60.8	379	22 AAB67716	Amino acid sequenc
15	449.5	41.5	380	22 AAB67717	Amino acid sequenc
16	146.5	13.5	225	20 AAY41136	Rat CD28 protein s
17	145.5	13.4	221	21 AAY32286	Feline CD28. Feli
18	145.5	13.4	221	21 AAY32279	Cat CD28 receptor.
19	139.5	12.9	220	13 AAR20805	Human CD28 antigen
20	139.5	12.9	220	13 AAR27103	Sequence encoded b
21	139.5	12.9	220	17 AAW02131	Human CD28 CDNA pr
22	139.5	12.9	220	17 AAR91433	Human CD28 antigen
23	139.5	12.9	220	18 AAW38413	CD28. Homo sapien
24	139.5	12.9	220	19 AAW80442	Human CD28 antigen
25	139.5	12.9	220	20 AAW88451	Human CD28 antigen
26	139.5	12.9	220	21 AAY96128	Human cell surface
27	139.5	12.9	220	21 AAY44294	Human CD28 recepto
28	139.5	12.9	220	22 AAU02437	Human lymphocyte c
29	134	12.4	225	20 AAY41135	Mouse CD28 protein
30	126	11.6	223	20 AAY41137	Human CD28 protein
31	120.5	11.1	367	18 AAW35862	Human CD28:IgG2a c
32	119.5	11.0	134	18 AAW35846	Human CD28 for use
33	119.5	11.0	152	16 AAR67706	CD28 extracellular
34	89.5	8.3	117	20 AAY24469	Human CD28 gene pr
35	89	8.2	305	22 AAG66371	Human partial olfa
36	89	8.2	319	22 AAG71916	Human olfactory re
37	89	8.2	321	22 AAB46999	Human OLFXY protei
38	87.5	8.1	213	22 AAE04561	Human G-protein co
39	87	8.0	330	8 AAP70445	Sequence of mouse
40	86	7.9	223	18 AAW25111	Soluble human CTLA
41	86	7.9	223	22 AAG66519	Human CTLA4. Homo
42	86	7.9	223	22 AAU00687	Human CTLA4 protei
43	85.5	7.9	187	19 AAW29728	Soluble CTLA4 muta
44	84.5	7.8	209	21 AAY94998	Human secreted pro
45	84	7.8	223	21 AAY15129	Human CTLA-4 prote

ALIGNMENTS

RESULT 1

AAW75956

ID AAW75956 standard; Protein; 199 AA.

XX AC AAW75956;

XX XX

DF 11-DEC-1998 (first entry)

XX Human cell surface protein #1.

DE

XX Human; cell surface protein; thymocyte; lymphocyte; cell adhesion;

KW signal transmission; autoimmune disorder; allergy; diagnosis;

KW mitogen-stimulated.

XX OS Homo sapiens.

XX PN WO9838216-A1.

XX PD 03-SEP-1998.

XX PF 27-FEB-1998; 98WO-JP00837.

XX PR 26-FEB-1998; 98JP-0062217.

XX PA 27-FEB-1997; 97JP-0062290.

XX (NIBS) JAPAN TOBACCO INC.

XX PI Tamatani T, Tezuka K;

XX WPI; 1998-481144/41.

XX DR N-PSDB; AAW53198.

XX Cell surface molecule expressed in thymocytes and lymphocytes and -
PT mediating signal transmission and cell adhesion, and antibodies to

PT it useful in treatment of auto:immune and allergic disorders.

XX
PS Claim 2; Page 99-101; 149pp; Japanese.

XX
CC The present sequence represents a human cell surface protein which is expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell surface protein induces adhesion of mitogen-stimulated lymphocytes to antibodies recognising the cell surface protein. These antibodies also produce an increase in peripheral blood lymphocytes in the presence of an antibody recognising CD3 antigen. The cell surface protein contains the amino acid sequence FDPFPF in its extracellular region and the sequence YMF in its intracellular region. The cell surface protein can be used in the prevention and treatment of autoimmune and allergic diseases, and in the diagnosis and investigation of such disorders.

XX
SQ Sequence 199 AA;

Query Match 100.0%; Score 1082; DB 19; Length 199;
Best Local Similarity 100.0%; Pred. No. 6.6e-116;
Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MKSLGWYFFLCRLIKVLTEINGSANYEMFIFHNGGVQVILCKYDPDVOQFKMQLLKGQ 60
|||||
Db 1 mksglwyfflclrlkvltgeingsanyemfifhnggvqilckypdivqfkmqlkggq 60

61 ILCDLTKTGSGNTVSIKSLKFSCHSOLSNNSVSFFLYNLDSHANYFCNLSIFDPPPPK 120
|||||
Db 61 ilcdltktgsgntvsikskslkschsolnsnsvsfflynldshanyfncnlsifdppppk 120

121 VLTGGLHYHYESQLCCQLKFWLPICGAFFVVCILGCLICWLTKKKYSSSVHPDNGEY 180
|||||
Db 121 vltgglhyhyesqlccqlkfwlpigcaafvvcilgclilcwltkkkysssvhpdngey 180

181 MFMRAVNTAKKSLRLTDVTL 199
|||||
Db 181 mfmravntakkrltdvtl 199

RESULT 2
AAW75957
ID AAW75957 standard; Protein; 199 AA.

XX
AC AAW75957;

XX
DT 11-DEC-1998 (first entry)

XX
DE Human cell surface protein #2.

XX
KW Human; cell surface protein; thymocyte; lymphocyte; cell adhesion; signal transmission; autoimmune disorder; allergy; diagnosis; mitogen-stimulated.

XX
OS Homo sapiens.

XX
PN W09838216-A1.

XX
PD 03-SEP-1998.

XX
PF 27-FEB-1998; 98WO-JP00837.

XX
PR 26-FEB-1998; 98JP-0062217.

XX
PR 27-FEB-1997; 97JP-0062290.

XX
PA (NISR) JAPAN TOBACCO INC.

XX
PI Tamatani T, Tezuka K;

XX
PI WPI; 1998-481144/41.

XX
DR N-PSDB; AAV53199.

XX
PT Cell surface molecule expressed in thymocytes and lymphocytes and - mediating signal transmission and cell adhesion, and antibodies to

PT it useful in treatment of auto:immune and allergic disorders.

XX
PS Claim 9; Page 101-105; 149pp; Japanese.

XX
CC The present sequence represents a human cell surface protein which is expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell surface protein induces adhesion of mitogen-stimulated lymphocytes to antibodies recognising the cell surface protein. These antibodies also produce an increase in peripheral blood lymphocytes in the presence of an antibody recognising CD3 antigen. The cell surface protein contains the amino acid sequence FDPFPF in its extracellular region and the sequence YMF in its intracellular region. The cell surface protein can be used in the prevention and treatment of autoimmune and allergic diseases, and in the diagnosis and investigation of such disorders.

XX
SQ Sequence 199 AA;

Query Match 100.0%; Score 1082; DB 19; Length 199;
Best Local Similarity 100.0%; Pred. No. 6.6e-116;
Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MKSLGWYFFLCRLIKVLTEINGSANYEMFIFHNGGVQVILCKYDPDVOQFKMQLLKGQ 60
|||||
Db 1 mksglwyfflclrlkvltgeingsanyemfifhnggvqilckypdivqfkmqlkggq 60

61 ILCDLTKTGSGNTVSIKSLKFSCHSOLSNNSVSFFLYNLDSHANYFCNLSIFDPPPPK 120
|||||
Db 61 ilcdltktgsgntvsikskslkschsolnsnsvsfflynldshanyfncnlsifdppppk 120

121 VLTGGLHYHYESQLCCQLKFWLPICGAFFVVCILGCLICWLTKKKYSSSVHPDNGEY 180
|||||
Db 121 vltgglhyhyesqlccqlkfwlpigcaafvvcilgclilcwltkkkysssvhpdngey 180

181 MFMRAVNTAKKSLRLTDVTL 199
|||||
Db 181 mfmravntakkrltdvtl 199

RESULT 3
AAW08026
ID AAW08026 standard; Protein; 199 AA.

XX
AC AAW08026;

XX
DT 08-JUL-1999 (first entry)

XX
DE Human activated T-lymphocyte protein 8F4.

XX
KW T-lymphocyte; human; 8F4; T cell co-stimulation; activated; CD4+; CD8+; anticancer; antiviral; anti-asthma; immunomodulator; proliferation; T cell activation; cytokine synthesis; regulatory element; B cell; T cell-dependent antibody production; treatment; prevention; cancer; autoimmune disease; transplant rejection; immune system regulation; disorder; acquired immune deficiency syndrome; AIDS; asthma.

OS Homo sapiens.

XX
PN W09915553-A2.

XX
PD 01-APR-1999.

XX
PF 23-SEP-1998; 98WO-DE02896.

XX
PR 11-MAY-1998; 98DE-1021060.

XX
PR 23-SEP-1997; 97DE-1041929.

XX
PA (DEKO-) DEUT KOCH INST ROBERT.

XX
PA (BUND) BUNDESREPUBLIK DEUT PAUL-EHRlich-INST.

XX
PI Krocsek R;

XX
DR WPI; 1999-276975/23.

DR N-PSDB; AAX37661.
 XX Polypeptide 8F4 co-stimulates T cells and is present only on
 PT activated cells
 XX
 PS Claim 2; Page 24; 47pp; German.
 XX This invention describes a novel human protein, 8F4, and its encoding
 CC nucleic acid which co-stimulates T cells and is present on activated CD4+
 CC and CD8+ T cells but not on resting or activated B cells, granulocytes,
 CC monocytes, natural killer or dendritic cells. 8F4 has anticancer,
 CC antiviral, anti-asthma and immunomodulatory activity. 8F4 provides a
 CC strong co-stimulatory signal for T cell activation, i.e. it amplifies
 CC proliferation of T cells, synthesis of certain cytokines and other
 CC regulatory agents, and improves T cell-dependent antibody production
 CC by B cells. Agents that inhibit 8F4 are used to treat or prevent
 CC autoimmune diseases, to prevent transplant rejection and to treat
 CC disorders of immune system regulation. 8F4, or cells that express it,
 CC is/are used to treat or prevent cancers, acquired immune deficiency
 CC syndrome, asthma and chronic infectious diseases (e.g. hepatitis B or C).
 XX
 SQ Sequence 199 AA;
 Query Match 100.0%; Score 1082; DB 20; Length 199;
 Best Local Similarity 100.0%; Pred. No. 6.6e-116;
 Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MKSGLWYFFLCRLIKVLTGEINGSANYEMFIHNGGVQILCKYPDIVQOQFMQLLKGGQ 60
 DB 1 MKSGLWYFFLCRLIKVLTGEINGSANYEMFIHNGGVQILCKYPDIVQOQFMQLLKGGQ 60
 QY 61 ILCDLTKTGSGNTVSIKSLKFCCHSOLSNNSVSFFLYNLDHSHANYFCNLSIFDPPPPK 120
 DB 61 ILCDLTKTGSGNTVSIKSLKFCCHSOLSNNSVSFFLYNLDHSHANYFCNLSIFDPPPPK 120
 QY 121 VTLTGGYLIHYESQLCCQLKFWLPICGAAFFVYVVCILGCLICWLTKKKYSSSVHPDNGEY 180
 DB 121 VTLTGGYLIHYESQLCCQLKFWLPICGAAFFVYVVCILGCLICWLTKKKYSSSVHPDNGEY 180
 QY 181 MFMRVNTAKKSLRLTDVTL 199
 DB 181 MFMRVNTAKKSLRLTDVTL 199
 RESULT 4
 AAB08731
 AAB08731 standard; Protein; 199 AA.
 AAB08731;
 XX
 DT 02-JAN-2001 (first entry)
 XX Amino acid sequence of a human CRP1 polypeptide.
 DE CRP1; CD28 related protein-1; B7RP1; B7 related protein-1;
 KW T-lymphocyte activation; type I transmembrane protein; T cell activation;
 KW T cell proliferation; T-cell mediated disorder.
 XX Homo sapiens.
 XX
 FH Key
 FT Peptide 1..20 Location/Qualifiers
 FT Protein /note= "signal peptide" 21..199
 FT Domain /note= "mature protein" 21..140
 FT Domain /note= "extracellular domain" 141..161
 FT Domain /note= "predicted transmembrane domain" 162..199
 FT Domain /note= "intracellular domain"

PN WO200046240-A2.
 XX 10-AUG-2000.
 XX 27-JAN-2000; 2000WO-US01871.
 XX 03-FEB-1999; 99US-0244448.
 PR 08-MAR-1999; 99US-0264527.
 XX (AMGE-) AMGEN INC.
 PA Yoshinaga SK;
 PI WPI; 2000-543476/49.
 DR N-PSDB; AAA64558.
 XX Novel nucleic acids encoding the proteins CRP-1 and B7RP1 are useful
 PT in the treatment, prevention and diagnosis of T cell mediated disorders
 PT
 XX Disclosure; Fig 13A; 174pp; English.
 PS The present sequence represents a CRP1 (CD28 related protein-1)
 CC polypeptide. The specification also describes a B7RP1 (B7 related
 CC protein-1) polypeptide. The polypeptides are involved in T-lymphocyte
 CC activation, and represent a receptor-ligand pair. CRP1 and B7RP1 are
 CC predicted to be a type I transmembrane protein. The nucleic acids are
 CC useful for regulating T cell activation or proliferation in an animal.
 CC The polypeptides are useful for treating, preventing ameliorating or
 CC diagnosing a T-cell mediated disorder in an animal. They can also be
 CC used to identify test molecules that bind to the polypeptides.
 XX Sequence 199 AA;
 Query Match 100.0%; Score 1082; DB 21; Length 199;
 Best Local Similarity 100.0%; Pred. No. 6.6e-116;
 Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MKSGLWYFFLCRLIKVLTGEINGSANYEMFIHNGGVQILCKYPDIVQOQFMQLLKGGQ 60
 DB 1 MKSGLWYFFLCRLIKVLTGEINGSANYEMFIHNGGVQILCKYPDIVQOQFMQLLKGGQ 60
 QY 61 ILCDLTKTGSGNTVSIKSLKFCCHSOLSNNSVSFFLYNLDHSHANYFCNLSIFDPPPPK 120
 DB 61 ILCDLTKTGSGNTVSIKSLKFCCHSOLSNNSVSFFLYNLDHSHANYFCNLSIFDPPPPK 120
 QY 121 VTLTGGYLIHYESQLCCQLKFWLPICGAAFFVYVVCILGCLICWLTKKKYSSSVHPDNGEY 180
 DB 121 VTLTGGYLIHYESQLCCQLKFWLPICGAAFFVYVVCILGCLICWLTKKKYSSSVHPDNGEY 180
 QY 181 MFMRVNTAKKSLRLTDVTL 199
 DB 181 MFMRVNTAKKSLRLTDVTL 199
 RESULT 5
 AAE03428
 ID AAE03428 standard; Protein; 199 AA.
 XX
 AC AAE03428;
 XX
 DT 10-AUG-2001 (first entry)
 XX Human gene 2 encoded secreted protein HP2SG64, SEQ ID NO: 111.
 DE Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
 KW foetal abnormality; developmental abnormality; haematopoietic disorder;
 KW immune system disease; AIDS; autoimmune disease; rheumatoid arthritis;
 KW Parkinson's disease; cognitive disorder; schizophrenia; skin disorder;
 KW psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
 KW inflammation; neurological disorder; Alzheimer's disease; food additive;
 KW angiogenic disorder; kidney disorder; gastrointestinal disorder; allergy;

KW pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW cell culture; chemotaxis; vulnery; binding partner identification;
OS gene therapy.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..19
FT Protein /label= Signal_peptide
FT 20..111
FT /note= "Mature human secreted protein"
XX
PN WO200132675-A1.
XX
PD 10-MAY-2001.
XX
PF 25-OCT-2000; 2000WO-US29363.
XX
PR 29-OCT-1999; 99US-0162239.
PR 30-JUN-2000; 2000US-0215139.
XX
PI (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Komatsoulis GA, Wei P, Baker KP, Young PE;
XX WPI; 2001-328772/34.
XX N-PSDB; AAD07810.
XX
PT .Thirty two human secreted proteins, useful for treating cancers,
PT hyperproliferative disorders, inflammatory disorders, neurological
PT disorders, autoimmune diseases and cardiovascular disorders -
XX
PS Claim 11; Page 471; 576pp; English.
XX
CC AAD07809-AAD07907 represent cDNAs corresponding to 32 human secreted
CC protein genes, and AAE03427-AAE03523 represent the proteins they encode.
CC AAE03524-AAE03537 represent human secreted protein fragments or variants.
CC The secreted proteins and their genes are useful for preventing, treating
CC or ameliorating medical conditions, e.g., by protein or gene therapy.
CC Pathological conditions can be diagnosed by determining the amount of the
CC new protein in a sample or by determining the presence of mutations in
CC based on the tissues in which they are most highly expressed, and include
CC developing products for the diagnosis or treatment of proliferative
CC disorders, cancer, tumours, foetal and developmental abnormalities,
CC haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
CC diseases (e.g., rheumatoid arthritis), inflammation, allergies,
CC neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
CC cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
CC psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
CC angioenic disorders, kidney disorders, gastrointestinal disorders,
CC pregnancy-related disorders, endocrine disorders, and infections. The
CC proteins can also be used to aid wound healing and epithelial cell
CC proliferation, to prevent skin aging due to sunburn, to maintain organs
CC before transplantation, for supporting cell culture of primary tissues,
CC to regenerate tissues, to identify their cognate ligands or binding
CC partners, and in chemotaxis, and can be used as a food additive or
CC preservative to modify storage properties. Antibodies specific for a
CC protein of the invention can be used in alleviating symptoms associated
CC with the disorders mentioned above, and in diagnostic immunoassays e.g.,
CC radioimmunoassay or enzyme linked immunosorbent assay (ELISA).
CC The present sequence represents a human secreted protein of
CC the invention.
XX
SQ Sequence 199 AA;

Query Match 100.0%; Score 1082; DB 22; Length 199;
Best Local Similarity 100.0%; Pred. No. 6.6e-116;
Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKSGLWYFFLCRIKVLGTGEINGSANYEMFIFHNGGVQILCKYDPDIVQKFMQLKGGQ 60
|||||

Db 1 mksglwfflclrikvltgeingsanyemfifhnggvqilckypdivqkfmqlkggq 60
QY 61 ILCDLTKTKGSGNTVSIKSLKFKCHSOLSNNSVFFLYNLDSHANYFCNLSTFQPPPFK 120
Db 61 ILCDLTKTKGSGNTVSIKSLKFKCHSOLSNNSVFFLYNLDSHANYFCNLSTFQPPPFK 120
QY 121 VLTGGYLHIYESQLCCQLKFWLPICGAFFVVCILGCLICLWLTKKKYSVVHPDPNGEY 180
Db 121 VLTGGYLHIYESQLCCQLKFWLPICGAFFVVCILGCLICLWLTKKKYSVVHPDPNGEY 180
QY 181 MFMRAVNTAKKSRLLTDVTL 199
Db 181 MFMRAVNTAKKSRLLTDVTL 199
RESULT 6
AAE03460
ID AAE03460 standard; Protein; 199 AA.
XX
AC AAE03460;
XX
DT 10-AUG-2001 (first entry)
XX
DE Human gene 2 encoded secreted protein HT2SG64, SEQ ID NO: 143.
XX
KW Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
KW foetal abnormality; developmental abnormality; haematopoietic disorder;
KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW Parkinson's disease; cognitive disorder; schizophrenia; skin disorder;
KW psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
KW inflammation; neurological disorder; Alzheimer's disease; food additive;
KW angioenic disorder; kidney disorder; gastrointestinal disorder; allergy;
KW pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW cell culture; chemotaxis; vulnery; binding partner identification;
KW gene therapy.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..19
FT Protein /label= Signal_peptide
FT 20..199
FT /note= "Mature human secreted protein"
XX
PN WO200132675-A1.
XX 10-MAY-2001.
XX 25-OCT-2000; 2000WO-US29363.
XX 29-OCT-1999; 99US-0162239.
XX 30-JUN-2000; 2000US-0215139.
XX (HUMA-) HUMAN GENOME SCI INC.
XX Ruben SM, Komatsoulis GA, Wei P, Baker KP, Young PE;
XX WPI; 2001-328772/34.
XX N-PSDB; AAD07842.
XX
PT Thirty two human secreted proteins, useful for treating cancers,
PT hyperproliferative disorders, inflammatory disorders, neurological
PT disorders, autoimmune diseases and cardiovascular disorders -
XX
PS Claim 11; Page 489-490; 576pp; English.
XX
CC AAD07809-AAD07907 represent cDNAs corresponding to 32 human secreted
CC protein genes, and AAE03427-AAE03523 represent the proteins they encode.
CC AAE03524-AAE03537 represent human secreted protein fragments or variants.
CC The secreted proteins and their genes are useful for preventing, treating
CC or ameliorating medical conditions, e.g., by protein or gene therapy.
CC Pathological conditions can be diagnosed by determining the amount of the
CC new protein in a sample or by determining the presence of mutations in

the new genes. Specific uses are described for each of the 32 genes, based on the tissues in which they are most highly expressed, and include developing products for the diagnosis or treatment of proliferative disorders, cancer, tumours, foetal and developmental abnormalities, haematopoietic disorders, diseases of the immune system, AIDS, autoimmune diseases (e.g., rheumatoid arthritis), inflammation, allergies, neurological disorders (e.g., Alzheimer's disease, Parkinson's disease), cognitive disorders, schizophrenia, asthma, skin disorders (e.g., psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders, angioinetic disorders, kidney disorders, gastrointestinal disorders, pregnancy-related disorders, endocrine disorders, and infectious. The proteins can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues, to identify their cognate ligands or binding partners, and in chemotaxis, and can be used as a food additive or preservative to modify storage properties. Antibodies specific for a protein of the invention can be used in alleviating symptoms associated with the disorders mentioned above, and in diagnostic immunoassays e.g., radioimmunoassay or enzyme linked immunosorbent assay (ELISA). The present sequence represents a human secreted protein of the invention.

XX Sequence 199 AA;

Query Match 100.0%; Score 1082; DB 22; Length 199;
Best Local Similarity 100.0%; Pred. No. 6.6e-116;
Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKSGLWYFFLCIRIKVLTGEINGSANYEMFIFHNGGVQILCKYDIPVQOQFMQLKGGQ 60
Db 1 mksglwyfflclrikvltgeingsanyemfifhnggvqilckypdivqfkmqlkggq 60

QY 61 ILCDLTKTGSGNTVSIKSLKFCCHSQLSNNVSFFLYNLDSHANYFCNLISFDPPEPK 120
Db 61 ilcdltktgsgntvsiaklkschsqslsnnvsfflynlldshanyfncnlisfdppepk 120

QY 121 VLTGGYLIHYESQCCQLKFWLPICGAFFVVCVILGCLICWLTKKKYSSSVHPDNGEY 180
Db 121 vltggylihyesqccqlkfwlpigcaaffvvcvllgcllclwltkkkysssvhpdpngey 180

QY 181 MPMRAVNTAKSRRLTDVTL 199
Db 181 mpmravntaksrlltdvtl 199

RESULT 7

AAE03525 standard; Protein; 199 AA.

AC AAE03525;

XX 10-AUG-2001 (first entry)

XX Human secreted protein variant, SEQ ID NO: 211.

DE Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
KW foetal abnormality; developmental abnormality; haematopoietic disorder;
KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW Parkinson's disease; cognitive disorder; schizophrenia; skin disorder;
KW psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
KW inflammation; neurological disorder; Alzheimer's disease; food additive;
KW angioinetic disorder; kidney disorder; gastrointestinal disorder; allergy;
KW pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW cell culture; chemotaxis; vulnery; binding partner identification;
KW gene therapy.

OS Homo sapiens.

XX WO200132675-A1.

XX 10-MAY-2001.

XX 25-OCT-2000; 2000WO-US29363.

XX 29-OCT-1999; 99US-0162239.

PR 30-JUN-2000; 2000US-0215139.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Ruben SM, Komatsoulis GA, Wei P, Baker KP, Young PE;
WPI; 2001-328772/34.

XX Thirty two human secreted proteins, useful for treating cancers,
PT hyperproliferative disorders, inflammatory disorders, neurological,
PT disorders, autoimmune diseases and cardiovascular disorders.

XX Disclosure; Page 524; 576pp; English.

XX AAD07809-AAD07907 represent cDNAs corresponding to 32 human secreted
protein genes, and AAE03427-AAE03523 represent the proteins they encode.
CC AAE03524-AAE03537 represent human secreted protein fragments or variants.
CC The secreted proteins and their genes are useful for preventing, treating
or ameliorating medical conditions, e.g., by protein or gene therapy.
CC pathological conditions can be diagnosed by determining the amount of the
new protein in a sample or by determining the presence of mutations in
the new genes. Specific uses are described for each of the 32 genes,
CC based on the tissues in which they are most highly expressed, and include
developing products for the diagnosis or treatment of proliferative
disorders, cancer, tumours, foetal and developmental abnormalities,
CC haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
diseases (e.g., rheumatoid arthritis), inflammation, allergies,
CC neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
CC cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
CC angioinetic disorders, kidney disorders, gastrointestinal disorders,
CC pregnancy-related disorders, endocrine disorders, and infectious. The
proteins can also be used to aid wound healing and epithelial cell
proliferation, to prevent skin aging due to sunburn, to maintain organs
before transplantation, for supporting cell culture of primary tissues,
CC to regenerate tissues, to identify their cognate ligands or binding
partners, and in chemotaxis, and can be used as a food additive or
preservative to modify storage properties. Antibodies specific for a
protein of the invention can be used in alleviating symptoms associated
with the disorders mentioned above, and in diagnostic immunoassays e.g.,
radioimmunoassay or enzyme linked immunosorbent assay (ELISA).
CC The present sequence represents a human secreted protein variant
referred to in the disclosure of the invention.

XX Sequence 199 AA;

Query Match 100.0%; Score 1082; DB 22; Length 199;
Best Local Similarity 100.0%; Pred. No. 6.6e-116;
Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKSGLWYFFLCIRIKVLTGEINGSANYEMFIFHNGGVQILCKYDIPVQOQFMQLKGGQ 60
Db 1 mksglwyfflclrikvltgeingsanyemfifhnggvqilckypdivqfkmqlkggq 60

QY 61 ILCDLTKTGSGNTVSIKSLKFCCHSQLSNNVSFFLYNLDSHANYFCNLISFDPPEPK 120
Db 61 ilcdltktgsgntvsiaklkschsqslsnnvsfflynlldshanyfncnlisfdppepk 120

QY 121 VLTGGYLIHYESQCCQLKFWLPICGAFFVVCVILGCLICWLTKKKYSSSVHPDNGEY 180
Db 121 vltggylihyesqccqlkfwlpigcaaffvvcvllgcllclwltkkkysssvhpdpngey 180

QY 181 MPMRAVNTAKSRRLTDVTL 199
Db 181 mpmravntaksrlltdvtl 199

RESULT 8

DR WPI: 2001-244938/25.
XX N-PSDB; AAF79940.
PT New isolated nucleic acid encoding a GL50 polypeptide for modulating a
PT immune response and reducing the proliferation of a tumour cell -
XX
PS Disclosure: Fig 27B; 195pp; English.
XX
CC The present sequence represents a fusion protein, comprising murine ICOS
CC (MICOS) and murine IgG2a (mIgG2A). The fusion protein is used in the
CC course of the invention. The specification describes GL50 polypeptides.
CC GL50 molecules are antigens on the surface of antigen presenting cells,
CC which costimulate T cell proliferation and bind to costimulatory receptor
CC ligands on T cells. GL50 modulating agents are used to modulate an immune
CC response in a subject. GL50 polypeptides are used to modulate T cell
CC costimulation, and to reduce the proliferation of a tumour cell. Diseases
CC that can be treated using GL50 molecules are graft-versus-host disease,
CC autoimmune disease, allergies, acquired immune deficiency syndrome
CC (AIDS), and viral infections. The GL50 molecules can be used in vaccines.
CC GL50 polynucleotides can be used to locate gene regions associated with
CC genetic disease, in tissue typing, and in forensic identification of a
CC biological sample.
XX
SQ Sequence 380 AA;

Query Match 41.5%; Score 449.5; DB 22; Length 380;
Best Local Similarity 70.2%; Pred. No. 6.5e-43;
Matches 85; Conservative 13; Mismatches 22; Indels 1; Gaps 1;
QY 21 EINGSNYEMFTHNGGVOILCKYDPDVOQFRMQLKGGQILCDLTKTKGSGNTVSIKSL 80
Db : |||||: || ||||| ||||| |||||: |||||: ||||| ||||| |||||
26 eingsadhrmfshnggvqiskypetvqqlkmrlfrerevliceltktkgsgnavsiknp 85
QY 81 KECHSOLSNNSVSEFLYNLDHSHANYFCNLSIFDPPPKV-TLTGGYLHIYESQLCCOL 139
Db : ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
86 mlclhlnsnsvsfflnnpdssqgsyfcslsifdpppfqernlsggyihiesqlcoql 145
QY 140: K 140
Db :
146 k 146

Search completed: September 18, 2002, 15:26:25
Job time: 808 sec

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein_search, using sw model

Run on: September 18, 2002, 15:15:32 ; Search time 28.8 Seconds
(Without alignments)
168.774 Million cell updates/sec

Title: US-09-383-551B-2
Perfect score: 1082
Sequence: 1 MKSLWFFFLCFLRIKVLGT.....YMFRAVNTAKSKSLTDVTL 199

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 231628 seqs, 24425594 residues

number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents_AA:*
1: /cgn2_6/ptodata/2/1aa/5A_COMB.pep:*
2: /cgn2_6/ptodata/2/1aa/5B_COMB.pep:*
3: /cgn2_6/ptodata/2/1aa/6A_COMB.pep:*
4: /cgn2_6/ptodata/2/1aa/6B_COMB.pep:*
5: /cgn2_6/ptodata/2/1aa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/2/1aa/backfiles1.pep:*

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	163	15.1	218	3	US-08-228-208A-20
2	146.5	13.5	225	1	US-08-505-058-4
3	146.5	13.5	225	2	US-08-459-818-24
4	146.5	13.5	225	2	US-08-889-666-24
5	146.5	13.5	225	2	US-08-465-078-24
6	146.5	13.5	225	2	US-08-725-776-24
7	146.5	13.5	225	2	US-08-488-062-24
8	140	12.9	218	3	US-08-228-208A-19
9	134.5	12.4	220	3	US-08-228-208A-21
10	134	12.4	225	1	US-08-505-058-3
11	134	12.4	225	2	US-08-459-818-23
12	134	12.4	225	2	US-08-889-666-23
13	134	12.4	225	2	US-08-465-078-23
14	134	12.4	225	2	US-08-725-776-23
15	134	12.4	225	2	US-08-488-062-23
16	126	11.6	223	1	US-08-505-058-5
17	126	11.6	223	2	US-08-459-818-25
18	126	11.6	223	2	US-08-889-666-25
19	126	11.6	223	2	US-08-465-078-25
20	126	11.6	223	2	US-08-725-776-25
21	126	11.6	223	2	US-08-488-062-25
22	120.5	11.1	367	3	US-08-630-172-19
23	120.5	11.1	367	4	US-09-375-419-19
24	119.5	11.0	134	3	US-08-630-172-3
25	119.5	11.0	134	4	US-09-375-419-3
26	110.5	10.2	110	4	US-09-460-384-33
27	93	8.6	221	3	US-08-228-208A-22

28	89.5	8.3	117	2	US-08-529-878B-39	Sequence 39, Appl
29	87	8.0	330	2	US-08-332-562A-81	Sequence 81, Appl
30	87	8.0	330	2	US-08-332-562A-134	Sequence 134, App
31	86.5	8.0	209	4	US-09-430-503-20	Sequence 20, Appl
32	84.5	7.8	209	4	US-09-430-503-18	Sequence 18, Appl
33	84.5	7.8	209	4	US-09-430-503-24	Sequence 24, Appl
34	84	7.8	223	3	US-08-228-208A-17	Sequence 17, Appl
35	84	7.8	283	2	US-08-332-562A-136	Sequence 136, App
36	82.5	7.6	209	4	US-09-430-503-22	Sequence 22, Appl
37	81.5	7.5	187	1	US-08-067-684-14	Sequence 14, Appl
38	81.5	7.5	187	1	US-08-008-898-14	Sequence 14, Appl
39	81.5	7.5	187	2	US-08-459-818-14	Sequence 14, Appl
40	81.5	7.5	187	2	US-08-889-666-14	Sequence 14, Appl
41	81.5	7.5	187	2	US-08-465-078-14	Sequence 14, Appl
42	81.5	7.5	187	2	US-08-725-776-14	Sequence 14, Appl
43	81.5	7.5	187	2	US-08-488-062-14	Sequence 14, Appl
44	81.5	7.5	187	3	US-08-228-208A-14	Sequence 14, Appl
45	81.5	7.5	187	5	PCT-US95-06726-36	Sequence 36, Appl

ALIGNMENTS

RESULT 1
US-08-228-208A-20
; Sequence 20, Application US/08228208A
; Patent No. 6090914
; GENERAL INFORMATION:
; APPLICANT: Linsley, Peter S.
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Damle, Nitin K.
; APPLICANT: Brady, William
; APPLICANT: Wallace, Philip M.
; TITLE OF INVENTION: CTLA4/CD28 Ig HYBRID FUSION
; TITLE OF INVENTION: PROTEINS AND USES THEREOF
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 11150 Santa Monica Boulevard, Suite 400
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/228,208A
; FILING DATE: 15-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/008,898
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: 07/723,617
; FILING DATE: 27-JUN-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Adriano, Sarah B
; REGISTRATION NUMBER: 34,470
; REFERENCE/DOCKET NUMBER: 30436-30US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 310 445-1140
; TELEFAX: 310 445-9031
; TELEX:
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 218 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-228-208A-20

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:16:17 ; Search time 37.55 Seconds
(without alignments)
509.235 Million cell updates/sec

Title: US-09-383-551B-2
Perfect score: 1082
Sequence: 1 MKSGLWYFFLCLRIKVLGT.....YMFRAVNTAKKSLTDTVL 199

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283138 seqs, 96089334 residues

Number of hits satisfying chosen parameters: 283138

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_71:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	1082	100.0	199	2 S78540	inducible T-cell c
2	701	64.8	200	2 JC7397	activation-inducib
3	696	64.3	216	2 JC7396	activation-inducib
4	152	14.0	218	2 S24113	T-cell surface gly
5	150.5	13.9	221	2 I46689	CD28 precursor - r
6	139.5	12.9	173	2 I46197	cell surface prote
7	139.5	12.9	220	1 RWHU28	T-cell surface gly
8	138	12.8	218	2 A43523	T-cell surface gly
9	103.5	9.6	988	2 T18986	hypothetical prote
10	97	9.0	221	2 S25168	CHT28 protein - ch
11	91.5	8.5	383	2 T21946	hypothetical prote
12	87	8.0	330	2 A40071	Fc gamma (IgG) rec
13	87	8.0	330	2 I49660	Fc-gamma-1/gamma-2
14	87	8.0	563	2 T32479	hypothetical prote
15	86.5	8.0	223	2 A29063	cytotoxic T-lympho
16	86	7.9	223	2 T09536	cytotoxic T-lympho
17	84	7.8	283	1 FCMSG1	Fc gamma (IgG) rec
18	84	7.8	285	2 D69440	conserved hypotet
19	83.5	7.7	186	2 S08614	cytotoxic T-lympho
20	82.5	7.6	248	1 QBRE4L	probable glycoprot
21	81	7.5	276	2 S20690	31.6K glycoprotei
22	81	7.5	680	2 JC5895	killer cell inhibi
23	81	7.5	1584	2 S57161	hypothetical prote
24	80.5	7.4	247	2 D90028	hypothetical prote
25	80.5	7.4	635	2 JC5896	killer cell inhibi
26	78	7.2	231	2 T23136	hypothetical prote
27	77.5	7.2	80	2 F86027	hypothetical prote
28	77.5	7.2	220	2 A48581	37K proline-rich s
29	77.5	7.2	1070	2 JC4593	protein-tyrosine k

30	77	7.1	338	2 T34364	hypothetical prote
31	77	7.1	2104	2 D91286	hypothetical prote
32	77	7.1	2104	2 H86127	hypothetical prote
33	76.5	7.1	223	2 I46696	CTLA-4 precursor -
34	76.5	7.1	323	2 S06946	Fc gamma (IgG) rec
35	76.5	7.1	1237	2 A54080	protein-tyrosine-p
36	76	7.0	301	2 I54209	hypothetical prote
37	76	7.0	317	2 J10118	Fc gamma (IgG) rec
38	76	7.0	546	2 S22053	cytochrome-c oxida
39	75.5	7.0	261	2 S29360	Fc gamma (IgG) rec
40	75.5	7.0	277	2 T21330	hypothetical prote
41	75.5	7.0	2135	2 T14602	variant-specific s
42	75	6.9	418	2 AD3417	transporter, mfs s
43	75	6.9	1132	1 QSBPL	host specificity p
44	74.5	6.9	201	2 G90134	hypothetical prote
45	74.5	6.9	235	2 I50610	T-cell surface gly

ALIGNMENTS

RESULT 1

S78540
inducible T-cell co-stimulator ICOS precursor - human
C:Species: Homo sapiens (man)
C:Date: 05-Mar-1999 #sequence_revision 05-Mar-1999 #text_change 07-May-1999
C:Accession: S78540; S78748; S78749
R:KroczeK, R.
submitted to the Protein Sequence Database, June 1998
A:Reference number: S78540
A:Accession: S78540
A:Molecule type: mRNA
A:Residues: 1-199 <KRO>
A:Experimental source: cell line MOLT-4V
R:Hutloff, A.; Dittlich, A.M.; Beier, K.C.; Eljaschewitsch, B.; Kraft, R.; Anagnostop
Nature 397, 263-266, 1999
A:Title: ICOS is an inducible T-cell co-stimulator structurally and functionally rela
A:Reference number: S78748; MUID:99127892
A:Accession: S78748
A:Molecule type: mRNA
A:Residues: 1-199 <HUT1>
A:Experimental source: cell line MOLT-4V
A:Accession: S78749
A:Molecule type: protein
A:Residues: 'X', 193-198 <HUT2>
A:Experimental source: cell line MOLT-4V
C:Complex: homodimer
C:Superfamily: immunoglobulin homology
C:Keywords: dimer; glycoprotein; T-cell; transmembrane protein
F:1-19/Domain: (or 1-20) signal sequence #status predicted <SIG>
F:20-199/Product: (or 21-199) inducible costimulator ICOS #status predicted <MAT>
F:21-138/Domain: extracellular #status predicted <EXT>
F:26-132/Domain: immunoglobulin homology <IMM>
F:139-164/Domain: transmembrane #status predicted <TM>
F:165-199/Domain: intracellular #status predicted <INT>
F:23,89,110/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 100.0%; Score 1082; DB 2; Length 199;
Best Local Similarity 100.0%; Pred. No. 3,1e-97;
Matches 199; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy	1	MKSGLWYFFLCLRIKVLGTGEINGSANYEMFFHNGGVQILCKYDPDIVQOQFKMOLLKGQ	60
Db	1	MKSGLWYFFLCLRIKVLGTGEINGSANYEMFFHNGGVQILCKYDPDIVQOQFKMOLLKGQ	60
Oy	61	ILCDLTTKTGSGNTVSIKSKFCHSOLSNNVSFFLYNLDHSHANYFCNLSIFPPPPPK	120
Db	61	ILCDLTTKTGSGNTVSIKSKFCHSOLSNNVSFFLYNLDHSHANYFCNLSIFPPPPPK	120
Oy	121	VLTGGLYHIESQLCCQLKFWLPICGAFAVYVVCILGICILICWLTKKKYSSSSVHPDNGEY	180
Db	121	VLTGGLYHIESQLCCQLKFWLPICGAFAVYVVCILGICILICWLTKKKYSSSSVHPDNGEY	180

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:25:12 ; Search time 20.28 Seconds
(without alignments)
379.940 Million cell updates/sec

Title: US-09-383-551B-2

Perfect score: 1082

Sequence: 1 MKSLNYFFLECLRIKVLG.....YMFRAVNTAKSKRLTDVIL 199

Scoring table:

BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 105224 seqs, 38719550 residues

Number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	159	14.7	218	1	CD28_RAT
2	150.5	13.9	221	1	CD28_RABIT
3	141	13.0	219	1	CD28_BOVIN
4	139.5	12.9	220	1	CD28_HUMAN
5	138	12.8	218	1	CD28_MOUSE
6	97	9.0	221	1	CD28_CHICK
7	89	8.2	321	1	OSV1_HUMAN
8	87	8.0	330	1	FCG2_MOUSE
9	86.5	8.0	223	1	CTL4_MOUSE
10	86	7.9	223	1	CTL4_HUMAN
11	82.5	7.6	248	1	VGL2_EBV
12	81	7.5	1382	1	MET_RAT
13	81	7.5	1584	1	YJ9G_YEAST
14	77.5	7.2	324	1	CRFB_SHEEP
15	77.5	7.2	1070	1	PRK7_HUMAN
16	76.5	7.1	223	1	CTL4_RABIT
17	76.5	7.1	323	1	FCG3_HUMAN
18	76	7.0	317	1	FCGA_HUMAN
19	76	7.0	448	1	BCN1_MOUSE
20	76	7.0	450	1	BCN1_HUMAN
21	76	7.0	466	1	ALAA_RABIT
22	76	7.0	562	1	ALAD_MOUSE
23	75.5	7.0	261	1	FCG3_MOUSE
24	75	6.9	462	1	CATC_MOUSE
25	75	6.9	1132	1	VHSJ_LAMBDA
26	74.5	6.9	761	1	AD24_MOUSE
27	74	6.8	344	1	OM40_DROME
28	74	6.8	367	1	NUIM_PODAN
29	73.5	6.8	285	1	FCG2_RAT
30	73.5	6.8	322	1	CRFB_MOUSE
31	73.5	6.8	360	1	CCPH_HSVSA
32	73.5	6.8	496	1	GRB_MOUSE
33	73.5	6.8	496	1	GRB_RAT

34	73.5	6.8	497	1	GRB_HUMAN	P48167 homo sapien
35	73.5	6.8	1162	1	BXEN_CLOBU	Q08366 clostridium
36	73	6.7	275	1	YD84_YEAST	Q12359 saccharomyc
37	73	6.7	916	1	SCR2_LIMPO	Q25386 limulus pol
38	72.5	6.7	654	1	BFR2_HUMAN	Q01742 homo sapien
39	72	6.7	561	1	ALAD_RAT	P23944 rattus norv
40	72	6.7	569	1	YL53_YEAST	Q06567 saccharomyc
41	71.5	6.6	634	1	YCX3_EUGER	P31916 euglena gra
42	71.5	6.6	1051	1	PKT7_CHICK	Q91048 gallus gall
43	71	6.6	212	1	KITH_ENCCU	O96720 encephalito
44	71	6.6	466	1	ALAA_BOVIN	P18130 bos taurus
45	70.5	6.5	524	1	VLL_HPV58	P26535 human papil

ALIGNMENTS

RESULT 1

ID	CD28_RAT	STANDARD:	PRT:	218 AA.
AC	P31042;			
DT	01-JUL-1993 (Rel. 26, Created)			
DT	01-JUL-1993 (Rel. 26, Last sequence update)			
DT	01-MAR-2002 (Rel. 41, Last annotation update)			
DE	T-cell-specific surface glycoprotein CD28 precursor.			
OS	CD28.			
OS	Rattus norvegicus (Rat).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Rattus.			
OX	NCBI_TaxID=10116;			
RP	[1]			
RC	SEQUENCE FROM N.A.			
RC	STRAIN=DA; TISSUE=Lymphoid;			
RX	MEDLINE=92104640; PubMed=1309509;			
RT	Clark G.J., Dallman M.J.;			
RT	"Identification of a cDNA encoding the rat CD28 homologue.";			
RL	Immunogenetics 35:54-57(1992).			
CC	-!- FUNCTION: POSSIBLY INVOLVED IN T-CELL ACTIVATION. BINDS TO B7-1			
CC	AND B7-2 (B70).			
CC	-!- SUBUNIT: HOMODIMER; DISULFIDE-LINKED.			
CC	-!- SUBCELLULAR LOCATION: Type I membrane protein.			
CC	-!- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.			
CC	-!- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN			

CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC	EMBL; X55288; CAA39003.1; -
DR	PIR; S38722; S38722.
DR	InterPro; IPR003600; Ig_Like.
DR	SMART; SM00410; Ig_Like; I.
KW	Immunoglobulin domain; T-cell; Glycoprotein; Signal; Transmembrane.
FT	SIGNAL 1 19 BY SIMILARITY.
FT	CHAIN 20 218 T-CELL-SPECIFIC SURFACE GLYCOPROTEIN
FT	CD28
FT	DOMAIN 20 150 EXTRACELLULAR (POTENTIAL).
FT	TRANSMEM 151 177 POTENTIAL.
FT	DOMAIN 178 218 CYTOPLASMIC (POTENTIAL).
FT	DOMAIN 29 138 IG-LIKE V-TYPE DOMAIN.
FT	CARBOHYD 72 72 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 93 93 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 106 106 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT	CARBOHYD 130 130 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ	SEQUENCE 218 AA; 25170 MW; 2E151C8F324C0B6E CRC64;

Query Match 14.7%; Score 159; DB 1; Length 218;
Best Local Similarity 26.5%; Pred. No. 2.1e-08;

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:26:32 ; Search time 63.42 Seconds
(without alignments)
542.825 Million cell updates/sec

Title: US-09-383-551B-2
Perfect score: 1082
Sequence: 1 MKSGLWYFFLCRLIKVLGT.....YMFRAVNTAKSRSLTDVTL 199

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 562222 seqs, 172994929 residues

Total number of hits satisfying chosen parameters: 562222

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SPTREMBL_19:
1: sp_archaea:
2: sp_bacteria:
3: sp_fungi:
4: sp_human:
5: sp_invertebrate:
6: sp_mammal:
7: sp_mhc:
8: sp_organelle:
9: sp_phage:
10: sp_plant:
11: sp_rodent:
12: sp_virus:
13: sp_vertebrate:
14: sp_unclassified:
15: sp_rvirus:
16: sp_bacteriaph:
17: sp_archaeap:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1082	100.0	199	4 Q9Y6W8	Q9Y6W8 homo sapien
2	737.5	68.2	200	11 Q9WVS0	Q9WVS0 mus musculus
3	734	67.8	200	11 Q9JL17	Q9JL17 mus musculus
4	701	64.8	200	11 Q9RLT7	Q9RLT7 rattus norv
5	696	64.3	216	11 Q9WVR9	Q9WVR9 rattus norv
6	146.5	13.5	221	11 Q9JLV4	Q9JLV4 marmota mon
7	145.5	13.4	221	6 Q9N214	Q9N214 felis silve
8	145.5	13.4	221	6 Q02757	Q02757 felis silve
9	145	13.4	219	6 Q97630	Q97630 ovis aries
10	140.5	13.0	221	6 Q9GKP3	Q9GKP3 canis fami
11	140.5	13.0	221	6 Q9N0N8	Q9N0N8 canis fami
12	139.5	12.9	173	6 Q28289	Q28289 canis fami
13	136.5	12.6	220	6 Q9BDM8	Q9BDM8 macaca neme
14	135.5	12.5	220	6 Q9BDN5	Q9BDN5 cercocebus
15	130.5	12.1	220	6 Q9BDM6	Q9BDM6 macaca mula
16	125.5	11.6	220	6 Q9BDN8	Q9BDN8 papio anubi

17	115.5	10.7	220	6 Q9BDN2	Q9BDN2 callithrix
18	103.5	9.6	988	5 Q17710	Q17710 caenorhabdi
19	91.5	8.5	485	5 Q20139	Q20139 caenorhabdi
20	87	8.0	223	6 Q9BDP1	Q9BDP1 aotus trivi
21	84.5	7.8	209	4 Q9NYK4	Q9NYK4 homo sapien
22	84.5	7.8	223	11 Q9QZ27	Q9QZ27 mus musculu
23	84	7.8	223	4 Q56P43	Q56P43 homo sapien
24	84	7.8	285	17 Q28747	Q28747 archaeglob
25	84	7.8	419	13 Q9IA91	Q9IA91 morone saxa
26	83.5	7.7	223	11 Q9JLV3	Q9JLV3 marmota mon
27	83	7.7	1239	10 Q9FHM1	Q9FHM1 arabidopsis
28	82.5	7.6	223	11 Q62859	Q62859 rattus norv
29	82	7.6	223	6 Q9BDC4	Q9BDC4 macaca mula
30	82	7.6	223	6 Q9BDM7	Q9BDM7 papio anubi
31	81	7.5	276	12 Q98822	Q98822 human adeno
32	81	7.5	276	12 Q64861	Q64861 human adeno
33	81	7.5	680	11 Q55001	Q55001 mus musculu
34	80.5	7.4	247	16 Q99RX6	Q99RX6 staphylococ
35	80.5	7.4	635	11 Q55002	Q55002 mus musculu
36	80.5	7.4	663	11 Q70434	Q70434 mus musculu
37	79.5	7.3	269	4 Q95297	Q95297 homo sapien
38	79	7.3	370	4 Q9BZW8	Q9BZW8 homo sapien
39	78.5	7.3	310	11 Q9EQ87	Q9EQ87 mus musculu
40	78	7.2	231	5 Q45668	Q45668 caenorhabdi
41	77.5	7.2	311	11 Q9EQ86	Q9EQ86 mus musculu
42	77	7.1	323	6 Q9BDM2	Q9BDM2 cercopithec
43	77	7.1	338	5 Q22576	Q22576 caenorhabdi
44	77	7.1	539	12 P88842	P88842 avian infec
45	77	7.1	619	10 Q9XGG1	Q9XGG1 sorghum bic

ALIGNMENTS

RESULT 1

Q9Y6W8 ID Q9Y6W8 PRELIMINARY; PRT; 199 AA.
AC Q9Y6W8;
DT 01-NOV-1999 (TREMREL. 12, Created)
DT 01-NOV-1999 (TREMREL. 12, Last sequence update)
DT 01-DEC-2001 (TREMREL. 19, Last annotation update)
DE ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE AILIM
DE PRECURSOR (INDUCIBLE T-CELL CO-STIMULATOR PRECURSOR) (INDUCIBLE
DE COSTIMULATOR PRECURSOR).
GN ICOS.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=BLOOD;
RA Tezuka K., Tamatani T.;
RT "Cell surface molecule mediating cell adhesion and signal
transmission."
RL Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=99127892; PubMed=9930702;
RA Hutloff A., Dittlich A.M., Beier K.C., Eljaschewitsch B., Kraft R.,
RA Anagnostopoulos I., Krocsek R.A.;
RT "ICOS is an inducible T-cell co-stimulator structurally and
functionally related to CD28."
RL Nature 397:263-266(1999).
RN [3]
RP SEQUENCE FROM N.A.
RA Beier K.C., Hutloff A., Dittlich A.M., Heuck C., Mages H.W.,
RA Buechner K., Henn V., Rauch A., Krocsek R.A.;
RT "Detailed analysis of human ICOS and its ligand."
RL Submitted (MAY-2000) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RC TISSUE=THYMUS;

RX MEDLINE-20243570;
RA Aicher A., Hayden-Ledbetter M., Brady W.A., Pezzutto A., Richter G.,
RA Magaletti D., Buckwalter S., Ledbetter J.A., Clark E.A.;
RT "Characterization of human inducible costimulator ligand expression
and function.";
RL J. Immunol. 164:4689-4696(2000).
DR EMBL; AB023135; BAA82129.1; -;
DR EMBL; AJ277832; CAC06612.1; -;
DR EMBL; AF218312; AAF71301.1; -;
KW SIGNAL. 1 20 POTENTIAL.
FT SIGNAL. 1 20 POTENTIAL.
SQ SEQUENCE 199 AA; 22624 MW; 214EC741C9BDC9FC CRC64;

Query Match 100.0%; Score 1082; DB 4; Length 199;
Best Local Similarity 100.0%; Pred. No. 2.8e-109; Indels 0; Gaps 0;
Matches 199; Conservative 0; Mismatches 0;

Qy 1 MKSGLWYFFFLCRLIKVLTGEINGSANYEMFIFHNGGVQIICKYDPDIQQFKMQLLKGQ 60
|||||
1 MKSGLWYFFFLCRLIKVLTGEINGSANYEMFIFHNGGVQIICKYDPDIQQFKMQLLKGQ 60
61 ILCDLTKTGSGNTVSIKSLKFCQSLSNNSVSFFLYNLDHSHANYFCNLISIFDPPPFK 120
|||||
61 ILCDLTKTGSGNTVSIKSLKFCQSLSNNSVSFFLYNLDHSHANYFCNLISIFDPPPFK 120
Qy 121 VLTGGYLHIYESQLCCOLKFWLPICGAAFFVVCILGCILICWLTKKKYSSSVHDPNGEY 180
|||||
121 VLTGGYLHIYESQLCCOLKFWLPICGAAFFVVCILGCILICWLTKKKYSSSVHDPNGEY 180
Db 181 MFMAVNTAKKSLRLDVT 199
|||||
181 MFMAVNTAKKSLRLDVT 199

RESULT 2
Q9WVS0 PRELIMINARY; PRT; 200 AA.
AC Q9WVS0;
DT 01-NOV-1999 (Tremblrel. 12, Created)
DT 01-NOV-1999 (Tremblrel. 12, Last sequence update)
DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)
DE ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE AILIM
DE PRECURSOR (CCLP PRECURSOR) (SURFACE PROTEIN).
GN CCLP OR ICOS.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
[1]
RP SEQUENCE FROM N.A.
RC TISSUE=SPLEEN;
RA Tezuka K., Tamatani T.;
RT "Cell surface molecule mediating cell adhesion and signal
transmission.";
RL Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/C; TISSUE=SPLEEN;
RA Wu D., Giannoni M.A., Kiesecker C.L., Faas S.J., Mickle A.P.,
RA Matis L.A., Rother R.P.;
RT "CCLP, A novel molecule that regulates T cell activation.";
RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/C; TISSUE=SPLEEN;
RX Mages H.W., Hutloff A., Heuck C., Buchner K., Himmelbauer H.,
RA Oliveri F., Kroccek R.A.;
RT "Molecular cloning and characterization of murine ICOS and
its identification of B7h as ICOS ligand.";
RN Immunol. 30:1040-1047(2000).
[3132; BAA82126.1; -;

DR EMBL; AF257230; AAF70099.1; -;
DR EMBL; AJ250559; CAB71153.1; -;
DR MGD; MGI:1858745; ICOS.
KW SIGNAL. 1 20 POTENTIAL.
FT SIGNAL. 1 20 POTENTIAL.
SQ SEQUENCE 200 AA; 22690 MW; 9B2278E4CAB1DB47 CRC64;

Query Match 68.2%; Score 737.5; DB 11; Length 200;
Best Local Similarity 69.3%; Pred. No. 6e-72; Indels 1; Gaps 1;
Matches 138; Conservative 20; Mismatches 40;

Qy 1 MKSGLWYFFFLCRLIKVLTGEINGSANYEMFIFHNGGVQIICKYDPDIQQFKMQLLKGQ 60
|||||
1 MKPYCFYVFCFLRLITGEINGSADHMFHNGGVQISCKYPETVQOLKMLFRERE 60
Qy 61 ILCDLTKTGSGNTVSIKSLKFCQSLSNNSVSFFLYNLDHSHANYFCNLISIFDPPPFK 120
|||||
61 VLCELTKTGSGNAVSIKPNMLCLYHLSNNSVSFFLNPNDSQSGSYFCSLSIFDPPPFQ 120
Qy 121 V-TLTGGYLHIYESQLCCOLKFWLPICGAAFFVVCILGCILICWLTKKKYSSSVHDPNGE 179
|-|||||
121 ERNUSGGYLHIYESQLCCOLKFWLPICGAAFFVVCILGCILICWLTKKKYSSSVHDPNGE 180
Db 180 YMFMAVNTAKKSLRLDVT 198
|||||
181 YMFMAVNTAKKSLRLDVT 199

RESULT 3
Q9JLI7 PRELIMINARY; PRT; 200 AA.
AC Q9JLI7;
DT 01-OCT-2000 (Tremblrel. 15, Created)
DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)
DT 01-MAR-2001 (Tremblrel. 16, Last annotation update)
DE CD28-RELATED PROTEIN 1 (INDUCIBLE COSTIMULATORY PROTEIN)
DE (FRAGMENT).
GN ICOS.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
NCBI_TaxID=10090;
[1]
RP SEQUENCE FROM N.A.
RC TISSUE=INTESTINAL INTRA-EPITHELIAL;
RA Yoshinaga S.K., Whoriskey J.S., Khare S.D., Sarmiento U., Guo J.,
RA Horan T., Shih G., Zhang M., Coccia M.A., Kohno T., Tafuri-Bladt A.,
RA Campbell P., Chang D., Chiu L., Bai T., Duncan G., Elliott G.S.,
RA Hui A., McCabe S.M., Scully S., Shaklee C.L., Van G., Mak T.W.,
RA Senaldi G.;
RT "T-cell co-stimulation through B7RP-1 and ICOS.";
RL Nature 0:0-0(2000).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=129/OLA;
RA McAdam A.J., Greenwald R.J., Levin M.A., Chernova T., Malenkovich N.,
RA Ling V., Freeman G.J., Sharpe A.H.;
RT "The inducible costimulatory (ICOS) molecule is critical for CD40-
mediated antibody class switching.";
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF216748; AAF45150.1; -;
DR EMBL; AF327185; AAG48732.1; -;
DR EMBL; AF327184; AAG48732.1; JOINED.
FT NON_TER 200
SQ SEQUENCE 200 AA; 22709 MW; 87D97F0DC44ADCA7 CRC64;

Query Match 67.8%; Score 734; DB 11; Length 200;
Best Local Similarity 70.4%; Pred. No. 1.4e-71;
Matches 138; Conservative 19; Mismatches 35; Indels 4; Gaps 2;

Qy 7 YF---FLFCRLIKVLTGEINGSANYEMFIFHNGGVQIICKYDPDIQQFKMQLLKGQILC 63

QY 74 TVSIKSLKF-----CHSLSNNSVSFFLYNLDHSHANYFCNLSIFDPPPF--KVLT 124
Db 75 ----HQLQFYSTGTGCDGKLGNERVTVYLRNLYVNDIYFCKIEVMPYPPYLDNKS 130
QY 125 GGYLHIYESQLCCQ-----KFW-LPIGCAAFVVCVILGCGILICWLTKKYSSSVHDP 176
Db 131 GTVIHVKNENICPGVPSPKPFMTLVVFGVLGIYSLTMLLCYLTWTKRQTRL--L 188
QY 177 NGEYMF 183
Db 189 QSDYNM 195

RESULT 7
Q9N214
ID Q9N214 PRELIMINARY; PRT: 221 AA.
AC Q9N214;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
CD28.
OS Felis silvestris catus (Cat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Felidae; Felis.
OX NCBI_TaxID=9685;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20094001; PubMed=10630305;
RA Nishimura Y., Miyazawa T., Ikeda Y., Izumiya Y., Nakamura K., Sato E.,
RA Mikami T., Takahashi E.;
RT "Molecular cloning and sequencing of a cDNA encoding the feline T-cell
antigen CD28 homologue."
RL Immunogenetics 50:369-370(1999).
DR EMBL: AB025316; BAA92349.1; -
DR InterPro: IPR003600; Ig_like.
DR SMART: SM00410; Ig_like; 1.
SQ SEQUENCE 221 AA; 25283 MW; B17B76C52BA18DCB CRC64;

Query Match 13.4%; Score 145.5; DB 6; Length 221;
Best Local Similarity 28.3%; Pred. No. 9.8e-08;
Matches 45; Conservative 22; Mismatches 65; Indels 27; Gaps 8;

QY 32 IFHNGGVQILCKYPD--IVQQFKMQLLKGQILCDLTTKG--SGNTVSIKSLKF-CHSQ 86
Db 31 VVYNNEVNLCKYTHNLFSEKFRASLYKGVDSAVECVVNGYSHQPOFYSTGDCDGK 90

QY 87 LSNNVSFFLYNLDHSHANYFCNLSIFDPPPF--KVLTGGYLIHYESQLC-CQLK--- 140
Db 91 LGNETVTVYLRNLFVNDIYFCKIEVMPYPPYIDNEKSNGTIIHVKEKHLCPAQLSPES 150
QY 141 ---FWLPIGCAAFVVVCILG-----CILICWLTKKK 168
Db 151 SKPFW-----ALVVVGILGFYSLLATVALGACWMTKR 184

RESULT 8
O02757
ID O02757 PRELIMINARY; PRT: 221 AA.
AC O02757;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE T-CELL SPECIFIC SURFACE GLYCOPROTEIN CD28.
OS Felis silvestris catus (Cat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Felidae; Felis.
OX NCBI_TaxID=9685;
RN [1]
RP SEQUENCE FROM N.A.
RX Hash S.M., Carpino M.R., Collisson E.W.;
RT "Felis catus t-cell specific surface glycoprotein CD28.";

Query Match 13.4%; Score 145.5; DB 6; Length 221;
Best Local Similarity 28.3%; Pred. No. 9.8e-08;
Matches 45; Conservative 22; Mismatches 65; Indels 27; Gaps 8;

QY 32 IFHNGGVQILCKYPD--IVQQFKMQLLKGQILCDLTTKG--SGNTVSIKSLKF-CHSQ 86
Db 31 VVYNNEVNLCKYTHNLFSEKFRASLYKGVDSAVECVVNGYSHQPOFYSTGDCDGK 90

QY 87 LSNNVSFFLYNLDHSHANYFCNLSIFDPPPF--KVLTGGYLIHYESQLC-CQLK--- 140
Db 91 LGNETVTVYLRNLFVNDIYFCKIEVMPYPPYIDNEKSNGTIIHVKEKHLCPAQLSPES 150
QY 141 ---FWLPIGCAAFVVVCILG-----CILICWLTKKK 168
Db 151 SKPFW-----ALVVVGILGFYSLLATVALGACWMTKR 184

Query Match 13.4%; Score 145.5; DB 6; Length 221;
Best Local Similarity 28.3%; Pred. No. 9.8e-08;
Matches 45; Conservative 22; Mismatches 65; Indels 27; Gaps 8;

QY 32 IFHNGGVQILCKYPD--IVQQFKMQLLKGQILCDLTTKG--SGNTVSIKSLKF-CHSQ 86
Db 31 VVYNNEVNLCKYTHNLFSEKFRASLYKGVDSAVECVVNGYSHQPOFYSTGDCDGK 90

QY 87 LSNNVSFFLYNLDHSHANYFCNLSIFDPPPF--KVLTGGYLIHYESQLC-CQLK--- 140
Db 91 LGNETVTVYLRNLFVNDIYFCKIEVMPYPPYIDNEKSNGTIIHVKEKHLCPAQLSPES 150
QY 141 ---FWLPIGCAAFVVVCILG-----CILICWLTKKK 168
Db 151 SKPFW-----ALVVVGILGFYSLLATVALGACWMTKR 184

Query Match 13.4%; Score 145.5; DB 6; Length 221;
Best Local Similarity 28.3%; Pred. No. 9.8e-08;
Matches 45; Conservative 22; Mismatches 65; Indels 27; Gaps 8;

QY 32 IFHNGGVQILCKYPD--IVQQFKMQLLKGQILCDLTTKG--SGNTVSIKSLKF-CHSQ 86
Db 31 VVYNNEVNLCKYTHNLFSEKFRASLYKGVDSAVECVVNGYSHQPOFYSTGDCDGK 90

QY 87 LSNNVSFFLYNLDHSHANYFCNLSIFDPPPF--KVLTGGYLIHYESQLC-CQLK--- 140
Db 91 LGNETVTVYLRNLFVNDIYFCKIEVMPYPPYIDNEKSNGTIIHVKEKHLCPAQLSPES 150
QY 141 ---FWLPIGCAAFVVVCILG-----CILICWLTKKK 168
Db 151 SKPFW-----ALVVVGILGFYSLLATVALGACWMTKR 184

RL Thesis (1996), Veterinary Pathobiology, Texas A&M Univ.
DR EMBL: U57754; AAB53574.1; -
DR InterPro: IPR003600; Ig_like.
DR SMART: SM00410; Ig_like; 1.
SQ SEQUENCE 221 AA; 25317 MW; 5B71717E461AE5E3 CRC64;

Query Match 13.4%; Score 145.5; DB 6; Length 221;
Best Local Similarity 28.3%; Pred. No. 9.8e-08;
Matches 45; Conservative 22; Mismatches 65; Indels 27; Gaps 8;

QY 32 IFHNGGVQILCKYPD--IVQQFKMQLLKGQILCDLTTKG--SGNTVSIKSLKF-CHSQ 86
Db 31 VVYNNEVNLCKYTHNLFSEKFRASLYKGVDSAVECVVNGYSHQPOFYSTGDCDGK 90

QY 87 LSNNVSFFLYNLDHSHANYFCNLSIFDPPPF--KVLTGGYLIHYESQLC-CQLK--- 140
Db 91 LGNETVTVYLRNLFVNDIYFCKIEVMPYPPYIDNEKSNGTIIHVKEKHLCPAQLSPES 150
QY 141 ---FWLPIGCAAFVVVCILG-----CILICWLTKKK 168
Db 151 SKPFW-----ALVVVGILGFYSLLATVALGACWMTKR 184

RESULT 9
O97630
ID O97630 PRELIMINARY; PRT: 219 AA.
AC O97630;
DT 01-MAY-1999 (TrEMBLrel. 10, Created)
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE T-CELL SPECIFIC SURFACE GLYCOPROTEIN CD28.
GN Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Caprinae; Ovis.
OX NCBI_TaxID=9940;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99309828; PubMed=10380709;
RA Chaplin P.J., Pietrala L.N., Scheerlinck J.P.;
RT "Cloning and sequence comparison of sheep CD28 and CTLA-4."
RL Immunogenetics 49:583-584(1999).
DR EMBL: AF092739; AAD04379.1; -
DR InterPro: IPR003600; Ig_like.
DR SMART: SM00410; Ig_like; 1.
SQ SEQUENCE 219 AA; 25158 MW; D50AD339E5BC2327 CRC64;

Query Match 13.4%; Score 145; DB 6; Length 219;
Best Local Similarity 23.5%; Pred. No. 1.1e-07;
Matches 40; Conservative 35; Mismatches 75; Indels 20; Gaps 8;

QY 30 MFIFHNGGVQILCKYPD--IVQQFKMQLLKGQILCDLTTKG--GNTVSIKSLKF-CHS 85
Db 28 MLVYNDNEVNLCKYTYNLFSEKFRASLYKGADSAVECAVNGNHSHPQLQSNKEFNCV 87

QY 86 QLSNNSVSFFLYNLDHSHANYFCNLSIFDPPPF--KVLTGGYLIHYESQLC----- 136
Db 88 KVGNETVTVYLRNLFVNDIYFCKIEVLPYPPYIDNEKSNGTIIHVKEKHLCPSPQSPE 147
QY 137 CQLKFWLP---GCAAFVVVCILGCGILICWLTKKYSSSVHDPNCEYMF 183
Db 148 SSKPFWALVVVGVVLYFVSLVVALCNCWMTKR--NRMH--QSDYNM 193

RESULT 10
O9GKP3
ID O9GKP3 PRELIMINARY; PRT: 221 AA.
AC O9GKP3;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run On: September 18, 2002, 15:26:25 ; Search time 75.12 Seconds
(without alignments)
295.724 Million cell updates/sec

Title: US-09-383-551B-13

Perfect score: 1070

Sequence: 1 MKPYFCVFVFCFLIKLTG.....YMFMAAVNTNKSRLAGMTS 200

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_032802.*

1: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDS1/gcgdata/hold-geneseq/geneseq-emb1/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1070	100.0	200	19 AAW71874	Rat cell surface p
2	1056	98.7	216	19 AAW71875	Rat cell surface p
3	922	86.2	200	21 AAB08723	Amino acid sequenc
4	922	86.2	200	21 AAY92212	Murine Th2-specifi
5	907	84.8	200	19 AAW75958	Mouse cell surface
6	701	65.5	199	19 AAW75956	Human cell surface
7	701	65.5	199	19 AAW75957	Human cell surface
8	701	65.5	199	20 AAY08026	Human activated T-
9	701	65.5	199	21 AAB08731	Amino acid sequenc
10	701	65.5	199	22 AAE03428	Human gene 2 encod
11	701	65.5	199	22 AAE03460	Human gene 2 encod

12	701	65.5	199	22 AAE03525	Human secreted pro
13	685.5	64.1	198	21 AAY92213	Human Th2-specific
14	552	51.6	380	22 AAB67717	Amino acid sequenc
15	430.5	40.2	379	22 AAB67716	Amino acid sequenc
16	141	13.2	220	13 AAR20805	Human CD28 antigen
17	141	13.2	220	13 AAR27103	Sequence encoded b
18	141	13.2	220	17 AAW02131	Human CD28 cDNA pr
19	141	13.2	220	17 AAR91433	Human CD28 antigen
20	141	13.2	220	18 AAW38413	CD28. Homo sapien
21	141	13.2	220	19 AAW80442	Human CD28 antigen
22	141	13.2	220	20 AAW88451	Human CD28 antigen
23	141	13.2	220	21 AAY96128	Human cell surface
24	141	13.2	220	21 AAY44294	Human CD28 recepto
25	141	13.2	220	22 AAU02437	Human lymphocyte c
26	130.5	12.2	223	20 AAY41137	Human CD28 protein
27	117	10.9	221	21 AAY32286	Feline CD28. Feli
28	117	10.9	221	21 AAY32279	Cat CD28 receptor.
29	116.5	10.9	134	18 AAR35846	Human CD28 for use
30	116.5	10.9	152	16 AAR67706	CD28 extracellular
31	112.5	10.5	367	18 AAW35862	Human CD28:IG2a c
32	108.5	10.1	225	20 AAY41136	Rat CD28 protein s
33	86	8.0	225	20 AAY41135	Mouse CD28 protein
34	82	7.7	244	20 AAY00161	Enterococcus faeca
35	82	7.7	269	20 AAY00160	Enterococcus faeca
36	82	7.7	503	22 AAB92984	Human protein sequ
37	81.5	7.6	117	20 AAY24469	Human CD28 gene pr
38	81.5	7.6	226	20 AAY41138	Chicken CD28 prote
39	77.5	7.2	964	21 AAB13634	C. trachomatis pmp
40	77.5	7.2	964	22 AAG83202	Protein encoded by
41	77.5	7.2	977	21 AAB13640	C. trachomatis pmp
42	77.5	7.2	977	22 AAG83208	Protein encoded by
43	76	7.1	223	21 AAY32287	Feline CTLA-4. Fe
44	76	7.1	223	21 AAY32280	Cat CTLA-4 recepto
45	76	7.1	803	13 AAR29030	Bacillus thuringie

ALIGNMENTS

RESULT 1

AAW71874
ID AAW71874 standard; Protein; 200 AA.
AC AAW71874;
XX
DT 11-DEC-1998 (first entry)
DE
DE Rat cell surface protein #1.
XX
KW Rat: cell surface protein; thymocyte; lymphocyte; cell adhesion;
KW signal transmission; autoimmune disorder; allergy; diagnosis;
KW mitogen-stimulated.
XX
OS Rattus sp.
XX
PN WO9838216-A1.
XX
PD 03-SEP-1998.
XX
PF 27-FEB-1998; 98WO-JP00837.
XX
PR 26-FEB-1998; 98JP-0062217.
XX
PR 27-FEB-1997; 97JP-0062290.
(NISB) JAPAN TOBACCO INC.
Tamatani T, Tezuka K;
WPI: 1998-481144/41.
N-PSDB; AAV61357.

Cell surface molecule expressed in thymocytes and lymphocytes and -
mediating signal transmission and cell adhesion, and antibodies to

PT it useful in treatment of auto:immune and allergic disorders.

PS Claim 9; Page 106-109; 149pp; Japanese.

XX The present sequence represents a rat cell surface protein which is
 CC expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell
 CC surface protein induces adhesion of mitogen-stimulated lymphocytes to
 CC antibodies recognising the cell surface protein. These antibodies also
 CC produce an increase in peripheral blood lymphocytes in the presence of
 CC an antibody recognising CD3 antigen. The cell surface protein contains
 CC the amino acid sequence FPPPPF in its extracellular region and the
 CC sequence YMFEM in its intracellular region. The cell surface protein can
 CC be used in the prevention and treatment of autoimmune and allergic
 CC diseases, and in the diagnosis and investigation of such disorders.

XX Sequence 200 AA;

Query Match 100.0%; Score 1070; DB 19; Length 200;
 Best Local Similarity 100.0%; Pred. No. 2.3e-112; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MKPYFSCVFVFCFLIKLTGTSELNDLANHRMFSFHDGGVQVQISCNYPETVQQLKMLFKDRE 60
 Db 1 mkpyfscvfvfcflilktlgtelndlanhrmfsfhdggvgvqiscnypetvqqlkmlfkdre 60
 Qy 61 VLCDLTKTKSGNTVSIKNPMSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPPFQ 120
 Db 61 vldcltkksgntvsi knpmscopyqlsnnsvsffldnadssqgsyflcslsifdpppfq 120
 Qy 121 EKNLSGGYLLIYESQLCCQLKLWLPVGCFAFVAALLFGCIFVWFPAKKYRSSVHDPNSE 180
 Db 121 eknlsggylliyesqlccqlklwlpvgcaafvaallfgciffvwfakkyrssvhdpnse 180
 Qy 181 YMFMAAVNTNKKSLAGMTS 200
 Db 181 ymfmaavntnkkslagmts 200

RESULT 2

AAW71875
 ID AAW71875 standard; Protein; 216 AA.

XX AAW71875;

XX 11-DEC-1998 (first entry)

XX Rat cell surface protein #2.

XX Rat; cell surface protein; thymocyte; lymphocyte; cell adhesion;
 KW signal transmission; autoimmune disorder; allergy; diagnosis;
 KW mitogen-stimulated.

XX Rattus sp.

XX WO9838216-A1.

XX 03-SEP-1998.

XX 27-FEB-1998; 98WO-JP00837.

XX 26-FEB-1998; 98JP-0062217.

XX 27-FEB-1997; 97JP-0062290.

XX (NISB) JAPAN TOBACCO INC.

XX Tamatani T, Tezuka K;

XX YPI; 1998-481144/41.

XX N-PSDB; AAV61358.

XX Cell surface molecule expressed in thymocytes and lymphocytes and -
 PT mediating signal transmission and cell adhesion, and antibodies to

PT it useful in treatment of auto:immune and allergic disorders.

PS Claim 9; Page 112-115; 149pp; Japanese.

XX The present sequence represents a rat cell surface protein which is
 CC expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell
 CC surface protein induces adhesion of mitogen-stimulated lymphocytes to
 CC antibodies recognising the cell surface protein. These antibodies also
 CC produce an increase in peripheral blood lymphocytes in the presence of
 CC an antibody recognising CD3 antigen. The cell surface protein contains
 CC the amino acid sequence FPPPPF in its extracellular region and the
 CC sequence YMFEM in its intracellular region. The cell surface protein can
 CC be used in the prevention and treatment of autoimmune and allergic
 CC diseases, and in the diagnosis and investigation of such disorders.

XX Sequence 216 AA;

Query Match 98.7%; Score 1056; DB 19; Length 216;
 Best Local Similarity 100.0%; Pred. No. 9.6e-111; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MKPYFSCVFVFCFLIKLTGTSELNDLANHRMFSFHDGGVQVQISCNYPETVQQLKMLFKDRE 60
 Db 1 mkpyfscvfvfcflilktlgtelndlanhrmfsfhdggvgvqiscnypetvqqlkmlfkdre 60
 Qy 61 VLCDLTKTKSGNTVSIKNPMSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPPFQ 120
 Db 61 vldcltkksgntvsi knpmscopyqlsnnsvsffldnadssqgsyflcslsifdpppfq 120
 Qy 121 EKNLSGGYLLIYESQLCCQLKLWLPVGCFAFVAALLFGCIFVWFPAKKYRSSVHDPNSE 180
 Db 121 eknlsggylliyesqlccqlklwlpvgcaafvaallfgciffvwfakkyrssvhdpnse 180
 Qy 181 YMFMAAVNTNKKSLAG 197
 Db 181 ymfmaavntnkkslag 197

RESULT 3

AA08723
 ID AAB08723 standard; Protein; 200 AA.

XX AAB08723;

XX 02-JAN-2001 (first entry)

XX Amino acid sequence of a murine CRP1 polypeptide.

XX CRP1; CD28 related protein-1; B7RP1; B7 related protein-1;
 KW T-lymphocyte activation; type I transmembrane protein; T cell activation;
 KW T cell proliferation; T-cell mediated disorder.

XX Mus sp.

XX Key Location/Qualifiers

XX Peptide 1..20

XX /note= "signal peptide"

XX Protein 21..200

XX /note= "mature protein"

XX Domain 21..145

XX /note= "extracellular domain"

XX Domain 146..163

XX /note= "predicted transmembrane domain"

XX Domain 164..200

XX /note= "intracellular domain"

XX WO200046240-A2.

XX 10-AUG-2000.

XX 27-JAN-2000; 2000WO-US01871.

XX


```
PR 03-FEB-1999; 99US-0244448.
PR 08-MAR-1999; 99US-0264527.
XX
XX (AMGE-) AMGEN INC.
XX
XX Yoshinaga SK;
XX
XX WPI; 2000-543476/49.
XX N-PSDB; AAA64554.
XX
XX Novel nucleic acids encoding the proteins CRP-1 and B7RP1 are useful
XX in the treatment, prevention and diagnosis of T cell mediated disorders
XX
XX Claim 11; Fig 1A; 174pp; English.
XX
XX The present sequence represents a CRP1 (CD28 related protein-1)
XX polypeptide. The specification also describes a B7RP1 (B7 related
XX protein-1) polypeptide. The polypeptides are involved in T-lymphocyte
XX activation, and represent a receptor-ligand pair. CRP1 and B7RP1 are
XX predicted to be a type I transmembrane protein. The nucleic acids are
XX useful for regulating T cell activation or proliferation in an animal.
XX The polypeptides are useful for treating, preventing ameliorating or
XX diagnosing a T-cell mediated disorder in an animal. They can also be
XX used to identify test molecules that bind to the polypeptides.
XX
XX Sequence 200 AA;
SQ
Query Match 86.2%; Score 922; DB 21; Length 200;
Best Local Similarity 85.0%; Pred. No. 1.le-95;
Matches 170; Conservative 14; Mismatches 16; Indels 0; Gaps 0;
QY 1 MKPYSCVFVFCFLIKLTGELNDLANHRMFSFHGGVQVOISCNYPETVQOLKMQLFKDR 60
DB 1 mkpyfcrvfvcflirlitgeingsadhrmfsfhggvgqiskypetvqqlkmrlfrere 60
QY 61 VLCDLTGKSGNTVTSIKNPMSCPYQLSNNSVSRFLDNADSSQGSYFCLSLIFDPPPFQ 120
DB 61 vlceltkkgsgnavsknplmclclhlnsnsvsfflnpdsqsgsyfcsisifpppfq 120
QY 121 EKNLSGGYLLIYESQCCQLKWLPGVCAAFVAALLFGCIFVWFPAKKYRSSVHDPNSE 180
DB 121 ernlsggylhiesqlccqlklwlpvgcaafvvlfgcilliwfskkkygssvhdnpse 180
QY 181 YMFMAAVNTNKKSLAGMTS 200
DB 181 ymfmaavntnkkksrlagvts 200
QY 181 YMFMAAVNTNKKSLAGMTS 200
DB 181 ymfmaavntnkkksrlagvts 200
RESULT 5
AAW75958
ID AAW75958 standard; Protein; 200 AA.
XX
XX AC AAW75958;
XX
```

/note= "common in CD28 and CTLA-4; necessary for CD28-mediated phosphatidylinositol 3-kinase activity"

WO200019988-A1.

13-APR-2000.

06-OCT-1999; 99WO-US23156.

07-OCT-1998; 98US-0168229.

26-FEB-1999; 99US-0258670.

06-OCT-1999; 99US-0413136.

(MILL-) MILLENNIUM PHARM INC.

Lehar S, Manning S, Coyle AJ, Gutierrez-ramos J;

WPI; 2000-303619/26.

N-PSDB; AAA09054.

T helper (Th) 2 nucleic acids and encoded proteins, useful for the diagnosis and treatment of immune and respiratory disorders such as Crohn's diseases, arthritis, insulin dependent diabetes and autoimmunity

Claim 16; Page 130-131; 159pp; English.

This Th2-specific polypeptide is encoded by a murine orthologue m1288. The protein shares homology with both human and murine CD28 and CTLA-4. A novel method for modulating a Th2 response, an immune response, or suppressing airway inflammation or hyperresponsiveness in a mammal comprises administering a Th2-specific polypeptide of the invention, an antibody to such a polypeptide or allelic variants of the genes. The novel DNA and polypeptide sequences are useful for treatment and diagnosis of Th cell and Th cell-like disorders such as Crohn's diseases, arthritis, insulin dependent diabetes, autoimmunity, multiple sclerosis, sarcoidosis, asthma, allergies, conjunctivitis, glomerular nephritis, viral infections (including human immunodeficiency virus (HIV)), bacterial infections, bronchitis, cystic fibrosis, diphtheria, emphysema, pneumonia, and Legionnaires disease.

Sequence 200 AA;

Query Match 86.2%; Score 922; DB 21; Length 200;

Best Local Similarity 85.0%; Pred. No. 1.le-95;

Matches 170; Conservative 14; Mismatches 16; Indels 0; Gaps 0;

QY 1 MKPYSCVFVFCFLIKLTGELNDLANHRMFSFHGGVQVOISCNYPETVQOLKMQLFKDR 60

DB 1 mkpyfcrvfvcflirlitgeingsadhrmfsfhggvgqiskypetvqqlkmrlfrere 60

QY 61 VLCDLTGKSGNTVTSIKNPMSCPYQLSNNSVSRFLDNADSSQGSYFCLSLIFDPPPFQ 120

DB 61 vlceltkkgsgnavsknplmclclhlnsnsvsfflnpdsqsgsyfcsisifpppfq 120

QY 121 EKNLSGGYLLIYESQCCQLKWLPGVCAAFVAALLFGCIFVWFPAKKYRSSVHDPNSE 180

DB 121 ernlsggylhiesqlccqlklwlpvgcaafvvlfgcilliwfskkkygssvhdnpse 180

QY 181 YMFMAAVNTNKKSLAGMTS 200

DB 181 ymfmaavntnkkksrlagvts 200

RESULT 5

AAW75958

ID AAW75958 standard; Protein; 200 AA.

XX

XX AC AAW75958;

XX

DT 11-DEC-1998 (first entry)
 XX Mouse cell surface protein.
 DE
 XX
 KW Mouse; cell surface protein; thymocyte; lymphocyte; cell adhesion;
 KW signal transmission; autoimmune disorder; allergy; diagnosis;
 KW mitogen-stimulated.
 XX
 XX Mus sp.
 XX
 XX WO9838216-A1.
 PN
 XX
 PD 03-SEP-1998.
 PD
 XX 27-FEB-1998; 98WO-JP00837.
 XX
 XX 26-FEB-1998; 98JP-0062217.
 PR
 PR 27-FEB-1997; 97JP-0062290.
 PR
 XX
 XX (NISR) JAPAN TOBACCO INC.
 PA
 XX Tamatani T, Tezuka K;
 XX
 XX WPI; 1998-481144/41.
 DR
 DR N-PSDB; AAV53200.
 XX
 XX Cell surface molecule expressed in thymocytes and lymphocytes and -
 PT mediating signal transmission and cell adhesion, and antibodies to
 PT it useful in treatment of auto-immune and allergic disorders.
 XX
 XX Claim 9; Page 110-112; 149pp; Japanese.
 PS
 XX The present sequence represents a mouse cell surface protein which is
 CC expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell
 CC surface protein induces adhesion of mitogen-stimulated lymphocytes to
 CC antibodies recognising the cell surface protein. These antibodies also
 CC produce an increase in peripheral blood lymphocytes in the presence of
 CC an antibody recognising CD3 antigen. The cell surface protein contains
 CC the amino acid sequence FPPPP in its extracellular region and the
 CC sequence YPMF in its intracellular region. The cell surface protein can
 CC be used in the prevention and treatment of autoimmune and allergic
 CC diseases, and in the diagnosis and investigation of such disorders.
 CC
 XX Sequence 200 AA;
 SQ
 Query Match 84.8%; Score 907; DB 19; Length 200;
 Best Local Similarity 84.0%; Pred. No. 5.6e-94;
 Matches 168; Conservative 14; Mismatches 18; Indels 0; Gaps 0;
 Qy 1 MKPYFSCVFCFLIKLTGELNDLANHRMFSFHDGGVQISCNYPETVQQLKMLFKDRE 60
 Db 1 mkpyfchvfchfllrltgeingsadhrmfshngvgqiskypetvqqlkmlfrere 60
 Qy 61 VLCDLTTKSGNTVSTKNPMSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPPFQ 120
 Db 61 vlceltktgsgnavsiknplmcliyhsnnsvsfflnpdpssggyfcslsifdpppfq 120
 Qy 121 EKNLSGGVLLIYESQLCCOLKWLPGVCAAFVAALLFCCIFIVWFAKKYRSSVHDENSE 180
 Db 121 ernlsqgyllhyesqlccqkklwlpvglpafvllfgcillilwfskkygssvhdnpse 180
 Qy 181 YMFMAAVNTNKKSLAGMTS 200
 Db 181 ymfmaavntnkkslagmts 200
 RESULT 6
 AAW75956
 ID AAW75956 standard; Protein; 199 AA.
 XX
 AC AAW75956;
 XX

DT 11-DEC-1998 (first entry)
 XX Human cell surface protein #1.
 DE
 XX
 KW Human; cell surface protein; thymocyte; lymphocyte; cell adhesion;
 KW signal transmission; autoimmune disorder; allergy; diagnosis;
 KW mitogen-stimulated.
 XX
 XX Homo sapiens.
 XX
 XX WO9838216-A1.
 PN
 XX
 PD 03-SEP-1998.
 PD
 XX 27-FEB-1998; 98WO-JP00837.
 XX
 XX 26-FEB-1998; 98JP-0062217.
 PR
 PR 27-FEB-1997; 97JP-0062290.
 PR
 XX
 XX (NISB) JAPAN TOBACCO INC.
 PA
 XX Tamatani T, Tezuka K;
 XX
 XX WPI; 1998-481144/41.
 DR
 DR N-PSDB; AAV53198.
 XX
 XX Cell surface molecule expressed in thymocytes and lymphocytes and -
 PT mediating signal transmission and cell adhesion, and antibodies to
 PT it useful in treatment of auto-immune and allergic disorders.
 XX
 XX Claim 2; Page 99-101; 149pp; Japanese.
 PS
 XX The present sequence represents a human cell surface protein which is
 CC expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell
 CC surface protein induces adhesion of mitogen-stimulated lymphocytes to
 CC antibodies recognising the cell surface protein. These antibodies also
 CC produce an increase in peripheral blood lymphocytes in the presence of
 CC an antibody recognising CD3 antigen. The cell surface protein contains
 CC the amino acid sequence FPPPP in its extracellular region and the
 CC sequence YPMF in its intracellular region. The cell surface protein can
 CC be used in the prevention and treatment of autoimmune and allergic
 CC diseases, and in the diagnosis and investigation of such disorders.
 CC
 XX Sequence 199 AA;
 SQ
 Query Match 65.5%; Score 701; DB 19; Length 199;
 Best Local Similarity 67.9%; Pred. No. 9.7e-71;
 Matches 133; Conservative 17; Mismatches 42; Indels 4; Gaps 2;
 Qy 4 YFSCVFCFLIKLTGELNDLANHRMFSFHDGGVQISCNYPETVQQLKMLFKDREVL 63
 Db 7 yf---flfclrikvltgeingsanyemfifhngvgqilckypdivqqlkmlkggqilc 63
 Qy 64 DLTKTKSGNTVSTKNPMSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPPFQ 123
 Db 64 dltktksgntvstksikfchsqisnnsvsfflnldshanyfclnlsifdpppf-kvt 122
 Qy 124 LSGGYLLIYESQLCCOLKWLPGVCAAFVAALLFCCIFIVWFAKKYRSSVHDENSEYMF 183
 Db 123 ltgsgyllhyesqlccqkklwlpvglpafvllfgcillilwfskkygssvhdnpgeymf 182
 Qy 184 MAAVNTNKKSLAGMT 199
 Db 183 mravntakksrltdvt 198
 RESULT 7
 AAW75957
 ID AAW75957 standard; Protein; 199 AA.
 XX
 AC AAW75957;
 XX

[illegible]

CC haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
CC diseases (e.g., rheumatoid arthritis), inflammation, allergies, autoimmune
CC neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
CC cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
CC psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
CC angioinfectious disorders, kidney disorders, gastrointestinal disorders,
CC pregnancy-related disorders, endocrine disorders, and infections. The
CC proteins can also be used to aid wound healing and epithelial cell
CC proliferation, to prevent skin aging due to sunburn, to maintain organs
CC before transplantation, for supporting cell culture of primary tissues,
CC to regenerate tissues, to identify their cognate ligands or binding
CC partners, and in chemotaxis, and can be used as a food additive or
CC preservative to modify storage properties. Antibodies specific for a
CC protein of the invention can be used in alleviating symptoms associated
CC with the disorders mentioned above, and in diagnostic immunoassays e.g.,
CC radioimmunoassay or enzyme linked immunosorbent assay (ELISA).
CC The present sequence represents a human secreted protein of
CC the invention.
XX
SQ Sequence 199 AA;
Query Match 65.5%; Score 701; DB 22; Length 199;
Best Local Similarity 67.9%; Pred. No. 9.7e-71;
Matches 133; Conservative 17; Mismatches 42; Indels 4; Gaps 2;
QY 4 YFSCVVFVFCFLIKLTGELNDLANHRMFSFHDGGVQVSCNYPETVQQLKMQLFKDREVLG 63
Db 7 YF---fifclrikvltgeingsanyemfifhngvgvqlckypdivqfkmqlkggqilc 63
QY 64 DLTKGSGNTVSTKNMSPCYQLSNNSVSFFLNDADSSQGSYFLCSLSIFDPPPFQEN 123
Db 64 dltkgsgntvstkslckfchqslsnsvsflyndhshanyfncslsfidpppf-kvt 122
QY 124 LSGGYLLIYESQLCCQLKMLPVGCAAFVAALLFGCIFVWFAKKYRSSHVDNPSYMF 183
Db 123 ltggyllhyesqlccqlkfwlpigcaafvvcilgclilcwlttkkysvshvdpngymf 182
QY 184 MAAVNTNKKSLAGMT 199
Db 183 mravntakksrltdvt 198
RESULT 11
AAE03460
ID AAE03460 standard; Protein; 199 AA.
AC AAE03460;
XX
DY 0-AUG-2001 (first entry)
XX Human gene 2 encoded secreted protein HT25G64, SEQ ID NO: 143.
XX
KW Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
KW foetal abnormality; developmental abnormality; haematopoietic disorder;
KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW Parkinson's disease; cognitive disorder; schizophrenia; skin disorder;
KW psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
KW inflammation; neurological disorder; Alzheimer's disease; food additive;
KW angioinfectious disorder; kidney disorder; gastrointestinal disorder; allergy;
KW pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW cell culture; chemotaxis; vulnerable; binding partner identification;
KW gene therapy.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX 1..19
XX /label= Signal_peptide
XX 20..199
XX /note= "Mature human secreted protein"
XX
XX W0200132675-A1.

XX 10-MAY-2001.
XX
XX 25-OCT-2000; 2000WO-US29363.
XX
XX 29-OCT-1999; 99US-0162239.
XX
XX 30-JUN-2000; 2000US-0215139.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ruben SM, Komatsoulis GA, Wei P, Baker KP, Young PE;
XX WPI; 2001-328772/34.
XX
XX N-PSDB; AAD07842.
XX
XX Thirty two human secreted proteins, useful for treating cancers,
XX hyperproliferative disorders, inflammatory disorders, neurological
XX disorders, autoimmune diseases and cardiovascular disorders -
XX
XX Claim 11; Page 489-490; 576pp; English.
XX
XX AAD07809-AAD07907 represent cDNAs corresponding to 32 human secreted
XX protein genes, and AAE03427-AAE03523 represent the proteins they encode.
XX AAE03524-AAE03537 represent human secreted protein fragments or variants.
XX The secreted proteins and their genes are useful for preventing, treating
XX or ameliorating medical conditions, e.g., by protein or gene therapy.
XX Pathological conditions can be diagnosed by determining the amount of the
XX new protein in a sample or by determining the presence of mutations in
XX the new genes. Specific uses are described for each of the 32 genes,
XX based on the tissues in which they are most highly expressed, and include
XX developing products for the diagnosis or treatment of proliferative
XX disorders, cancer, tumours, foetal and developmental abnormalities,
XX haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
XX diseases (e.g., rheumatoid arthritis), inflammation, allergies,
XX neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
XX cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
XX psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
XX angioinfectious disorders, kidney disorders, gastrointestinal disorders,
XX pregnancy related disorders, endocrine disorders, and infections. The
XX proteins can also be used to aid wound healing and epithelial cell
XX proliferation, to prevent skin aging due to sunburn, to maintain organs
XX before transplantation, for supporting cell culture of primary tissues,
XX to regenerate tissues, to identify their cognate ligands or binding
XX partners, and in chemotaxis, and can be used as a food additive or
XX preservative to modify storage properties. Antibodies specific for a
XX protein of the invention can be used in alleviating symptoms associated
XX with the disorders mentioned above, and in diagnostic immunoassays e.g.,
XX radioimmunoassay or enzyme linked immunosorbent assay (ELISA).
XX The present sequence represents a human secreted protein of
XX the invention.
XX
SQ Sequence 199 AA;
Query Match 65.5%; Score 701; DB 22; Length 199;
Best Local Similarity 67.9%; Pred. No. 9.7e-71;
Matches 133; Conservative 17; Mismatches 42; Indels 4; Gaps 2;
QY 4 YFSCVVFVFCFLIKLTGELNDLANHRMFSFHDGGVQVSCNYPETVQQLKMQLFKDREVLG 63
Db 7 YF---fifclrikvltgeingsanyemfifhngvgvqlckypdivqfkmqlkggqilc 63
QY 64 DLTKGSGNTVSTKNMSPCYQLSNNSVSFFLNDADSSQGSYFLCSLSIFDPPPFQEN 123
Db 64 dltkgsgntvstkslckfchqslsnsvsflyndhshanyfncslsfidpppf-kvt 122
QY 124 LSGGYLLIYESQLCCQLKMLPVGCAAFVAALLFGCIFVWFAKKYRSSHVDNPSYMF 183
Db 123 ltggyllhyesqlccqlkfwlpigcaafvvcilgclilcwlttkkysvshvdpngymf 182
QY 184 MAAVNTNKKSLAGMT 199
Db 183 mravntakksrltdvt 198

PT Crohn's diseases, arthritis, insulin dependent diabetes and
XX autoimmunity

PS Claim 16; Page 138-139; 159pp; English.

XX This Th2-specific polypeptide, which has similarity to human CD28 and
CC human CTLA-4 is encoded by human orthologue h1228.
CC A novel method for modulating a Th2 response, an immune response, or
CC suppressing airway inflammation or hyperresponsiveness in a mammal
CC comprises administering a Th2-specific polypeptide of the invention, an
CC antibody to such a polypeptide or allelic variants of the genes. The
CC novel DNA and polypeptide sequences are useful for treatment and
CC diagnosis of Th cell and Th cell-like disorders such as Crohn's diseases,
CC arthritis, insulin dependent diabetes, autoimmunity, multiple sclerosis,
CC dermatitis, psoriasis, graft rejection, graft versus host diseases,
CC sarcoidosis, asthma, allergies, conjunctivitis, glomerular nephritis,
CC viral infections (including human immunodeficiency virus (HIV)),
CC bacterial infections, bronchitis, cystic fibrosis, diptheria,
CC emphysema, pneumonia, and Legionnaires disease.

SC Sequence 198 AA;

Query Match 64.1%; Score 685.5; DB 21; Length 198;
Best Local Similarity 67.3%; Pred. No. 5.4e-69;
Matches 132; Conservative 17; Mismatches 42; Indels 5; Gaps 3;

QY 4 YFSCVFVFCFLIKLTGEINLIANHRMFSFHDGGVQVQISCNYPETVQQLKMQLFKDEVLIC 63
DB 7 YF---fLcLrIkvtgeinsanyemfifngvgqilckypdivgqfkmqlkggqilc 63
QY 64 DITKTKGSGNTVSIKPNMPCPYQLSNNSVSFLDNADSSQGSYFLCSLSIFDPPPFQEK 123
DB 64 dltktkgsgntvsklksfchsqslsnnsvsfflynlhdshanyfcnlisifdpppf-kvt 122
QY 124 LSGGYLLIYESOLCCQLKLWLPVGCFAAFVAALLFGCIFTWFAKKYRSSVHDPNSEYMF 183
DB 123 lsggyllhyesqlccqlkfwlpigcaafvvcilgcilicwlt-kkyssvhdngymf 181
QY 184 MAAVNTNKKSLAGMT 199
DB 182 mravntakksrltdvt 197

RESULT 14
AAB67717
ID AAB67717 standard; Protein; 380 AA.

XX AAB67717;

DT 11-JUN-2001 (first entry)

DE Amino acid sequence of mICOS-mIgG2am fusion protein.

XX GL50; antigen; antigen presenting cell; T cell proliferation; tumour;
KW graft-versus-host disease; autoimmune disease; allergy; viral infection;
KW acquired immune deficiency syndrome; AIDS; vaccine.

OS Synthetic.

OS Mus musculus.

XX WO200121796-A2.

XX 29-MAR-2001.

XX 21-SEP-2000; 2000WO-US25892.

XX 21-SEP-1999; 99US-0155043.

XX (GEMY) GENETICS INST INC.

XX Ling V, Dunussi-Joannopolulos K;

XX

WPI: 2001-244938/25.
N-PSDB; AAF79940.

DR New isolated nucleic acid encoding a GL50 polypeptide for modulating a
XX immune response and reducing the proliferation of a tumour cell -
PT Immune response; Fig 27B; 195pp; English.
PS Disclosure; Fig 27B; 195pp; English.

XX The present sequence represents a fusion protein, comprising murine ICOS
CC (mICOS) and murine IgG2a (mIgG2A). The fusion protein is used in the
CC course of the invention. The specification describes GL50 polypeptides.
CC GL50 molecules are antigens on the surface of antigen presenting cells,
CC which costimulate T cell proliferation and bind to costimulatory receptor
CC ligands on T cells. GL50 modulating agents are used to modulate an immune
CC response in a subject. GL50 polypeptides are used to modulate T cell
CC costimulation, and to reduce the proliferation of a tumour cell. Diseases
CC that can be treated using GL50 molecules are graft-versus-host disease,
CC autoimmune disease, allergies, acquired immune deficiency syndrome
CC (AIDS), and viral infections. The GL50 molecules can be used in vaccines.
CC GL50 polynucleotides can be used to locate gene regions associated with
CC genetic disease, in tissue typing, and in forensic identification of a
CC biological sample.

SC Sequence 380 AA;

Query Match 51.6%; Score 552; DB 22; Length 380;
Best Local Similarity 83.6%; Pred. No. 1.6e-53;
Matches 102; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

QY 21 ELNDLIANHRMFSFHDGGVQVQISCNYPETVQQLKMQLFKDEVLICLTKTGSGNTVSIKPN 80
DB 26 eangsadhmrtsfhngvgqiscypetvqqlkmrlfrerevceltktkgsgnavsiknp 85
QY 81 MSCPTQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPPFQEKNLGGYLLIYESQLCCOL 140
DB 86 mclcyhlslsnnsvsfflnpdssgsgyyfcslsifdpppfqernlsggyhlhyesqlccql 145
QY 141 KL 142
DB 146 kl 147

RESULT 15
AAB67716
ID AAB67716 standard; Protein; 379 AA.

XX AAB67716;

DT 11-JUN-2001 (first entry)

DE Amino acid sequence of hICOS-mIgG2am fusion protein.

XX GL50; antigen; antigen presenting cell; T cell proliferation; tumour;
KW graft-versus-host disease; autoimmune disease; allergy; viral infection;
KW acquired immune deficiency syndrome; AIDS; vaccine.

OS Synthetic.

OS Homo sapiens.

OS Mus musculus.

XX WO200121796-A2.

XX 29-MAR-2001.

XX 21-SEP-2000; 2000WO-US25892.

XX 21-SEP-1999; 99US-0155043.

XX (GEMY) GENETICS INST INC.

XX Ling V, Dunussi-Joannopolulos K;

XX

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:27:00 ; Search time 28.8 Seconds
(without alignments)
169.622 Million cell updates/sec

Title: US-09-383-551B-13
Perfect score: 1070
Sequence: 1 MKPYSCVFVFCFLIKLLTG.....YMFMAVNTNKKSLAGWTS 200

Scoring table: BLOSUMP62
Gapop 10.0 , Gapext 0.5

Searched: 231628 seqs, 24425594 residues

Total number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/2/iaa/5A.COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B.COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A.COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B.COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/6C.COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	140	13.1	220	3	US-08-228-208A-21
2	130.5	12.2	223	1	Sequence 21, Appli
3	130.5	12.2	223	1	Sequence 5, Appli
4	130.5	12.2	223	2	US-08-459-818-25
5	130.5	12.2	223	2	Sequence 25, Appli
6	130.5	12.2	223	2	Sequence 25, Appli
7	130.5	12.2	223	2	Sequence 25, Appli
8	130.5	12.2	223	2	Sequence 25, Appli
9	120.5	11.3	218	3	US-08-228-208A-20
10	116.5	10.9	134	3	US-08-630-172-3
11	116.5	10.9	134	4	US-09-375-419-3
12	112.5	10.5	367	3	US-08-630-172-19
13	112.5	10.5	367	4	US-09-375-419-19
14	110.5	10.3	110	4	US-09-460-384-33
15	108.5	10.1	225	1	US-08-505-058-4
16	108.5	10.1	225	2	US-08-459-818-24
17	108.5	10.1	225	2	US-08-889-666-24
18	108.5	10.1	225	2	US-08-465-078-24
19	108.5	10.1	225	2	US-08-488-062-24
20	97	9.1	218	3	US-08-228-208A-19
21	90.5	8.5	221	3	US-08-228-208A-22
22	86	8.0	225	1	US-08-505-058-3
23	86	8.0	225	2	US-08-459-818-23
24	86	8.0	225	2	US-08-889-666-23
25	86	8.0	225	2	US-08-465-078-23
26	86	8.0	225	2	US-08-725-776-23
27	86	8.0	225	2	US-08-488-062-23

28 81.5 7.6 117 2 US-08-529-878B-39 Sequence 39, Appli
29 81.5 7.6 226 1 US-08-505-058-6 Sequence 6, Appli
30 81.5 7.6 226 2 US-08-459-818-26 Sequence 26, Appli
31 81.5 7.6 226 2 US-08-889-666-26 Sequence 26, Appli
32 81.5 7.6 226 2 US-08-465-078-26 Sequence 26, Appli
33 81.5 7.6 226 2 US-08-725-776-26 Sequence 26, Appli
34 81.5 7.6 226 2 US-08-488-062-26 Sequence 26, Appli
35 76 7.1 803 1 US-08-158-232-10 Sequence 10, Appli
36 76 7.1 803 1 US-08-304-626-10 Sequence 10, Appli
37 76 7.1 803 1 US-08-316-301A-12 Sequence 12, Appli
38 76 7.1 803 2 US-08-611-928-10 Sequence 10, Appli
39 76 7.1 803 3 US-09-173-891-10 Sequence 10, Appli
40 76 7.1 803 4 US-09-076-137-12 Sequence 12, Appli
41 76 7.1 803 5 PCT-US92-03624-12 Sequence 12, Appli
42 75 7.0 682 2 US-08-436-900A-4 Sequence 4, Appli
43 74.5 7.0 223 3 US-08-228-208A-17 Sequence 17, Appli
44 73.5 6.9 474 4 US-09-362-473-4 Sequence 4, Appli
45 73 6.8 187 1 US-08-067-684-14 Sequence 14, Appli

ALIGNMENTS

RESULT 1
US-08-228-208A-21
; Sequence 21, Application US/08228208A
; Patent No. 6090914
; GENERAL INFORMATION:
; APPLICANT: Linsley, Peter S.
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Damle, Nitin K.
; APPLICANT: Brady, William
; APPLICANT: Wallace, Philip M.
; TITLE OF INVENTION: CTAA/CD28Ig HYBRID FUSION
; TITLE OF INVENTION: PROTEINS AND USES THEREOF
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 11150 Santa Monica Boulevard, Suite 400
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/228,208A
; FILING DATE: 15-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/008,898
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: 07/723,617
; FILING DATE: 27-JUN-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Adriano, Sarah B
; REGISTRATION NUMBER: 34,470
; REFERENCE/DOCKET NUMBER: 30436-30US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 310 445-1140
; TELEFAX: 310 445-9031
; TELEX:
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 220 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-228-208A-21

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:27:45 ; Search time 37.55 Seconds
(without alignments)
511.794 Million cell updates/sec

Title: US-09-383-551b-13
Perfect score: 1070
Sequence: 1 MKPYFSCVFVFCFLIKLLTG.....YMFMAAVNTNKKSLAGMTS 200

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283138 seqs, 96089334 residues

To: number of hits satisfying chosen parameters: 283138

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

PIR_71.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	1070	100.0	200	2 JC7397	activation-inducib
2	1056	98.7	216	2 JC7396	activation-inducib
3	701	65.5	199	2 S78340	inducible T-cell c
4	141	13.2	220	1 RWH028	T-cell surface gly
	131	12.2	221	2 I46689	CD28 precursor - r
	108.5	10.1	218	2 S24413	T-cell surface gly
	104	9.7	173	2 I46197	cell surface prote
8	99	9.3	218	2 A43523	T-cell surface gly
9	92.5	8.6	221	2 S25168	CHR28 protein - ch
10	84.5	7.9	402	2 S58477	rdsl protein - fis
11	80.5	7.5	360	2 T26270	hypothetical prote
12	79.5	7.4	658	2 T39495	hypothetical prote
13	79	7.4	383	2 T21946	hypothetical prote
14	78	7.3	488	2 A42491	NADH dehydrogenase
15	77.5	7.2	964	2 E71460	probable outer mem
16	77.5	7.2	1036	2 S55984	probable membrane
17	77	7.2	817	2 T25758	hypothetical prote
18	76.5	7.1	1475	2 T29809	hypothetical prote
19	75.5	7.1	694	2 T33561	hypothetical prote
20	75.5	7.1	1351	2 C71607	hypothetical prote
21	75	7.0	186	2 S08614	cytotoxic T-lympho
22	75	7.0	223	2 T09536	cytotoxic T-lympho
23	75	7.0	681	2 S27868	givr-1 protein - m
24	74.5	7.0	1289	2 F72308	hypothetical prote
25	74	6.9	597	1 S53711	C4BP alpha chain p
26	74	6.9	2120	2 T30243	alpha tectorin - c
27	73.5	6.9	346	1 S03347	retinal degenerati
28	73.5	6.9	426	2 T41682	hypothetical prote
29	73	6.8	274	2 A54419	neutrophil inhibit

30 73 6.8 277 2 AH1710 maltodextrase util
31 73 6.8 787 2 H90543 conserved hypothet
32 72.5 6.8 489 2 S25943 NADH dehydrogenase
33 72.5 6.8 572 2 B28474 phosphotransferase
34 72.5 6.8 636 2 T06793 receptor kinase ho
35 72 6.7 260 2 T28119 hypothetical prote
36 72 6.7 647 2 D95098 topoisomerase IV,
37 72 6.7 758 2 C96749 hypothetical prote
38 72 6.7 1296 2 I40645 botulinum neurotox
39 72 6.7 1317 2 A54831 nuclear pore compl
40 71.5 6.7 184 2 A81280 probable integral
41 71.5 6.7 426 2 T51861 hypothetical prote
42 71.5 6.7 454 2 JC4886 bleomycin hydrolas
43 71.5 6.7 679 2 I52822 leukemia virus rec
44 71.5 6.7 1290 2 S73653 DNA-directed RNA p
45 71.5 6.7 1337 2 B64993 hypothetical prote

ALIGNMENTS

RESULT 1

JC7397

activation-inducible lymphocyte immuno-mediatory molecule-2 - rat

C:Species: Rattus norvegicus (Norway rat)

C:Date: 17-Nov-2000 #sequence_revision 17-Nov-2000 #text_change 17-Nov-2000

C:Accession: JC7397; PC7100

R:Tezuka, K.; Tsuji, T.; Hirano, D.; Tamatani, T.; Sakamaki, K.; Kobayashi, Y.; Kamad

Biochem. Biophys. Res. Commun. 276, 335-345, 2000

A:Title: Identification and characterization of rat ALLIM/ICOS, a novel T-cell costim

A:Reference number: JC7396

A:Contents: Spleen

A:Accession: JC7397

A:Molecule type: mRNA

A:Residues: 1-200 <TEZ>

A:Cross-references: DDBJ:AB023134

A:Accession: PC7100

A:Molecule type: protein

A:Residues: 21-40 <TE2>

C:Comment: This protein is an inducible cell surface glycoprotein, and a type I trans on, and plays an important role for the maturation or selection of T cells in thymus.

C:Genetics:

A:Gene: ailim-2

C:Keywords: glycoprotein; T-cell; transmembrane protein

Query Match 100.0%; Score 1070; DB 2; Length 200;
Best Local Similarity 100.0%; Pred. No. 2e-94;
Matches 200; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MKPYFSCVFVFCFLIKLLTGELNDLANHRMFSFHDGGVQISCNYPETVQOLKMLQDKRE 60

Db 1 MKPYFSCVFVFCFLIKLLTGELNDLANHRMFSFHDGGVQISCNYPETVQOLKMLQDKRE 60

Qy 61 VLCDLTTRKSGNTVSIKNPMNSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPFPQ 120

Db 61 VLCDLTTRKSGNTVSIKNPMNSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPFPQ 120

Qy 121 EKNLSGGVLLIYESOLCCQLKMLPVGCAAFVAALLFGCIFVWFPAKKKKYRSSVHDNPSE 180

Db 121 EKNLSGGVLLIYESOLCCQLKMLPVGCAAFVAALLFGCIFVWFPAKKKKYRSSVHDNPSE 180

Qy 181 YMFMAAVNTNKKSLAGMTS 200

Db 181 YMFMAAVNTNKKSLAGMTS 200

RESULT 2

JC7396

activation-inducible lymphocyte immuno-mediatory molecule-1 - rat

C:Species: Rattus norvegicus (Norway rat)

C:Date: 17-Nov-2000 #sequence_revision 17-Nov-2000 #text_change 17-Nov-2000

C:Accession: JC7396; PC7099

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:33:24 ; Search time 20.28 Seconds
(without alignments)
381.850 Million cell updates/sec

Title: US-09-383-551B-13

Perfect score: 1070

Sequence: 1 MKPYFSCVFCEFLIKLLTG.....YMFMAAVNTNKKSLAGMTS 200

Scoring table:

BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 105224 seqs, 38719550 residues

TC: number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	141	13.2	220	1 CD28_HUMAN	P10747 homo sapien
2	131	12.2	221	1 CD28_RABIT	P42069 oryctolagus
3	129.5	12.1	219	1 CD28_BOVIN	Q28071 bos taurus
4	115.5	10.8	218	1 CD28_RAT	P31042 rattus norv
5	99	9.3	218	1 CD28_MOUSE	P31041 mus musculu
6	92.5	8.6	221	1 CD28_CHICK	P31043 gallus gall
7	84.5	7.9	402	1 RDS1_SCHPO	P53693 schizosacch
8	77.5	7.2	1036	1 YG35_YEAST	O48477 chlamydia t
9	77.5	7.2	1036	1 YG35_YEAST	P53273 saccharomyc
10	77	7.2	488	1 NU2M_OENBE	P93401 oenothera b
11	76	7.1	803	1 CDA4_BACTU	O45755 bacillus th
12	75	7.0	223	1 CTL4_HUMAN	P16410 homo sapien
13	73.5	6.9	346	1 RDS_MOUSE	P15499 mus musculu
14	72.5	6.8	489	1 NU2M_MARPO	P26846 marchantia
15	72.5	6.8	572	1 PTLB_STAAR	P11162 staphylococ
16	72	6.7	259	1 PSA3_CAEEL	O09583 caenorhabdi
17	72	6.7	647	1 PARE_STREN	O59961 streptococc
18	72	6.7	1295	1 BXA2_CLOBO	O45894 clostridium
19	72	6.7	1317	1 N145_YEAST	P49687 saccharomyc
20	71.5	6.7	454	1 BLMH_RAT	P70645 rattus norv
21	71.5	6.7	1290	1 RPOC_MYCPN	P75271 mycoplasma
22	71	6.6	260	1 PCNA_DROME	P17917 drosophila
23	71	6.6	345	1 RDS_BOVIN	P17810 bos taurus
24	71	6.6	1277	1 NPC1_PIG	P56941 sus scrofa
25	71	6.6	1419	1 MDR_PLAFF	P13568 plasmodium
26	70.5	6.6	198	1 MCRC_METTM	P11566 methanobact
27	70.5	6.6	354	1 RDS_CHICK	O42281 gallus gall
28	70.5	6.6	563	1 SVR_CHLTR	O84460 chlamydia t
29	70.5	6.6	896	1 IF2_CHLMU	O98ku0 chlamydia m
30	70	6.5	223	1 CTL4_RABIT	P42072 oryctolagus
31	70	6.5	343	1 SLAM_MOUSE	Q9qum4 mus musculu
32	70	6.5	495	1 SPKF_SYNY3	P73469 synechocyst
33	70	6.5	1295	1 BXA1_CLOBO	P10845 clostridium

34 70 6.5 2146 1 INSR_DROME P09208 drosophila
35 70 6.5 2516 1 CCAD_DROME Q24270 drosophila
36 69.5 6.5 346 1 RDS_CANFA P52204 canis faml
37 69.5 6.5 723 1 YE7A_SCHPO O14162 schizosacch
38 69.5 6.5 1092 1 DHE2_YEAST P33327 saccharomyc
39 69 6.4 396 1 CSA_HUMAN O13216 homo sapien
40 69 6.4 1237 1 YG2L_YEAST P53254 saccharomyc
41 68.5 6.4 526 1 YHVL_YEAST P38849 saccharomyc
42 68.5 6.4 544 1 DSK1_SCHPO P36616 schizosacch
43 68.5 6.4 560 1 P2B2_DROME Q27889 drosophila
44 68.5 6.4 612 1 GIDA_MYCCE P47619 mycoplasma
45 68.5 6.4 856 1 NCKX_DROME Q9u6a0 drosophila

ALIGNMENTS

RESULT 1
CD28_HUMAN
ID CD28_HUMAN STANDARD; PRT; 220 AA.
AC P10747;
DT 01-JUL-1989 (Rel. 11, Created)
DT 01-JUL-1989 (Rel. 11, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE T-cell-specific surface glycoprotein CD28 precursor (TP44).
GN CD28.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=88068631; PubMed=2825196;
RA Aruffo A., Seed B.;
RT "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell
expression system";
RL Proc. Natl. Acad. Sci. U.S.A. 84:8573-8577(1987).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=90293482; PubMed=2162892;
RA Lee K.P., Taylor C., Petryniak B., Turka L.A., June C.H.,
Thompson C.B.;
RT "The genomic organization of the CD28 gene. Implications for the
regulation of CD28 mRNA expression and heterogeneity";
RL J. Immunol. 145:344-352(1990)
CC -!- FUNCTION: POSSIBLY INVOLVED IN T-CELL ACTIVATION. BINDS TO B7-1
AND B7-2 (B70).
CC -!- SUBUNIT: HOMODIMER; DISULFIDE-LINKED.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -!- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.
CC -!- DATABASE: NAME=PROW; NOTE=CD guide CD28 entry;
WWW="http://www.ncbi.nlm.nih.gov/prow/cd/cd28.htm".

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).

EMBL; J02988; AAA60581.1; -;
EMBL; M37815; AAA51944.1; -;
EMBL; M37812; AAA51944.1; JOINED.
EMBL; M37813; AAA51944.1; JOINED.
EMBL; M37814; AAA51944.1; JOINED.
PIR; A39983; RWHU28.
HSP; P16410; 1AHL.
MIM; I86760; -;
InterPro; IPR003600; Ig-like.
SMART; SM00410; IG-like; 1.
KW Immunoglobulin domain; T-cell; Glycoprotein; Signal; Transmembrane.

```
FT SIGNAL 1 18
FT CHAIN 19 220
FT T-CELL-SPECIFIC SURFACE GLYCOPROTEIN
FT CD28.
FT EXTRACELLULAR (POTENTIAL).
FT TRANSMEM
FT DOMAIN 153 179
FT DOMAIN 180 220
FT CYTOPLASMIC (POTENTIAL).
FT IG-LIKE V-TYPE DOMAIN.
FT CARBOHYD 37 137
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 38 137
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 71 71
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 92 92
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 105 105
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 129 129
FT N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 220 AA; 25066 MW; 1D9B6552A5878D0F CRC64;

Query Match 13.2%; Score 141; DB 1; Length 220;
Best Local Similarity 24.1%; Pred. No. 1.5e-06;
Matches 41; Conservative 34; Mismatches 77; Indels 18; Gaps 5;

30 MFSFHDGGVQISCNYPETV--QOLKMQLFKDRVCLDLTKTKGSGN---TVSIKNPMSCP 84
28 MLVAVDNVNLCKYSYNLFSREFRSLHKLGLDSAVEVCVVYGVNSQQLQVYSKGTGFNCD 87
85 YOLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPPFQEKNLGGYLLIYESQLCCQLK-- 142
88 KGLGNESTVTFYQLNLYVNTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKGHLCPSPLPF 147
143 -----WLPVGCAGFA--ALLFGCIFVWFAKKYRSSHVDNPNSEYMF 184
148 GPSKPFVWLVVGVGLACYSLVTVAFIFWVRSRSLH---SDYMMN 194

RESULT 2
CD28_RABIT
ID CD28_RABIT STANDARD; PRT; 221 AA.
AC P42069;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE T-cell-specific surface glycoprotein CD28 precursor.
GN CD28.
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OX NCBI_TaxID:9986;
RN [1]
RP SEQUENCE FROM N.A.
RA STRAIN-B/J X CHBB:HM;
RA MEDLINE=95369849; PubMed=7642234;
RT Isono T., Seto A.;
RT "Cloning and sequencing of the rabbit gene encoding T-cell
RT costimulatory molecules";
RL Immunogenetics 42:217-220(1995).
CC -!- FUNCTION: POSSIBLY INVOLVED IN T-CELL ACTIVATION. BINDS TO B7-1
CC AND B7-2 (B70). (BY SIMILARITY).
CC -!- SUBUNIT: HOMODIMER; DISULFIDE-LINKED (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -!- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL: D49841; BAA08641.1; -.
DR InterPro; IPR003600; Ig_like.
DR SMART; SM00410; Ig_like; 1.
KW Immunoglobulin domain; T-cell; Glycoprotein; Signal; Transmembrane.
FT SIGNAL 1 19
FT BY SIMILARITY.
```

```
FT CHAIN 20 221
FT T-CELL-SPECIFIC SURFACE GLYCOPROTEIN
FT CD28.
FT EXTRACELLULAR (POTENTIAL).
FT TRANSMEM
FT DOMAIN 151 177
FT DOMAIN 178 221
FT CYTOPLASMIC (POTENTIAL).
FT IG-LIKE V-TYPE DOMAIN.
FT CARBOHYD 38 38
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 72 72
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 93 93
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 106 106
FT N-LINKED (GLCNAC. .) (POTENTIAL).
FT CARBOHYD 130 130
FT N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 221 AA; 25307 MW; 3DF652C9CF14F13 CRC64;

Query Match 12.2%; Score 131; DB 1; Length 221;
Best Local Similarity 22.2%; Pred. No. 1.4e-05;
Matches 39; Conservative 32; Mismatches 75; Indels 30; Gaps 6;

30 MFSFHDGGVQISCNYPETV--QOLKMQLFKDRVCLDLTKTKGSGNTVSIRNP----- 80
29 MLVAVNNVNLCKTYNLFSEFRASLYKGADSAVEVCVVNG-----NFSHPHQFHSST 83
81 -MSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPPFQEKNLGGYLLIYESQLCC- 138
84 GFNCCKLGNETVTFYKLNLYVNTDIYFCKIEVMYPPPYLDNEKSNGTIIHVKEQHFCEP 143
139 -----QLKLWLPV---GCAAFVALLFGCIFVWFAKKYRSSHVDNPNSEYMF 184
144 AHPSPKSTLFVWLVVGVGLAFYSLVTVAFVLFSCWMSKKNRLL----QSDYMMN 195

RESULT 3
CD28_BOVIN
ID CD28_BOVIN STANDARD; PRT; 219 AA.
AC Q28071;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE T-cell-specific surface glycoprotein CD28 precursor.
GN CD28.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Eubovae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=96186531; PubMed=8606060;
RA Parsons K.R., Young J.R., Collins R.A., Howard C.J.;
RA "Cattle CTLA-4, CD28 and chicken CD28 bind CD86: MYPPEY is not
RT conserved in cattle CD28.";
RL Immunogenetics 43:388-391(1996).
CC -!- FUNCTION: POSSIBLY INVOLVED IN T-CELL ACTIVATION. BINDS TO B7-1
CC AND B7-2 (B70).
CC -!- SUBUNIT: HOMODIMER; DISULFIDE-LINKED (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -!- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC EMBL: X93304; CAA63707.1; -.
DR InterPro; IPR003600; Ig_like.
DR SMART; SM00410; Ig_like; 1.
KW Immunoglobulin domain; T-cell; Glycoprotein; Signal; Transmembrane.
FT SIGNAL 1 18
FT T-CELL-SPECIFIC SURFACE GLYCOPROTEIN
FT CHAIN 19 219
FT BY SIMILARITY.
```

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:34:34 ; Search time 63.42 Seconds
(without alignments)
545.553 Million cell updates/sec

Title: US-09-383-551b-13
Perfect score: 1070
Sequence: 1 MKPYFSCVFVFCFLIKLLTG.....YMFMAAVNTNKKSLAGMTS 200

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 562222 seqs, 172994929 residues

Tr number of hits satisfying chosen parameters: 562222

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

SPTREMBL_19:*

- 1: sp_archaea:*
- 2: sp_bacteria:*
- 3: sp_fungi:*
- 4: sp_human:*
- 5: sp_invertebrate:*
- 6: sp_mammal:*
- 7: sp_mhc:*
- 8: sp_organelle:*
- 9: sp_phase:*
- 10: sp_plant:*
- 11: sp_rodent:*
- 12: sp_virus:*
- 13: sp_vertebrate:*
- 14: sp_unclassified:*
- 15: sp_virus:*
- 16: sp_bacteriaph:*
- 17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1070	100.0	200	11	Q9RLT7
2	1056	98.7	216	11	Q9WVR9
3	922	86.2	200	11	Q9WVS0
4	922	86.2	200	11	Q9JL17
5	701	65.5	199	4	Q9Y6W8
6	137	12.8	220	6	Q9BDM8
7	131.5	12.3	219	6	Q97630
8	131	12.2	220	6	Q9BDM6
9	130	12.1	220	6	Q9BDN5
10	123	11.5	220	6	Q9BDN8
11	117	10.9	221	6	O02757
12	116	10.8	221	6	Q9N2I4
13	110.5	10.3	221	6	Q9N0N8
14	110	10.3	220	6	Q9BDN2
15	108	10.1	221	6	Q9GKP3
16	104	9.7	173	6	Q28289

17	100	9.3	221	11	Q9JLV4
18	88.5	8.3	223	6	Q9BDP1
19	87	8.1	579	10	Q9MAG9
20	87	8.1	3027	4	Q9Y4B5
21	83	7.8	401	4	Q96NFO
22	82	7.7	223	11	Q9JLV3
23	82	7.7	228	4	Q9H1E0
24	82	7.7	503	4	Q9NVP4
25	81	7.6	223	6	Q9BDC4
26	81	7.6	223	6	Q9BDN7
27	81	7.6	1531	4	Q96L95
28	80.5	7.5	360	5	Q9XUJ9
29	80	7.5	857	10	Q9LO97
30	79.5	7.4	658	3	Q94731
31	79	7.4	485	5	Q20139
32	77.5	7.2	332	13	Q9IB08
33	77.5	7.2	927	5	Q94232
34	77.5	7.2	2919	12	Q85431
35	76.5	7.1	1432	5	Q18647
36	76	7.1	139	1	Q9UXE6
37	76	7.1	682	11	Q9QVW6
38	75.5	7.1	337	5	Q9TZD7
39	75.5	7.1	417	8	Q9G341
40	75.5	7.1	650	5	Q9W1C7
41	75.5	7.1	1212	13	Q42347
42	73.5	7.1	1351	5	Q96242
43	75	7.0	681	11	Q61609
44	75	7.0	681	11	Q9LY09
45	74.5	7.0	417	8	Q9G3A1

ALIGNMENTS

RESULT 1

ID Q9RLT7 PRELIMINARY; PRT; 200 AA.
AC Q9RLT7;
DT 01-MAY-2000 (TRENBLrel. 13, Created)
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)
DT 01-DEC-2001 (TRENBLrel. 19, Last annotation update)
DE ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE AILIM
DE PRECURSOR.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20462959; PubMed=11006126;
RA Tezuka K., Tsuji T., Hirano D., Tamatani T., Sakamaki K.,
RA Kobayashi Y., Kamada M.;
RT "Identification and characterization of rat AILIM/ICOS, a novel T-cell
RT costimulatory molecule, related to the CD28/CTLA4 family.";
RL Biochem. Biophys. Res. Commun. 276:335-345(2000).
DR EMBL; AB023134; BAA82128.1; -.
KW Signal.
FT SIGNAL.
SQ SEQUENCE 200 AA; 22529 MW; 0A74C35581F129D4 CRC64;

Query Match 100.0%; Score 1070; DB 11; Length 200;
Best Local Similarity 100.0%; Pred. No. 1.4e-106;
Matches 200; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKPYFSCVFVFCFLIKLLTGELNDLANHRMFSFHGGVVOISCNYPETVQOLKMFCKDRE 60
|||||
DB 1 MKPYFSCVFVFCFLIKLLTGELNDLANHRMFSFHGGVVOISCNYPETVQOLKMFCKDRE 60
|||||
QY 61 VLCDLTKTGSGNTVSIKNPMSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPFPQ 120
|||||
DB 61 VLCDLTKTGSGNTVSIKNPMSCPYQLSNNSVSFFLDNADSSQGSYFLCSLSIFDPPFPQ 120
|||||

QY 121 EKNLSGGYLLIYESQLCCOLKWLPGVCAAFVAALLFGCIFTWFAKKYRSVHDPNSE 180
 DB 121 EKNLSGGYLLIYESQLCCOLKWLPGVCAAFVAALLFGCIFTWFAKKYRSVHDPNSE 180

QY 181 YMFMAAVNTNKKSLAGMVS 200
 DB 181 YMFMAAVNTNKKSLAGMVS 200

RESULT 2
 Q9WVR9 PRELIMINARY; PRT; 216 AA.
 ID Q9WVR9;
 AC Q9WVR9;
 DT 01-NOV-1999 (Tremblrel. 12, Created)
 DT 01-NOV-1999 (Tremblrel. 12, Last sequence update)
 DT 01-DEC-2001 (Tremblrel. 19, Last annotation update)
 DE ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE AILIM
 DE PRECURSOR.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=SPLEEN;
 RX MEDLINE=20462959; PubMed=11006126;
 RA Tezuka K., Tsuji T., Hirano D., Tamatani T., Sakamaki K.,
 RA Kobayashi Y., Kanada M.;
 RT "Identification and characterization of rat AILIM/ICOS, a novel T-cell
 RT costimulatory molecule, related to the CD28/CTLA4 family.";
 RL Biochem. Biophys. Res. Commun. 276:335-345(2000).
 DR EMBL; AB023133; BAA82127.1; -;
 KW Signal.
 FT SIGNAL.
 SQ SEQUENCE 1 20 POTENTIAL.
 SEQUENCE 216 AA; 24260 MW; 772E01320982B15A CRC64;

Query Match 98.7%; Score 1056; DB 11; Length 216;
 Best Local Similarity 100.0%; Pred. No. 4.8e-105;
 Matches 197; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKPYSCVVFVFCFLIKLTGELNDLANHRMFSFHGGVQVSCNYPETVQOLKMLFKDRE 60
 DB 1 MKPYSCVVFVFCFLIKLTGELNDLANHRMFSFHGGVQVSCNYPETVQOLKMLFKDRE 60

QY 61 VLCDLTKTGSGNTSVIKNPMSCPYQLSNNSVSFFLDNADSSQGSYFCLSLIFDPPPPQ 120
 DB 61 VLCDLTKTGSGNTSVIKNPMSCPYQLSNNSVSFFLDNADSSQGSYFCLSLIFDPPPPQ 120

QY 121 EKNLSGGYLLIYESQLCCOLKWLPGVCAAFVAALLFGCIFTWFAKKYRSVHDPNSE 180
 DB 121 EKNLSGGYLLIYESQLCCOLKWLPGVCAAFVAALLFGCIFTWFAKKYRSVHDPNSE 180

QY 181 YMFMAAVNTNKKSLAG 197
 DB 181 YMFMAAVNTNKKSLAG 197

RESULT 3
 Q9WVS0 PRELIMINARY; PRT; 200 AA.
 ID Q9WVS0;
 AC Q9WVS0;
 DT 01-NOV-1999 (Tremblrel. 12, Created)
 DT 01-NOV-1999 (Tremblrel. 12, Last sequence update)
 DT 01-JUN-2001 (Tremblrel. 17, Last annotation update)
 DE ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE AILIM
 DE PRECURSOR (CCLP PRECURSOR) (SURFACE PROTEIN).
 GN CCLP OR ICOS.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]

RP SEQUENCE FROM N.A.
 RC TISSUE=SPLEEN;
 RA Tezuka K., Tamatani T.;
 RT "Cell surface molecule mediating cell adhesion and signal
 RT transmission.";
 RL Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BAUB/C; TISSUE=SPLEEN;
 RA Wu D., Giannoni M.A., Kiesecker C.L., Faas S.J., Mickie A.P.,
 RA Matis L.A., Rother R.P.;
 RT "CCLP, A novel molecule that regulates T cell activation.";
 RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN=BAUB/C; TISSUE=SPLEEN;
 RX MEDLINE=20225659; PubMed=10760791;
 RA Mages H.W., Hutloff A., Heuck C., Buchner K., Himmelbauer H.,
 RA Oliveri F., Krocsek R.A.;
 RT "Molecular cloning and characterization of murine ICOS and
 RT identification of B7h as ICOS ligand.";
 RL Eur. J. Immunol. 30:1040-1047(2000).
 DR EMBL; AB023132; BAA82126.1; -;
 DR EMBL; AF257230; AAF70099.1; -;
 DR EMBL; AJ250559; CAB71153.1; -;
 DR MGD; MGI:1858745; ICOS.
 KW Signal.
 FT SIGNAL.
 SQ SEQUENCE 1 20 POTENTIAL.
 SEQUENCE 200 AA; 22690 MW; 9B2278E4CAB1DB47 CRC64;

Query Match 86.2%; Score 922; DB 11; Length 200;
 Best Local Similarity 85.0%; Pred. No. 9.6e-91;
 Matches 170; Conservative 14; Mismatches 16; Indels 0; Gaps 0;

QY 1 MKPYSCVVFVFCFLIKLTGELNDLANHRMFSFHGGVQVSCNYPETVQOLKMLFKDRE 60
 DB 1 MKPYSCVVFVFCFLIKLTGELNDLANHRMFSFHGGVQVSCNYPETVQOLKMLFKDRE 60

QY 61 VLCDLTKTGSGNTSVIKNPMSCPYQLSNNSVSFFLDNADSSQGSYFCLSLIFDPPPPQ 120
 DB 61 VLCDLTKTGSGNTSVIKNPMSCPYQLSNNSVSFFLDNADSSQGSYFCLSLIFDPPPPQ 120

QY 121 EKNLSGGYLLIYESQLCCOLKWLPGVCAAFVAALLFGCIFTWFAKKYRSVHDPNSE 180
 DB 121 EKNLSGGYLLIYESQLCCOLKWLPGVCAAFVAALLFGCIFTWFAKKYRSVHDPNSE 180

QY 181 YMFMAAVNTNKKSLAGMVS 200
 DB 181 YMFMAAVNTNKKSLAGMVS 200

RESULT 4
 Q9JL17 PRELIMINARY; PRT; 200 AA.
 ID Q9JL17;
 AC Q9JL17;
 DT 01-OCT-2000 (Tremblrel. 15, Created)
 DT 01-OCT-2000 (Tremblrel. 15, Last sequence update)
 DT 01-MAR-2001 (Tremblrel. 16, Last annotation update)
 DE CD28-RELATED PROTEIN 1 (INDUCIBLE COSTIMULATORY PROTEIN)
 DE (FRAGMENT).
 GN ICOS.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=INTESTINAL INTRA-EPITHELIAL;
 RA Yoshinaga S.K., Whoriskey J.S., Khare S.D., Sarmiento U., Guo J.,
 RA Horan T., Shih G., Zhang M., Coccia M.A., Kohno T., Tefuri-Bladt A.,
 RA Campbell P., Chang D., Chiu L., Dai T., Duncan G., Elliott G.S.,
 RA Hui A., McCabe S.M., Scully S., Shaklee C.L., Van G., Mak T.W.,

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:26:25 ; Search time 75.12 Seconds
(without alignments)
295.724 Million cell updates/sec

Title: US-09-383-551B-14
Perfect score: 1076
Sequence: 1 MKPYFCHVFVFCFLIRLTG.....YMFMAAVNTNKKSLAGVTS 200

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Tc number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_032802.*
1: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1980.DAT.*
2: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1981.DAT.*
3: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1982.DAT.*
4: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1983.DAT.*
5: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1984.DAT.*
6: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1985.DAT.*
7: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1986.DAT.*
8: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1987.DAT.*
9: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1988.DAT.*
10: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1989.DAT.*
11: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1990.DAT.*
12: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1991.DAT.*
13: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1992.DAT.*
14: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1993.DAT.*
15: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1994.DAT.*
16: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1995.DAT.*
17: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1996.DAT.*
18: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1997.DAT.*
19: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1998.DAT.*
20: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA1999.DAT.*
21: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA2000.DAT.*
22: /SIDSL/gcgdata/hold-geneseq/geneseq-emb1/AA2001.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1076	100.0	200	AAW75958	Mouse cell surface
2	1063	98.8	200	AA192212	Murine Th2-specific
3	1055	98.0	200	AA192212	Amino acid sequenc
4	907	84.3	200	AAW71874	Rat cell surface p
5	897	83.4	216	AAW71875	Rat cell surface p
6	722.5	67.1	199	AAW75956	Human cell surface
7	722.5	67.1	199	AAW75957	Human cell surface
8	722.5	67.1	199	AAW75958	Human activated T-
9	722.5	67.1	199	AAW75959	Amino acid sequenc
10	722.5	67.1	199	AAW75960	Human gene 2 encod
11	722.5	67.1	199	AAW75961	Human gene 2 encod

12	722.5	67.1	199	22	AAE03525	Human secreted pro
13	707	65.7	198	21	AAE03526	Human Th2-specific
14	657	61.1	380	22	AAE03527	Amino acid sequenc
15	449.5	41.8	379	22	AAE03528	Amino acid sequenc
16	136	12.6	220	13	AAE03529	Human CD28 antigen
17	136	12.6	220	13	AAE03530	Sequence encoded b
18	136	12.6	220	13	AAE03531	Human CD28 antigen
19	136	12.6	220	17	AAE03532	Human CD28 CDNA pr
20	136	12.6	220	17	AAE03533	Human CD28 antigen
21	136	12.6	220	19	AAE03534	CD28. Homo sapien
22	136	12.6	220	20	AAE03535	Human CD28 antigen
23	136	12.6	220	21	AAE03536	Human cell surface
24	136	12.6	220	21	AAE03537	Human CD28 recepto
25	136	12.6	220	21	AAE03538	Human lymphocyte c
26	131.5	12.2	223	20	AAE03539	Human CD28 protein
27	131	12.2	221	21	AAE03540	Feline CD28. Feli
28	131	12.2	221	21	AAE03541	Cat CD28 receptor.
29	121	11.2	134	18	AAE03542	Human CD28 for use
30	121	11.2	152	16	AAE03543	CD28 extracellular
31	117	10.9	367	18	AAE03544	Human CD28: IgG2a c
32	116.5	10.8	225	20	AAE03545	Rat CD28 protein s
33	94.5	8.8	225	20	AAE03546	Mouse CD28 protein
34	85.5	7.9	633	21	AAE03547	Eucalyptus grandis
35	84.5	7.9	223	18	AAE03548	Soluble human CTLA
36	84.5	7.9	223	22	AAE03549	Human CTLA4. Homo
37	84.5	7.9	223	22	AAE03550	Human CTLA4 protei
38	82.5	7.7	223	21	AAE03551	Feline CTLA-4. Fe
39	82.5	7.7	223	21	AAE03552	Human CTLA-4 prote
40	82.5	7.7	223	21	AAE03553	Cat CTLA-4 recepto
41	81.5	7.6	117	20	AAE03554	Human CD28 gene pr
42	80.5	7.5	226	20	AAE03555	Chicken CD28 prote
43	80	7.4	168	19	AAE03556	CTLA-4 extracellul
44	79.5	7.4	187	17	AAE03557	Human T cell speci
45	79.5	7.4	187	19	AAE03558	Soluble CTLA4 muta

ALIGNMENTS

RESULT 1
AAW75958
ID AAW75958 standard; Protein; 200 AA.
XX
AC AAW75958;
DT 11-DEC-1998 (first entry)
XX
DE Mouse cell surface protein.
XX
KW Mouse; cell surface protein; thymocyte; lymphocyte; cell adhesion;
KW signal transmission; autoimmune disorder; allergy; diagnosis;
KW mitogen-stimulated.
XX
OS Mus sp.
XX
PN W09838216-A1.
XX
PD 03-SEP-1998.
XX
PF 27-FEB-1998; 98WO-JP00837.
XX
PR 26-FEB-1998; 98JP-0062217.
PR 27-FEB-1997; 97JP-0062290.
XX
PA (NISR) JAPAN TOBACCO INC.
XX
PI Tamatani T, Tezuka K;
XX
DR WPI; 1998-481144/41.
XX
DR N-PSDB; AAV53200.
XX
PT Cell surface molecule expressed in thymocytes and lymphocytes and
PT mediating signal transmission and cell adhesion, and antibodies to

it useful in treatment of auto-immune and allergic disorders.

Claim 9; Page 110-112; 149pp; Japanese.

The present sequence represents a mouse cell surface protein which is expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell surface protein induces adhesion of mitogen-stimulated lymphocytes to antibodies recognising the cell surface protein. These antibodies also produce an increase in peripheral blood lymphocytes in the presence of an antibody recognising CD3 antigen. The cell surface protein contains the amino acid sequence FPPPPF in its extracellular region and the sequence YMF in its intracellular region. The cell surface protein can be used in the prevention and treatment of autoimmune and allergic diseases, and in the diagnosis and investigation of such disorders.

Sequence 200 AA;

Query Match 100.0%; Score 1076; DB 19; Length 200;
Best Local Similarity 100.0%; Pred. No. 4.4e-115;
Matches 200; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKPYFCHVFVFCFLIRLTGEINGSADHRMFSFHNGVQISCKYPETVQOLKMLRFRERE 60
DB 1 mkpyfchvfvcflirlltgeingsadhrmfsfhngvgvisckypetvqqlkmrlfrere 60
QY 61 VLCELTKTGSGNAVSIRKPNMLCLYHLNNSVSFFLNPNDSQSGSYFCSLSIFDPPPPQ 120
DB 61 vlceltktkgsgnavsikpnmlclyhlslsnnsvsfflnnpdssqsgsyfcslsifdpppfq 120
QY 121 ERNLSSGYLHYESQLCCQLKWLPGVLPFAFVVLVLLFGCILLIWFSSKKYGSVHDPNSE 180
DB 121 ernlsggylyhiesqlccqlklwlpvglpafvfvllfllgcilliwfskkygssvhdnpse 180

QY 181 YMFMAAVNTNKKSRLAGVTS 200
DB 181 ymfmaavntnkkksrlagvts 200

RESULT 2
AAY92212
ID AAY92212 standard; Protein; 200 AA.

AC AAY92212;
DT 10-AUG-2000 (first entry)

XX Murine Th2-specific polypeptide, ml228.

ml228; Th2-specific; T helper cell; anti-inflammatory; antiarthritic;
CD28; antidiabetic; immunosuppressive; neuroprotective; dermatological;
KW antipsoriatic; antiasthmatic; antiallergic; anti-viral; ophthalmological;
KW CTLA-4; nephrotropic; anti-HIV; antibacterial.

XX Mus musculus.

XX Key Location/Qualifiers
FH Peptide 114..119

FT /label= conserved_PPP_motif
FT /note= "common in CD28 and CTLA-4"

FT Peptide 181..184
FT /label= YXXM_motif
FT /note= "common in CD28 and CTLA-4; necessary for
FT CD28-mediated phosphatidylinositol 3-kinase
FT activity"

XX WO200019988-A1.

PN 13-APR-2000.

XX 06-OCT-1999; 99WO-US23156.

XX 07-OCT-1998; 98US-0168229.

PR 26-FEB-1999; 99US-0258670.
PR 06-OCT-1999; 99US-0413136.
XX (MILL-) MILLENNIUM PHARM INC.

XX Lehar S, Manning S, Coyle AJ, Gutierrez-ramos J;

XX WPI; 2000-303619/26.

XX N-PSDB; AAA09054.

XX T helper (Th) 2 nucleic acids and encoded proteins, useful for the
diagnosis and treatment of immune and respiratory disorders such as
Crohn's diseases, arthritis, insulin dependent diabetes and
autoimmunity

Claim 16; Page 130-131; 159pp; English.

XX This Th2-specific polypeptide is encoded by a murine orthologue ml228.
The protein shares homology with both human and murine CD28 and CTLA-4.
A novel method for modulating a Th2 response, an immune response, or
suppressing airway inflammation or hyperresponsiveness in a mammal
comprises administering a Th2-specific polypeptide of the invention, an
antibody to such a polypeptide or allelic variants of the genes. The
novel DNA and polypeptide sequences are useful for treatment and
diagnosis of Th cell and Th cell-like disorders such as Crohn's diseases,
arthritis, insulin dependent diabetes, autoimmunity, multiple sclerosis,
dermatitis, psoriasis, graft rejection, graft versus host diseases,
sarcoidosis, asthma, allergies, conjunctivitis, glomerular nephritis,
viral infections (including human immunodeficiency virus (HIV)),
bacterial infections, bronchitis, cystic fibrosis, diphtheria,
emphysema, pneumonia, and Legionnaires disease.

XX Sequence 200 AA;

Query Match 98.8%; Score 1063; DB 21; Length 200;
Best Local Similarity 99.0%; Pred. No. 1.4e-113;
Matches 198; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MKPYFCHVFVFCFLIRLTGEINGSADHRMFSFHNGVQISCKYPETVQOLKMLRFRERE 60
DB 1 mkpyfchvfvcflirlltgeingsadhrmfsfhngvgvisckypetvqqlkmrlfrere 60

QY 61 VLCELTKTGSGNAVSIRKPNMLCLYHLNNSVSFFLNPNDSQSGSYFCSLSIFDPPPPQ 120
DB 61 vlceltktkgsgnavsikpnmlclyhlslsnnsvsfflnpdssqsgsyfcslsifdpppfq 120

QY 121 ERNLSSGYLHYESQLCCQLKWLPGVLPFAFVVLVLLFGCILLIWFSSKKYGSVHDPNSE 180
DB 121 ernlsggylyhiesqlccqlklwlpvgcaafvfvllfllgcilliwfskkygssvhdnpse 180

QY 181 YMFMAAVNTNKKSRLAGVTS 200
DB 181 ymfmaavntnkkksrlagvts 200

RESULT 3
AAB08723
ID AAB08723 standard; Protein; 200 AA.

XX AAB08723;

XX 02-JAN-2001 (first entry)

XX Amino acid sequence of a murine CRP1 polypeptide.

CRP1; CD28 related protein-1; B7RP1; B7 related protein-1;
KW T-lymphocyte activation; type I transmembrane protein; T cell activation;
KW T cell proliferation; T-cell mediated disorder.

XX Mus sp.

XX Key Location/Qualifiers
FH Key

FT Peptide 1..20
 FT /note= "signal peptide"
 FT Protein 21..200
 FT /note= "mature protein"
 FT Domain 21..145
 FT /note= "extracellular domain"
 FT Domain 146..163
 FT /note= "predicted transmembrane domain"
 FT Domain 164..200
 FT /note= "intracellular domain"
 XX
 PN WO200046240-A2.
 XX
 PD 10-AUG-2000.
 XX
 PF 27-JAN-2000; 2000WO-US01871.
 XX
 PR 03-FEB-1999; 99US-0244448.
 PR 08-MAR-1999; 99US-0264527.
 XX
 PR (AMGE-) AMGEN INC.
 XX
 PI Yoshinaga SK;
 XX
 DR WPI; 2000-543476/49.
 DR N-PSDB; AAA64554.
 XX
 XX Novel nucleic acids encoding the proteins CRP-1 and B7RP1 are useful
 PT in the treatment, prevention and diagnosis of T cell mediated disorders
 PT
 XX
 PS Claim 11; Fig 1A; 174pp; English.
 XX
 CC The present sequence represents a CRP1 (CD28 related protein-1)
 CC polypeptide. The specification also describes a B7RP1 (B7 related
 CC protein-1) polypeptide. The polypeptides are involved in T-lymphocyte
 CC activation, and represent a receptor-ligand pair. CRP1 and B7RP1 are
 CC predicted to be a type I transmembrane protein. The nucleic acids are
 CC useful for regulating T cell activation or proliferation in an animal.
 CC The polypeptides are useful for treating, preventing ameliorating or
 CC diagnosing a T-cell mediated disorder in an animal. They can also be
 CC used to identify test molecules that bind to the polypeptides.
 XX
 SQ Sequence 200 AA;

Query Match 98.0%; Score 1055; DB 21; Length 200;
 Best Local Similarity 98.5%; Pred. No. 1.1e-112;
 Matches 197; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVOISCKYPTVQOLKMLFRERE 60
 DB 1 mkpyfcrvfvcflirlltgeingsadhrmfsfhnggvqiskypetvqqlkmrlfrere 60
 QY 61 VLCELTKTGSGNAVSINKPMLCLYHLSNNSVSFFLNPDSSQGSYFCSLSIFDPPPFQ 120
 DB 61 vlceltktkgsgnavsiknpmlclyhlsnnsvsfflnpdssqgsyfcslsifdpppfq 120
 QY 121 ERNLGGYLIHYESQICCOLKWLVPGLPAFVYVLLFGCILIIWFSKKYGSVHPDNPSE 180
 DB 121 ernlsggylhyiesqlccqlkwlpgvgaafvylfvcgclliwfskkygssvhdnpse 180
 QY 181 YMFMAAVNTNKKSRLAGVTS 200
 DB 181 ymfmaavntnkkslragvts 200
 RESULT 4
 ID AAW71874
 XX AAW71874 standard; Protein; 200 AA.
 AC AAW71874;
 XX

DT 11-DEC-1998 (first entry)
 XX
 DE Rat cell surface protein #1.
 XX
 KW Rat; cell surface protein; thymocyte; lymphocyte; cell adhesion;
 KW signal transmission; autoimmune disorder; allergy; diagnosis;
 KW mitogen-stimulated.
 XX
 OS Rattus sp.
 XX
 PN WO9838216-A1.
 XX
 PD 03-SEP-1998.
 XX
 PF 27-FEB-1998; 98WO-JP00837.
 XX
 PR 26-FEB-1998; 98JP-0062217.
 PR 27-FEB-1997; 97JP-0062290.
 XX
 PR (NIBS) JAPAN TOBACCO INC.
 XX
 PI Tamatani T, Tezuka K;
 XX
 DR WPI; 1998-481144/41.
 DR N-PSDB; AAV61357.
 XX
 XX Cell surface molecule expressed in thymocytes and lymphocytes and -
 PT mediating signal transmission and cell adhesion, and antibodies to
 PT it useful in treatment of auto:immune and allergic disorders.
 XX
 PS Claim 9; Page 106-109; 149pp; Japanese.
 XX
 CC The present sequence represents a rat cell surface protein which is
 CC expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell
 CC surface protein induces adhesion of mitogen-stimulated lymphocytes to
 CC antibodies recognising the cell surface protein. These antibodies also
 CC produce an increase in peripheral blood lymphocytes in the presence of
 CC an antibody recognising CD3 antigen. The cell surface protein contains
 CC the amino acid sequence FDPFPF in its extracellular region and the
 CC sequence YNFM in its intracellular region. The cell surface protein can
 CC be used in the prevention and treatment of autoimmune and allergic
 CC diseases, and in the diagnosis and investigation of such disorders.
 XX
 SQ Sequence 200 AA;
 Query Match 84.3%; Score 907; DB 19; Length 200;
 Best Local Similarity 84.0%; Pred. No. 1.1e-95;
 Matches 168; Conservative 14; Mismatches 18; Indels 0; Gaps 0;
 QY 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVOISCKYPTVQOLKMLFRERE 60
 DB 1 mkpyfcrvfvcflirlltgeindlanhrmfsfhnggvqiskypetvqqlkmrlfkdre 60
 QY 61 VLCELTKTGSGNAVSINKPMLCLYHLSNNSVSFFLNPDSSQGSYFCSLSIFDPPPFQ 120
 DB 61 vlceltktkgsgnavsiknpmlclyhlsnnsvsfflnpdssqgsyfcslsifdpppfq 120
 QY 121 ERNLGGYLIHYESQICCOLKWLVPGLPAFVYVLLFGCILIIWFSKKYGSVHPDNPSE 180
 DB 121 ernlsggylhyiesqlccqlkwlpgvgaafvaallfgcflwfskkygssvhdnpse 180
 QY 181 YMFMAAVNTNKKSRLAGVTS 200
 DB 181 ymfmaavntnkkslragvts 200
 RESULT 5
 ID AAW71875
 XX AAW71875 standard; Protein; 216 AA.
 AC AAW71875;
 XX

DT 11-DEC-1998 (first entry)
 XX Rat cell surface protein #2.
 DE
 XX
 KW Rat; cell surface protein; thymocyte; lymphocyte; cell adhesion;
 KW signal transmission; autoimmune disorder; allergy; diagnosis;
 KW mitogen-stimulated.
 XX
 OS Rattus sp.
 XX
 XX WO9838216-A1.
 PN
 PD 03-SEP-1998.
 XX
 XX 27-FEB-1998; 98WO-JP00837.
 PF
 XX 26-FEB-1998; 98JP-0062217.
 PR
 PR 27-FEB-1997; 97JP-0062290.
 XX
 XX (NISR) JAPAN TOBACCO INC.
 PA
 PI Tamatani T, Tezuka K;
 XX
 XX WPI; 1998-481144/41.
 DR
 DR N-PSDB; AAV61358.
 XX
 XX Cell surface molecule expressed in thymocytes and lymphocytes and -
 PT mediating signal transmission and cell adhesion, and antibodies to
 PT it useful in treatment of autoimmune and allergic disorders.
 XX
 PS Claim 9; Page 112-115; 149pp; Japanese.
 XX
 XX The present sequence represents a rat cell surface protein which is
 CC expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell
 CC surface protein induces adhesion of mitogen-stimulated lymphocytes to
 CC antibodies recognising the cell surface protein. These antibodies also
 CC produce an increase in peripheral blood lymphocytes in the presence of
 CC an antibody recognising CD3 antigen. The cell surface protein contains
 CC the amino acid sequence FDPDPF in its extracellular region and the
 CC sequence YMF in its intracellular region. The cell surface protein can
 CC be used in the prevention and treatment of autoimmune and allergic
 CC diseases, and in the diagnosis and investigation of such disorders.
 XX
 SQ Sequence 216 AA;
 Query Match 83.4%; Score 897; DB 19; Length 216;
 Best Local Similarity 84.3%; Pred. No. 1.7e-94;
 Matches 166; Conservative 13; Mismatches 18; Indels 0; Gaps 0;
 QY 1 MKPYFCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPTVQOLKMLFRERE 60
 DB 1 mkpyfscvfvfclllkllgeindlanhrmfshdggvqiscnypetvqqlkmqlfkdre 60
 QY 61 VLCELTKTGSGNAVSINKPMCLYHLSNNSVSFFLNPNDSQSGSYFYFCSLIFDPPPFQ 120
 DB 61 vldcltktgsgntvsiknpsmcpyqlsnnsvsfflnhdadsggyfclslsifdpppfq 120
 QY 121 ERNLGGYLHIYESQLCCOLKWLPLVGLPAFVVLVLLFGCILLIWFSSKKYGGSSVHPDENSE 180
 DB 121 exnl99gylllyesqlccolklwlpvgcaafvaallfgcifiwfvakkyrsvhdnpse 180
 QY 181 YMFMAAVNTNKKSRLAG 197
 DB 181 ymfmaavntnkkksrlag 197
 RESULT 6
 ID AAW75956
 XX AAW75956 standard; Protein; 199 AA.
 AC AAW75956;
 XX

DT 11-DEC-1998 (first entry)
 XX Human cell surface protein #1.
 DE
 XX
 KW Human; cell surface protein; thymocyte; lymphocyte; cell adhesion;
 KW signal transmission; autoimmune disorder; allergy; diagnosis;
 KW mitogen-stimulated.
 XX
 OS Homo sapiens.
 XX
 XX WO9838216-A1.
 PN
 PD 03-SEP-1998.
 XX
 XX 27-FEB-1998; 98WO-JP00837.
 PF
 XX 26-FEB-1998; 98JP-0062217.
 PR
 PR 27-FEB-1997; 97JP-0062290.
 XX
 XX (NISR) JAPAN TOBACCO INC.
 PA
 PI Tamatani T, Tezuka K;
 XX
 XX WPI; 1998-481144/41.
 DR
 DR N-PSDB; AAV53198.
 XX
 XX Cell surface molecule expressed in thymocytes and lymphocytes and -
 PT mediating signal transmission and cell adhesion, and antibodies to
 PT it useful in treatment of autoimmune and allergic disorders.
 XX
 PS Claim 2; Page 99-101; 149pp; Japanese.
 XX
 XX The present sequence represents a human cell surface protein which is
 CC expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell
 CC surface protein induces adhesion of mitogen-stimulated lymphocytes to
 CC antibodies recognising the cell surface protein. These antibodies also
 CC produce an increase in peripheral blood lymphocytes in the presence of
 CC an antibody recognising CD3 antigen. The cell surface protein contains
 CC the amino acid sequence FDPDPF in its extracellular region and the
 CC sequence YMF in its intracellular region. The cell surface protein can
 CC be used in the prevention and treatment of autoimmune and allergic
 CC diseases, and in the diagnosis and investigation of such disorders.
 XX
 SQ Sequence 199 AA;
 Query Match 67.1%; Score 722.5; DB 19; Length 199;
 Best Local Similarity 68.3%; Pred. No. 1.6e-74;
 Matches 136; Conservative 20; Mismatches 42; Indels 1; Gaps 1;
 QY 1 MKPYFCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPTVQOLKMLFRERE 60
 DB 1 mksqglwyfflclrlkvtlgeingsanyemflhngvgvqlckypdivqqlkmlk99q 60
 QY 61 VLCELTKTGSGNAVSINKPMCLYHLSNNSVSFFLNPNDSQSGSYFYFCSLIFDPPPFQ 120
 DB 61 ilcdltktkgsgntvsiklckfchsqslsnnsvsfflylnhdshanyfynlsifdppfk 120
 QY 121 ERNLGGYLHIYESQLCCOLKWLPLVGLPAFVVLVLLFGCILLIWFSSKKYGGSSVHPDENSE 180
 DB 121 v-rltggylhiyesqlccolklwlpvgcaafvvcilgclilcwtlckkyssvhdnpge 179
 QY 181 YMFMAAVNTNKKSRLAGVT 199
 DB 180 ymfmaavntnkkksrltdvt 198
 RESULT 7
 ID AAW75957
 XX AAW75957 standard; Protein; 199 AA.
 AC AAW75957;
 XX

DT 11-DEC-1998 (first entry)
 XX Human cell surface protein #2.
 DE
 XX Human; cell surface protein; thymocyte; lymphocyte; cell adhesion;
 KW signal transmission; autoimmune disorder; allergy; diagnosis;
 KW mitogen-stimulated.
 KW
 XX Homo sapiens.
 OS
 XX WO9838216-A1.
 PN
 XX 03-SEP-1998.
 XX
 XX 27-FEB-1998; 98WO-JP00837.
 PF
 XX 26-FEB-1998; 98JP-0062217.
 PR
 XX 27-FEB-1997; 97JP-0062290.
 PR
 XX (NISE) JAPAN TOBACCO INC.
 PA
 XX Tamatani T, Tezuka K;
 XX WPI: 1998-481144/41.
 XX N-PSDB; AAV53199.
 DR
 XX Cell surface molecule expressed in thymocytes and lymphocytes and -
 PT mediating signal transmission and cell adhesion, and antibodies to
 PT it useful in treatment of auto:immune and allergic disorders.
 PT
 XX
 XX Claim 9; Page 101-105; 149pp; Japanese.
 PS
 XX The present sequence represents a human cell surface protein which is
 CC expressed by thymocytes and by mitogen-stimulated lymphocytes. The cell
 CC surface protein induces adhesion of mitogen-stimulated lymphocytes to
 CC antibodies recognising the cell surface protein. These antibodies also
 CC produce an increase in peripheral blood lymphocytes in the presence of
 CC an antibody recognising CD3 antigen. The cell surface protein contains
 CC the amino acid sequence FDRPPF in its extracellular region and the
 CC sequence YMF in its intracellular region. The cell surface protein can
 CC be used in the prevention and treatment of autoimmune and allergic
 CC diseases, and in the diagnosis and investigation of such disorders.
 XX
 XX Sequence 199 AA;
 SQ
 Query Match 67.1%; Score 722.5; DB 19; Length 199;
 Best Local Similarity 68.3%; Pred. No. 1.6e-74;
 Matches 136; Conservative 20; Mismatches 42; Indels 1; Gaps 1;
 QY 1 MKPYFCHVFCELIIRLLTGEINGSADHRMFSFHNGGVQISCKYPTVQOLKMLRFRERE 60
 DB - 1 mksglwyfflclrlkvtlgeingsanyemfifhngvgqilckypdivqgmqlkkgg 60
 QY 61 VLCELTKTGGSNVAVSIKPMCLLYHLNNSVSFFLNPDSSQGSYVFCSLSFDPDPFQ 120
 DB 61 icdltktgsgntsvsiksikfchsqslmsvfflyndhshanyfncslsfdpdpfk 120
 QY 121 ERLNSGGYLHIYESQLCCQLKWLPLVGLPAFVVLVLLFGCILIIWFSKKYKSSVHPDENSE 180
 DB 121 v-tltggylhiesqicccqlkfwlpigcaafvvcilgcilicwltckkkyssvhpdpnge 179
 QY 181 YMFMAAVNTNKSRLAGVT 199
 DB 180 ymfmravntakksrltdvt 198
 RESULT 8
 AAY08026
 ID AAY08026 standard; Protein; 199 AA.
 XX
 AC AAY08026;
 XX

DT 08-JUL-1999 (first entry)
 XX Human activated T-lymphocyte protein 8F4.
 DE
 XX T-lymphocyte; human; 8F4; T cell co-stimulation; activated; CD4+; CD8+;
 KW anticancer; antiviral; anti-asthma; immunomodulator; proliferation;
 KW T cell activation; cytokine synthesis; regulatory element; B cell;
 KW T cell-dependent antibody production; treatment; prevention; cancer;
 KW autoimmune disease; transplant rejection; immune system regulation;
 KW disorder; acquired immune deficiency syndrome; AIDS; asthma.
 XX
 OS Homo sapiens.
 XX
 XX WO9915553-A2.
 PN
 XX 01-APR-1999.
 PD
 XX 23-SEP-1998; 98WO-DE02896.
 PF
 XX 11-MAY-1998; 98DE-1021060.
 PR
 XX 23-SEP-1997; 97DE-1041929.
 PR
 XX (DEKO-) DEUT KOCH INST ROBERT.
 PA (BUND) BUNDESREPUBLIK DEUT PAUL-EHRlich-INST.
 XX
 XX Krocze R;
 XX WPI: 1999-276975/23.
 DR N-PSDB; AAX37661.
 DR
 XX Polypeptide 8F4 co-stimulates T cells and is present only on
 PT activated cells
 PT
 XX Claim 2; Page 24; 47pp; German.
 PS
 XX This invention describes a novel human protein, 8F4, and its encoding
 CC nucleic acid which co-stimulates T cells and is present on activated CD4+
 CC and CD8+ T cells but not on resting or activated B cells, granulocytes,
 CC monocytes, natural killer or dendritic cells. 8F4 has anticancer,
 CC antiviral, anti-asthma and immunomodulatory activity. 8F4 provides a
 CC strong co-stimulatory signal for T cell activation, i.e. it amplifies
 CC proliferation of T cells, synthesis of certain cytokines and other
 CC regulatory agents, and improves T cell-dependent antibody production
 CC by B cells. Agents that inhibit 8F4 are used to treat or prevent
 CC autoimmune diseases, to prevent transplant rejection and to treat
 CC disorders of immune system regulation. 8F4, or cells that express it,
 CC is/are used to treat or prevent cancers, acquired immune deficiency
 CC syndrome, asthma and chronic infectious diseases (e.g. hepatitis B or C).
 XX
 XX Sequence 199 AA;
 SQ
 Query Match 67.1%; Score 722.5; DB 20; Length 199;
 Best Local Similarity 68.3%; Pred. No. 1.6e-74;
 Matches 136; Conservative 20; Mismatches 42; Indels 1; Gaps 1;
 QY 1 MKPYFCHVFCELIIRLLTGEINGSADHRMFSFHNGGVQISCKYPTVQOLKMLRFRERE 60
 DB - 1 mksglwyfflclrlkvtlgeingsanyemfifhngvgqilckypdivqgmqlkkgg 60
 QY 61 VLCELTKTGGSNVAVSIKPMCLLYHLNNSVSFFLNPDSSQGSYVFCSLSFDPDPFQ 120
 DB 61 icdltktgsgntsvsiksikfchsqslmsvfflyndhshanyfncslsfdpdpfk 120
 QY 121 ERLNSGGYLHIYESQLCCQLKWLPLVGLPAFVVLVLLFGCILIIWFSKKYKSSVHPDENSE 180
 DB 121 v-tltggylhiesqicccqlkfwlpigcaafvvcilgcilicwltckkkyssvhpdpnge 179
 QY 181 YMFMAAVNTNKSRLAGVT 199
 DB 180 ymfmravntakksrltdvt 198

CC haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
CC diseases (e.g., rheumatoid arthritis), inflammation, allergies, asthma;
CC neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
CC cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
CC psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
CC angionenic disorders, kidney disorders, gastrointestinal disorders,
CC pregnancy-related disorders, endocrine disorders, and infections. The
CC proteins can also be used to aid wound healing and epithelial cell
CC proliferation, to prevent skin aging due to sunburn, to maintain organs
CC before transplantation, for supporting cell culture of primary tissues,
CC to regenerate tissues, to identify their cognate ligands or binding
CC partners, and in chemotaxis, and can be used as a food additive or
CC preservative to modify storage properties. Antibodies specific for a
CC protein of the invention can be used in alleviating symptoms associated
CC with the disorders mentioned above, and in diagnostic immunoassays e.g.,
CC radioimmunoassay or enzyme linked immunosorbent assay (ELISA).
CC The present sequence represents a human secreted protein of
CC the invention.
XX
S0 Sequence 199 AA;
Query Match 67.1%; Score 722.5; DB 22; Length 199;
Best Local Similarity 68.3%; Pred. No. 1.6e-74;
Matches 136; Conservative 20; Mismatches 42; Indels 1; Gaps 1;
QY 1 MKPYFCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVOISCKYPTVQOLKMLFRERE 60
Db 1 mksglwyfflclrlkvlkgeingsanyemfifhnggvqilckypdivqfkmqllkqgg 60
QY 61 VLCELTKTGSGNAVSINKPMCLVHLSNNSVSFFLNPNDSOGSYFCSLSIFDPPFPQ 120
Db 61 ilcdltktgsgntvsiksikfchsglsnnsvsfflnldshanyfncnlisfdpppfk 120
QY 121 ERNLGGYLIHYESQLCCOLKWLVPGLPAFVVVLLFGCILLIWFSSKKYGSVHDNPSE 180
Db 121 v-tltggylihyesqlccqlkfwlpgcaafvvcilgciliclwtkkkyssvhdnpge 179
QY 181 YMFMAAVNTNKKSLRAGVT 199
Db 180 ymfmravntakksrltdvt 198
RESULT 11
ID AAE03460
AC AAE03460
XX
DE 0-AUG-2001 (first entry)
XX
DE Human gene 2 encoded secreted protein HT2SG64, SEQ ID NO: 143.
XX
KW Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
KW foetal abnormality; developmental abnormality; haematopoietic disorder;
KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW Parkinson's disease; cognitive disorder; schizophrenia; skin disorder;
KW psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
KW inflammation; neurological disorder; Alzheimer's disease; food additive;
KW angionenic disorder; kidney disorder; gastrointestinal disorder; allergy;
KW pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW cell culture; chemotaxis; vulnery; binding partner identification;
KW gene therapy.
OS Homo sapiens.
XX
FH Location/Qualifiers
FT 1..19 /label= signal_peptide
FT 20..199 /note= "Mature human secreted protein"
FT
XX WO200132675-A1.

XX 10-MAY-2001.
PD 25-OCT-2000; 2000WO-US29363.
XX 29-OCT-1999; 990US-0162239.
PR 30-JUN-2000; 2000US-0215139.
XX (HUMA-) HUMAN GENOME SCI INC.
PA Ruben SM, Komatsoulis GA, Wei P, Baker KP, Young PE;
PI WPI; 2001-328772/34.
DR N-PSDB; AAD07842.
XX Thirty two human secreted proteins, useful for treating cancers,
PT hyperproliferative disorders, inflammatory disorders, neurological
PT disorders, autoimmune diseases and cardiovascular disorders -
XX
PS Claim 11; Page 489-490; 576pp; English.
XX
CC AAD07809-AAD07907 represent cDNAs corresponding to 32 human secreted
CC protein genes, and AAE03427-AAE03523 represent the proteins they encode.
CC AAE03524-AAE03537 represent human secreted protein fragments or variants.
CC The secreted proteins and their genes are useful for preventing, treating
CC or ameliorating medical conditions, e.g., by protein or gene therapy.
CC Pathological conditions can be diagnosed by determining the amount of the
CC new protein in a sample or by determining the presence of mutations in
CC the new genes. Specific uses are described for each of the 32 genes,
CC based on the tissues in which they are most highly expressed, and include
CC developing products for the diagnosis or treatment of proliferative
CC disorders, cancer, tumours, foetal and developmental abnormalities,
CC haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
CC diseases (e.g., rheumatoid arthritis), inflammation, allergies,
CC neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
CC cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
CC psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
CC angionenic disorders, kidney disorders, gastrointestinal disorders,
CC pregnancy-related disorders, endocrine disorders, and infections. The
CC proteins can also be used to aid wound healing and epithelial cell
CC proliferation, to prevent skin aging due to sunburn, to maintain organs
CC before transplantation, for supporting cell culture of primary tissues,
CC to regenerate tissues, to identify their cognate ligands or binding
CC partners, and in chemotaxis, and can be used as a food additive or
CC preservative to modify storage properties. Antibodies specific for a
CC protein of the invention can be used in alleviating symptoms associated
CC with the disorders mentioned above, and in diagnostic immunoassays e.g.,
CC radioimmunoassay or enzyme linked immunosorbent assay (ELISA).
CC The present sequence represents a human secreted protein of
CC the invention.
XX
S0 Sequence 199 AA;
Query Match 67.1%; Score 722.5; DB 22; Length 199;
Best Local Similarity 68.3%; Pred. No. 1.6e-74;
Matches 136; Conservative 20; Mismatches 42; Indels 1; Gaps 1;
QY 1 MKPYFCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVOISCKYPTVQOLKMLFRERE 60
Db 1 mksglwyfflclrlkvlkgeingsanyemfifhnggvqilckypdivqfkmqllkqgg 60
QY 61 VLCELTKTGSGNAVSINKPMCLVHLSNNSVSFFLNPNDSOGSYFCSLSIFDPPFPQ 120
Db 61 ilcdltktgsgntvsiksikfchsglsnnsvsfflnldshanyfncnlisfdpppfk 120
QY 121 ERNLGGYLIHYESQLCCOLKWLVPGLPAFVVVLLFGCILLIWFSSKKYGSVHDNPSE 180
Db 121 v-tltggylihyesqlccqlkfwlpgcaafvvcilgciliclwtkkkyssvhdnpge 179
QY 181 YMFMAAVNTNKKSLRAGVT 199
Db 180 ymfmravntakksrltdvt 198

CC The present sequence represents a human secreted protein variant
CC referred to in the disclosure of the invention.
XX
SQ Sequence 199 AA;

Query Match 67.1%; Score 722.5; DB 22; Length 199;
Best Local Similarity 68.3%; Pred. No. 1.6e-74;
Matches 136; Conservative 20; Mismatches 42; Indels 1; Gaps 1;

QY 1 MKPYFCHVFVFCFLIRLTGEINGSADHRMFSEHNGVGVOISCKYETVQOLKMRIFERE 60
|| : ||| : ||| ||||| : || ||||| |||| : ||| ||| :
Db 1 mksglwffilckrlkvltgeingsanyemfihngvgilckypdivgfkmlkqgq 60

QY 61 VLCELTKTGSGNAVSIKPNMCLVHLNNSVSFFLNPNDSOGSYFCSLSIFDPPPFQ 120
||| : ||| ||||| ||||| : ||| ||||| ||||| : ||| : ||| ||||| :
Db 61 llicdtktkgsnntsvsklchsqslsnsvsfflynldshanyyfcnlifppppfk 120

QY 121 ERNLGGYLHIYESQLCCQLKWLVPGLPAFVVLVFLGCLILIFWSKKYKSSVHDPNSE 180
||| : ||| ||||| ||||| : ||| : ||||| : ||||| : ||||| : ||||| :
Db 121 v-tlgtgylhiyesqlccqlkfwlpigcaafvvcilgcilcwtckkkyssvhdnpge 179

QY 181 YMFMAAVNTNKKSLAGVT 199
||| |||| |||| |||| ||
Db 180 ymfmravntakksritdvt 198

RESULT 13
AA92213
ID AAY92213 standard; Protein; 198 AA.
XX
AC AAY92213;
XX
DT 10-AUG-2000 (first entry)
XX
DE Human Th2-specific polypeptide, h1228.
XX
KW h1228; Th2-specific; T helper cell; anti-inflammatory; antiarthritic;
KW CD28; antidiabetic; immunosuppressive; neuroprotective; dermatological;
KW antipsoriatic; antiasthmatic; antiallergic; anti-viral; ophthalmological;
KW CTLA-4; nephrotropic; anti-HIV; antibacterial.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 113..118
FT /label= conserved_PPP_motif
FT /note= "common in CD28 and CTLA-4"
FT 178..181
FT /label= YXXM_motif
FT /note= "common in CD28 and CTLA-4; necessary for
FT CD28-mediated phosphatidylinositol 3-kinase
FT activity"
XX
WO200019988-A1.
XX
13-APR-2000.
XX
06-OCT-1999; 99WO-US23156.
XX
07-OCT-1998; 98US-0168229.
XX
26-FEB-1999; 99US-0258670.
XX
06-OCT-1999; 99US-0413136.
XX
(MILL-) MILLENNIUM PHARM INC.
XX
Lehar S, Manning S, Coyle AJ, Gutierrez-ramos J;
XX
WPI; 2000-303619/26.
XX
N-PSDB; AAA09056.
XX
T helper (Th) 2 nucleic acids and encoded proteins, useful for the
PT diagnosis and treatment of immune and respiratory disorders such as

RESULT 12
AAE03525
ID AAE03525 standard; Protein; 199 AA.
XX
AC AAE03525;
XX
DT 10-AUG-2001 (first entry)
XX
DE Human secreted protein variant, SEQ ID NO: 211.
XX
KW Human; secreted protein; proliferative disorder; cancer; tumour; asthma;
KW foetal abnormality; developmental abnormality; haematopoietic disorder;
KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW Parkinson's disease; cognitive disorder; schizophrenia; skin disorder;
KW psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
KW inflammation; neurological disorder; Alzheimer's disease; food additive;
KW anglogenetic disorder; kidney disorder; gastrointestinal disorder; allergy;
KW pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW cell culture; chemotaxis; vulnery; binding partner identification;
KW
XX
OS Homo sapiens.
XX
PN WO200132675-A1.
XX
PD 10-MAY-2001.
XX
PF 25-OCT-2000; 2000WO-US29363.
XX
PR 29-OCT-1999; 99US-0162239.
XX
PR 30-JUN-2000; 2000US-0215139.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Komatsoulis GA, Wei P, Baker KP, Young PE;
XX
WPI; 2001-328772/34.
XX
XX Thirty two human secreted proteins, useful for treating cancers,
PT hyperproliferative disorders, inflammatory disorders, neurological
PT disorders, autoimmune diseases and cardiovascular disorders -
XX
Disclosure; Page 524; 576pp; English.
XX
AA07809-AAD07907 represent cDNAs corresponding to 32 human secreted
XX protein genes, and AAE03427-AAE03523 represent the proteins they encode.
XX AAE03524-AAE03537 represent human secreted protein fragments or variants.
XX The secreted proteins and their genes are useful for preventing, treating
XX or ameliorating medical conditions, e.g., by protein or gene therapy.
XX Pathological conditions can be diagnosed by determining the amount of the
XX new protein in a sample or by determining the presence of mutations in
XX the new genes. Specific uses are described for each of the 32 genes,
XX based on the tissues in which they are most highly expressed, and include
XX developing products for the diagnosis or treatment of proliferative
XX disorders, cancer, tumours, foetal and developmental abnormalities,
XX haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
XX diseases (e.g., rheumatoid arthritis), inflammation, allergies,
XX neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
XX cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
XX psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
XX anglogenetic disorders, kidney disorders, gastrointestinal disorders,
XX pregnancy-related disorders, endocrine disorders, and infections. The
XX proteins can also be used to aid wound healing and epithelial cell
XX proliferation, to prevent skin aging due to sunburn, to maintain organs
XX before transplantation, for supporting cell culture of primary tissues,
XX to regenerate tissues, to identify their cognate ligands or binding
XX partners, and in chemotaxis, and can be used as a food additive or
XX preservative to modify storage properties. Antibodies specific for a
XX protein of the invention can be used in alleviating symptoms associated
XX with the disorders mentioned above, and in diagnostic immunoassays e.g.,
XX radioimmunoassay or enzyme linked immunosorbent assay (ELISA).

GenCore version 4.5
Copyright (C) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:27:00 : Search time 28.8 Seconds
(without alignments)
169.622 Million cell updates/sec

Title: US-09-383-551B-14
Perfect score: 1076
Sequence: 1 MKPVCHVFCEFLRLTLG.....YMFMAVNTNKKSLAGVTS 200

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 231628 seqs, 24425594 residues

The number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA: *
1: /cgn2_6/ptodata/2/1aa/5A_COMB.pep: *
2: /cgn2_6/ptodata/2/1aa/5B_COMB.pep: *
3: /cgn2_6/ptodata/2/1aa/6A_COMB.pep: *
4: /cgn2_6/ptodata/2/1aa/6B_COMB.pep: *
5: /cgn2_6/ptodata/2/1aa/PTUS_COMB.pep: *
6: /cgn2_6/ptodata/2/1aa/backfiles1.pep: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	132.5	12.3	218	3	US-08-228-208A-20
2	132	12.3	220	3	US-08-228-208A-21
3	131.5	12.2	223	1	US-08-505-058-5
4	131.5	12.2	223	2	US-08-459-818-25
5	131.5	12.2	223	2	US-08-889-666-25
6	131.5	12.2	223	2	US-08-465-078-25
7	131.5	12.2	223	2	US-08-725-776-25
8	131.5	12.2	223	3	US-08-488-062-25
9	121	11.2	134	3	US-08-630-172-3
10	121	11.2	134	4	US-09-375-419-3
11	117	10.9	367	3	US-08-630-172-19
12	117	10.9	367	3	US-09-375-419-19
13	116.5	10.8	225	1	US-08-505-058-4
14	116.5	10.8	225	2	US-08-459-818-24
15	116.5	10.8	225	2	US-08-889-666-24
16	116.5	10.8	225	2	US-08-465-078-24
17	116.5	10.8	225	2	US-08-725-776-24
18	116.5	10.8	225	2	US-08-488-062-24
19	110.5	10.3	110	4	US-09-460-384-33
20	105.5	9.8	218	3	US-08-228-208A-19
21	94.5	8.8	225	1	US-08-505-058-3
22	94.5	8.8	225	2	US-08-459-818-23
23	94.5	8.8	225	2	US-08-889-666-23
24	94.5	8.8	225	2	US-08-465-078-23
25	94.5	8.8	225	2	US-08-725-776-23
26	94.5	8.8	225	2	US-08-488-062-23
27	82.5	7.7	223	3	US-08-228-208A-17

28	81.5	7.6	117	2	US-08-529-878B-39	Sequence 19, Appl
29	81.5	7.6	221	3	US-08-228-208A-22	Sequence 22, Appl
30	80.5	7.5	226	1	US-08-505-058-6	Sequence 6, Appl
31	80.5	7.5	226	2	US-08-459-818-26	Sequence 26, Appl
32	80.5	7.5	226	2	US-08-889-666-26	Sequence 26, Appl
33	80.5	7.5	226	2	US-08-465-078-26	Sequence 26, Appl
34	80.5	7.5	226	2	US-08-725-776-26	Sequence 26, Appl
35	80.5	7.5	226	2	US-08-488-062-26	Sequence 26, Appl
36	79.5	7.4	187	1	US-08-067-684-14	Sequence 14, Appl
37	79.5	7.4	187	1	US-08-008-898-14	Sequence 14, Appl
38	79.5	7.4	187	2	US-08-459-818-14	Sequence 14, Appl
39	79.5	7.4	187	2	US-08-889-666-14	Sequence 14, Appl
40	79.5	7.4	187	2	US-08-465-078-14	Sequence 14, Appl
41	79.5	7.4	187	2	US-08-725-776-14	Sequence 14, Appl
42	79.5	7.4	187	2	US-08-488-062-14	Sequence 14, Appl
43	79.5	7.4	187	3	US-08-228-208A-14	Sequence 14, Appl
44	79.5	7.4	187	5	PCT-US95-06726-36	Sequence 36, Appl
45	77	7.2	124	3	US-08-630-172-4	Sequence 4, Appl

ALIGNMENTS

RESULT 1
US-08-228-208A-20
; Sequence 20, Application US/08228208A
; Patent No. 6090914
; GENERAL INFORMATION:
; APPLICANT: Linsley, Peter S.
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Damle, Nitin K.
; APPLICANT: Brady, William
; APPLICANT: Wallace, Philip M.
; TITLE OF INVENTION: CTLA4/CD28Ig HYBRID FUSION
; TITLE OF INVENTION: PROTEINS AND USES THEREOF
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Merchant & Gould
; STREET: 11150 Santa Monica Boulevard, Suite 400
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/228, 208A
; FILING DATE: 15-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/008,898
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: 07/723,617
; FILING DATE: 27-JUN-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Adriano, Sarah B.
; REGISTRATION NUMBER: 34,470
; REFERENCE/DOCKET NUMBER: 30436-30US01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 310 445-1140
; TELEFAX: 310 445-9031
; TELEX:
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 218 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-228-208A-20

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:27:46 ; Search time 37.55 seconds
(without alignments)
511.794 Million cell updates/sec

Title: US-09-383-551B-14
Perfect score: 1076
Sequence: 1 MKPYFCHVFVFCFLIRLLTG.....YMFMAAVNTNKKSLAGVTS 200

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283138 seqs, 96089334 residues

Number of hits satisfying chosen parameters: 283138

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_71:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	907	84.3	200	JC7397	activation-inducib
2	897	83.4	216	JC7396	activation-inducib
3	722.5	67.1	199	S78540	inducible T-cell c
4	138	12.8	221	I46689	CD28 precursor - r
5	136	12.6	220	RWHU28	T-cell surface gly
6	124.5	11.6	218	S24413	T-cell surface gly
7	122	11.3	173	I46197	cell surface prote
8	105.5	9.8	218	I43523	T-cell surface gly
9	89.5	8.3	221	S25168	CHT28 protein - ch
10	88	8.2	263	T16329	hypothetical prote
11	85.5	7.9	658	T39495	hypothetical prote
12	84.5	7.9	223	T09536	cytotoxic T-lympho
13	81.5	7.6	129	C25733	T-cell receptor al
14	81.5	7.6	186	S08614	cytotoxic T-lympho
15	80.5	7.5	336	T15727	hypothetical prote
16	78.5	7.3	470	D81353	threonine synthase
17	78	7.2	504	S45644	cytochrome P450 2K
18	77	7.2	676	H96970	endo-arabinase rel
19	76.5	7.1	223	I48696	CTLA-4 precursor
20	76.5	7.1	2167	S19444	hypothetical prote
21	75.5	7.0	417	A55524	aspartic proteinas
22	75.5	7.0	2210	RRXPLC	genome polypeptid
23	75	7.0	1315	T03167	hypothetical prote
24	74	6.9	471	T04911	hypothetical prote
25	74	6.9	988	T03307	hypothetical 109.6
26	74	6.9	1701	T09127	probable erythrocy
27	73.5	6.8	360	T26270	hypothetical prote
28	73.5	6.8	402	S58477	rdsl protein - fis
29	73.5	6.8	892	S57055	probable membrane

30	73	6.8	148	2	JC7235	receptor-activity-
31	73	6.8	972	2	F71608	hypothetical prote
32	72.5	6.7	461	2	S34498	phocsystem II chl
33	72.5	6.7	476	2	T27618	hypothetical prote
34	72.5	6.7	492	2	T30066	hypothetical prote
35	72.5	6.7	726	2	JQ2162	A-type inclusion p
36	72	6.7	490	2	T15097	hypothetical prote
37	72	6.7	657	1	FOV2FV	major core protein
38	71.5	6.6	418	2	S42073	aspartic proteins
39	71.5	6.6	457	2	A54604	regulatory protein
40	71.5	6.6	576	1	H71414	probable cytochrom
41	71.5	6.6	1256	2	T03096	CDO protein - rat
42	71.5	6.6	2339	2	A42566	omega-conotoxin-se
43	71	6.6	229	1	WMAD51	late 33k protein -
44	71	6.6	585	2	S43718	malate dehydrogena
45	71	6.6	964	2	E71460	probable outer mem

ALIGNMENTS

RESULT 1

JC7397
activation-inducible lymphocyte immuno-mediatory molecule-2 - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 17-Nov-2000 #sequence_revision 17-Nov-2000 #text_change 17-Nov-2000
C:Accession: JC7397; PC7100
R:Tezuka, K.; Tsujil, T.; Hirano, D.; Tamatani, T.; Sakamaki, K.; Kobayashi, Y.; Kanad
Biochem. Biophys. Res. Commun. 276, 335-345, 2000
A:Title: Identification and characterization of rat AILIM/ICOS, a novel T-cell costim
A:Reference number: JC7396
A:Contents: Spleen
A:Accession: JC7397
A:Molecule type: mRNA
A:Residues: 1-200 <TE2>
A:Cross-references: DDBJ:AB023134
A:Accession: PC7100
A:Molecule type: protein
A:Residues: 21-40 <TE2>
C:Comment: This protein is an inducible cell surface glycoprotein, and a type I trans
on, and plays an important role for the maturation or selection of T cells in thymus.
C:Genetics:
A:Gene: ailim-2
C:Keywords: glycoprotein; T-cell; transmembrane protein

Query Match 84.3%; Score 907; DB 2; Length 200;
Best Local Similarity 84.0%; Pred. No. 1.1e-80;
Matches 168; Conservative 14; Mismatches 18; Indels 0; Gaps 0;

QY	1	MKPYFCHVFVFCFLIRLLLTGEINGSADHRMFS	PHNGVQISCKYPETVQOLKWLRFERE	60
DB	1	MKPYFSCVFCFLIKLLLTGELDLNHRMFS	PHNGVQISCKYPETVQOLKWLRFERE	60
QY	61	VLCELTKTGSGNAVSTKPNMLCLYHLSNNSVS	FFLNPDSSQGSYFCSLSLTFDPPFQ	120
DB	61	VLCDLTKTGSGNTSVIKNPMSCPYQLSNNSVS	FFLNPDSSQGSYFCSLSLTFDPPFQ	120
QY	121	ERNLSGGYLHIYESQLCCCLKWLPGLPAFVV	VLFGCILIIWFSKKYKSSVHPDNPSE	180
DB	121	EKNLSGGYLLIYESQLCCCLKWLPVGCFAF	VALLFGCIFIWFAKKYKSSVHPDNPSE	180
QY	181	YMFMAAVNTNKKSLAGVTS	200	
DB	181	YMFMAAVNTNKKSLAGMTS	200	

RESULT 2

JC7396
activation-inducible lymphocyte immuno-mediatory molecule-1 - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 17-Nov-2000 #sequence_revision 17-Nov-2000 #text_change 17-Nov-2000
C:Accession: JC7396; PC7099

R:Tezuka, K.; Tsuji, T.; Hirano, D.; Tamatani, T.; Sakamaki, K.; Kobayashi, Y.; Kamada, Blochem. Biophys. Res. Commun. 276, 335-345, 2000
A:Title: Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule
A:Reference number: JC7396
A:Contents: Spleen
A:Accession: JC7396
A:Molecule type: mRNA
A:Residues: 1-216 <TE2>
A:Cross-references: DDBJ:AB023133
A:Accession: PC7099
A:Molecule type: protein
A:Residues: 21-40 <TE2>
A:Comment: This protein is an inducible cell surface glycoprotein, and a type I transmembrane protein, and plays an important role for the maturation or selection of T cells in thymus.
C:Genetics:
A:Gene: ailim-1
C:Keywords: glycoprotein; T-cell; transmembrane protein

Query Match 83.4%; Score 897; DB 2; Length 216;
Best Local Similarity 84.3%; Pred. No. 1,1e-79;
Matches 166; Conservative 13; Mismatches 18; Indels 0; Gaps 0;

QY 1 MKPYFCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVOISCKYPETVQOLKMLRFRERE 60
DB 1 MKPYFSCVFVFCFLIKLLTGEINDLANHRMFSFHDGGVOISCNYPETVQOLKMLFKDRE 60

QY 61 VLCELTKTGSGNNAVSIKPNMCLLYHLSNNSVSFFLNPNDSQGSYFCSLSFIFDPPFPQ 120
DB 61 VLCDLTKTGSGNTVSIKPNMPCPQLNSNNSVSFFLDNADSSQGSYFLCSLSIFDPPFPQ 120

QY 121 ERNLGGYLHIYESQLCCQLKWLPGVLPFAFVYVLLFGCILIIWFSKKYSGSVHDPNSE 180
DB 121 EKNLSGGLYLIYESQLCCQLKWLPGCAAFVALLFGCIEFIWFAKKYSSVHDPNSE 180

QY 181 YMFMAAVNTNKKSRLAG 197
DB 181 YMFMAAVNTNKKSRLAG 197

RESULT 3
S78540
Inducible T-cell co-stimulator ICOS precursor - human
C:Species: Homo sapiens (man)
C:Date: 05-Mar-1999 #sequence_revision 05-Mar-1999 #text_change 07-May-1999
C:Accession: S78540; S78748; S78749
R:Kroccek, R.
Submitted to the Protein Sequence Database, June 1998
Reference number: S78540
Accession: S78540
A:Molecule type: mRNA
A:Residues: 1-199 <KRO>
A:Experimental source: cell line MOLT-4V
R:Hutloff, A.; Dittrich, A.M.; Beier, K.C.; Eljaschewitsch, B.; Kraft, R.; Anagnostopoulou
Nature 397, 263-266, 1999
A:Title: ICOS is an inducible T-cell co-stimulator structurally and functionally related to BTLA
A:Reference number: S78748; MUID:99127892
A:Accession: S78748
A:Molecule type: mRNA
A:Residues: 1-199 <HUT1>
A:Experimental source: cell line MOLT-4V
A:Accession: S78749
A:Molecule type: protein
A:Residues: 'X', 193-198 <HUT2>
A:Experimental source: cell line MOLT-4V
C:Complex: homodimer
C:Superfamily: immunoglobulin homology
C:Keywords: dimer; glycoprotein; T-cell; transmembrane protein
F:1-19/Domain: (or 1-20) signal sequence #status predicted <SIG>
F:20-159/Product: (or 21-199) inducible costimulator ICOS #status predicted <MAT>
F:21-138/Domain: extracellular #status predicted <EXT>
F:26-132/Domain: immunoglobulin homology <IMM>
F:139-164/Domain: transmembrane #status predicted <TM>

F:165-199/Domain: intracellular #status predicted <INT>
F:23-89/110/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 67.1%; Score 722.5; DB 2; Length 199;
Best Local Similarity 68.3%; Pred. No. 9.2e-63;
Matches 136; Conservative 20; Mismatches 42; Indels 1; Gaps 1;

QY 1 MKPYFCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVOISCKYPETVQOLKMLRFRERE 60
DB 1 MKSGLWYFFLCRLIKVLTGEINGSANYEMFIFHNGVOILCKYPDIVQOQFKMLKGGQ 60

QY 61 VLCELTKTGSGNNAVSIKPNMCLLYHLSNNSVSFFLNPNDSQGSYFCSLSFIFDPPFPQ 120
DB 61 ILCDLTKTGSGNTVSIKSLKCHSQQLSNNSVSFFLYNLDSHANYFCNLISIFDPPPK 120

QY 121 ERNLGGYLHIYESQLCCQLKWLPGVLPFAFVYVLLFGCILIIWFSKKYSGSVHDPNSE 180
DB 121 V-TLGGVLIHIYESQLCCQLKFWLPTGCAAFVYVVGILGILICWLTKKKYSSVHDPNGE 179

QY 181 YMFMAAVNTNKKSRLAGVT 199
DB 180 YMFRAVNTAKSRLLTDTVT 198

RESULT 4
I46689
CD28 precursor - rabbit
C:Species: Oryzotolagus cuniculus (domestic rabbit)
C:Date: 14-Feb-1997 #sequence_revision 14-Feb-1997 #text_change 21-Jan-2000
R:Isono, T.; Seto, A.
Immunogenetics 42, 217-220, 1995
A:Title: Cloning and sequencing of the rabbit gene encoding T-cell costimulatory mole
A:Reference number: I46689; MUID:95369849
A:Accession: I46689
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-221 <ISO>
A:Cross-references: GB:D49841; NID:g755094; PID:BAA08641.1; PID:g755095
C:Superfamily: T-cell surface glycoprotein CD28; immunoglobulin homology
F:34-115/Domain: immunoglobulin homology <IMM>

Query Match 12.8%; Score 138; DB 2; Length 221;
Best Local Similarity 24.8%; Pred. No. 6.5e-06;
Matches 41; Conservative 24; Mismatches 66; Indels 34; Gaps 7;

QY 30 MFSFHNGGVOISCKYPETV--QOLKMLRFREREVLCELTKTGSGNAVSIKPN-- 80
DB 29 MLVNNNEVNLSCKYTYNLFSEFRASLYKGADSAVEVCVNG-----NFSHPHFHSTT 83

QY 81 -MLCLYHLSNNSVSFFLNPNDSQGSYFCSLSFIFDPPFPQERNLGG-YLHIYESQLC- 137
DB 84 GPNCDGKLGNETVTPYLNLYNQDTYFCKIEVMPYPYDNEKSNSTGTHVKEQHFCP 143

QY 138 -----COLKWLPGVLP-----FVYVLLFGCILIIWFSKKK 169
DB 144 AHPSPKSTLFWLVVVGAVLAFYSMLVTVLFSC-----WMKSKK 184

RESULT 5
RWHU28
T-cell surface glycoprotein CD28 precursor - human
C:Species: Homo sapiens (man)
C:Date: 31-Mar-1992 #sequence_revision 31-Mar-1992 #text_change 22-Jun-1999
C:Accession: A39983; A45895
R:Aruffo, A.; Seed, B.
Proc. Natl. Acad. Sci. U.S.A. 84, 8573-8577, 1987
A:Title: Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression sy
A:Reference number: A39983; MUID:88068631
A:Accession: A39983
A:Molecule type: mRNA

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:33:26 ; Search time 20.28 Seconds
(without alignments)
381.850 Million cell updates/sec

Title: US-09-383-551B-14

Perfect score: 1076

Sequence: 1 MKPYFCHVFVFCFLIRLLTG.....YMEAAVNTNKKSLAGVTS 200

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 105224 seqs, 38719550 residues

Top number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	138	12.8	221	1 CD28_RABIT	P42069 oryctolagus
2	136	12.6	220	1 CD28_HUMAN	P10747 homo sapien
3	131.5	12.2	218	1 CD28_RAT	P10742 rattus norv
4	130.5	12.1	219	1 CD28_BOVIN	O28071 bos taurus
5	105.5	9.8	218	1 CD28_MOUSE	P31041 mus musculus
6	89.5	8.3	221	1 CD28_CHICK	P31043 gallus gall
7	84.5	7.9	223	1 CTL4_HUMAN	P16410 homo sapien
8	78	7.2	504	1 CPK1_ONCMY	O93297 oncorhynch
9	76.5	7.1	223	1 CPK4_ONCMY	O93297 oncorhynch
10	76.5	7.1	2167	1 YCS2_YEAST	P42072 oryctolagus
11	75.5	7.0	417	1 CAR4_CANAL	P25356 saccharomyc
12	75.5	7.0	2210	1 RPPO_LYCYVA	P43093 candida alb
13	73.5	6.8	402	1 RDS1_SCHPO	P14240 lymphocytic
14	73.5	6.8	892	1 HUL4_YEAST	P53693 schizosacch
15	73.5	6.8	491	1 CPK3_ONCMY	P40985 saccharomyc
16	73	6.8	491	1 CPK3_ONCMY	O93299 oncorhynch
17	72.5	6.7	461	1 PSBC_EUGR	P05700 euglena gra
18	72.5	6.7	726	1 ATL1_CAMCP	Q05482 camelopox vi
19	72	6.7	657	1 VP4B_FOPPV	P17355 fowlpox vir
20	71.5	6.6	418	1 CAR6_CANAL	P43095 candida alb
21	71.5	6.6	457	1 GAL8_KLULA	O06433 kluyveromyc
22	71.5	6.6	576	1 C973_ARATH	O23365 arabidopsis
23	71.5	6.6	863	1 Y184_HUMAN	Q14689 homo sapien
24	71.5	6.6	978	1 PEX6_RAT	P54777 rattus norv
25	71.5	6.6	4829	1 BIR6_HUMAN	Q9nr09 homo sapien
26	71	6.6	228	1 V33P_ADE02	P24939 human adeno
27	71	6.6	229	1 V33P_ADE05	P24940 human adeno
28	71	6.6	510	1 ATPA_BUCAP	O51874 buchera ap
29	71	6.6	585	1 MAOX_MESCR	P37223 mesembryant
30	70.5	6.6	964	1 PMPE_CHLTR	O84877 chlamydia t
31	70.5	6.6	135	1 YAB0_METJA	Q58480 methanococc
32	70.5	6.6	329	1 CD86_HUMAN	P42081 homo sapien
33	70.5	6.6	879	1 MANB_CAPHI	Q95327 capra hircu

Query Match 12.8%; Score 138; DB 1; Length 221;

ALIGNMENTS

```

RESULT 1
CD28_RABIT
ID CD28_RABIT STANDARD; PRT; 221 AA.
AC P42069;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE T-cell-specific surface glycoprotein CD28 precursor.
GN CD28.
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OX NCBI_TaxID=9986;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-B/J X CHBB:HM;
RX MEDLINE=95369849; PubMed=7642234;
RA Isono T., Seto A.;
RT "Cloning and sequencing of the rabbit gene encoding T-cell
RT costimulatory molecules.";
RL Immunogenetics 42:217-220(1995).
CC -!- FUNCTION: POSSIBLY INVOLVED IN T-CELL ACTIVATION. BINDS TO B7-1
CC AND B7-2 (B70) (BY SIMILARITY).
CC -!- SUBUNIT: HOMODIMER; DISULFIDE-LINKED (BY SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -!- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
-----
EMBL; D49841; BAA08641.1; -.
InterPro: IPR003600; Ig_like.
SMART; SM00410; Ig_like; 1.
Immunoglobulin domain; T-cell; Glycoprotein; Signal; Transmembrane.
SIGNAL 1 19
CHAIN 20 221
T-CELL-SPECIFIC SURFACE GLYCOPROTEIN
CD28.
DOMAIN 20 150
EXTRACELLULAR (POTENTIAL).
TRANSMEM 151 177
POTENTIAL.
DOMAIN 178 221
CYTOPLASMIC (POTENTIAL).
DOMAIN 29 138
IG-LIKE V-TYPE DOMAIN.
CARBOHYD 38 38
N-LINKED (GLCNAC. .) (POTENTIAL).
CARBOHYD 72 72
N-LINKED (GLCNAC. .) (POTENTIAL).
CARBOHYD 93 93
N-LINKED (GLCNAC. .) (POTENTIAL).
CARBOHYD 106 106
N-LINKED (GLCNAC. .) (POTENTIAL).
CARBOHYD 130 130
N-LINKED (GLCNAC. .) (POTENTIAL).
SQ SEQUENCE 221 AA; 25307 MW; 3DF652C9CFC14F13 CRC64;

```

```
Best Local Similarity 24.8%; Pred. No. 1.3e-06;
Matches 41; Conservative 24; Mismatches 66; Indels 34; Gaps 7;

QY 30 MFSFHNGVQVISCYPETV--CQKMLRFREREVLCELTKTGSGNAVSIKNP-----80
DB 29 MLUVANNEVNLCKTYNLFSEFRASLYKGADSAVEVCVVG-----NFSHPHQFHSWT 83
QY 81 -MLCLYHLNNSVSFFLNPDSSQGSYFCSLSIFDPPQERNLSGG-YLHIYESQLC- 137
DB 84 GNCDCGKLGNEVTYFLNLYVNTDIFYCKIEVMYPPYLDNKSNGTIHVKEQFCP 143
QY 138 -----CQKMLPVLPA-----FVVLLFGCILIIWFSKKK 169
DB 144 AHPSPKSTLEWLVVVGAVLAFYSLNLTVALFSC-----WMKSKK 184

RESULT 2
CD28_HUMAN STANDARD; PRT; 220 AA.
ID CD28_HUMAN P10747;
DE 01-JUL-1989 (Rel. 11, Created)
DT 01-JUL-1989 (Rel. 11, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE T-cell-specific surface glycoprotein CD28 precursor (TP44).
GN CD28.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=88068631; PubMed=2825196;
RA Aruffo A., Seed B.;
RT "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell
RT expression system.";
RL Proc. Natl. Acad. Sci. U.S.A. 84:8573-8577(1987).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=90293482; PubMed=2162892;
RA Lee K.P., Taylor C., Petryniak B., Turka L.A., June C.H.,
RA Thompson C.B.;
RT "The genomic organization of the CD28 gene. Implications for the
RT regulation of CD28 mRNA expression and heterogeneity.";
RL J. Immunol. 145:344-352(1990).
CC -!- FUNCTION: POSSIBLY INVOLVED IN T-CELL ACTIVATION. BINDS TO B7-1
CC AND B7-2 (B70).
CC -!- SUBUNIT: HOMODIMER; DISULFIDE-LINKED.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -!- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.
CC -!- DATABASE: NAME=PROW; NOTE=CD guide CD28 entry;
CC WWW="http://www.ncbi.nlm.nih.gov/prov/cd/cd28.htm".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; J02988; AAA60581.1; -.
CC EMBL; M37815; AAA51944.1; -.
CC EMBL; M37812; AAA51944.1; JOINED.
CC EMBL; M37813; AAA51944.1; JOINED.
CC EMBL; M37814; AAA51944.1; JOINED.
CC PIR; A39983; RWU028.
CC HSSP; P16410; 1AH1.
CC MIM; 186760; -.
CC InterPro: IPR003600; Ig_like.
CC SMART: SM00410; IG-like; 1.
KW Immunoglobulin domain; T-cell; Glycoprotein; Signal; Transmembrane.
FT SIGNAL 1 18
```

```
FT CHAIN 19 220 T-CELL-SPECIFIC SURFACE GLYCOPROTEIN
FT DOMAIN 19 152 CD28.
FT TRANSMEM 153 179 EXTRACELLULAR (POTENTIAL).
FT DOMAIN 180 220 POTENTIAL.
FT DOMAIN 28 137 CYTOPLASMIC (POTENTIAL).
FT CARBOHYD 37 37 IG-LIKE V-TYPE DOMAIN.
FT CARBOHYD 71 71 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 92 92 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 105 105 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 129 129 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 220 AA; 25066 MW; ID9B6552A5878D0F CRC64;

Query Match 12.6%; Score 136; DB 1; Length 220;
Best Local Similarity 26.1%; Pred. No. 2e-06;
Matches 47; Conservative 26; Mismatches 69; Indels 38; Gaps 6;

QY 30 MFSFHNGVQVISCYPETVQQLKMLRFREREVLCELTKTGSGNAVSI-----77
DB 28 MLVAYDNAVNLSCKY-----SYNLF-SREFRASL--HKGLDSAVEVCVWYGNYSQQLQ 77
QY 78 ---KNPMLCLYHLNNSVSFFLNPDSSQGSYFCSLSIFDPPQERNLSGGYLHIYES 134
DB 78 VYSKTGFNCDCGKLGNESVTFYLNLYVNTDIFYCKIEVMYPPYLDNKSNGTIHVKG 137
QY 135 QLCQCLKWLPLVGLPAFVVLVGLFGCI-----LIWFSKKKYGSSVHPNSEYMF 184
DB 138 KHLCESPLEFGPSKPFWLVLVVGGLVACVSLVTVAFIIFWVRSRSLH---SDYMM 194

RESULT 3
CD28_RAT
ID CD28_RAT STANDARD; PRT; 218 AA.
AC P31042;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 01-MAR-2002 (Rel. 41, Last annotation update)
DE T-cell-specific surface glycoprotein CD28 precursor.
GN CD28.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=DA; TISSUE=Lymphoid;
RX MEDLINE=92104640; PubMed=1309509;
RA Clark G.J., Dallman W.J.;
RT "Identification of a cDNA encoding the rat CD28 homologue.";
RL Immunogenetics 35:54-57(1992).
CC -!- FUNCTION: POSSIBLY INVOLVED IN T-CELL ACTIVATION. BINDS TO B7-1
CC AND B7-2 (B70).
CC -!- SUBUNIT: HOMODIMER; DISULFIDE-LINKED.
CC -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC -!- SIMILARITY: BELONGS TO THE IMMUNOGLOBULIN SUPERFAMILY.
CC -!- SIMILARITY: CONTAINS 1 IMMUNOGLOBULIN-LIKE V-TYPE DOMAIN.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; X52888; CAA39003.1; -.
CC PIR; S38722; S38722.
CC InterPro: IPR003600; Ig_like.
CC SMART: SM00410; IG-like; 1.
KW Immunoglobulin domain; T-cell; Glycoprotein; Signal; Transmembrane.
FT SIGNAL 1 19
FT CHAIN 20 218 T-CELL-SPECIFIC SURFACE GLYCOPROTEIN
```


GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 18, 2002, 15:34:36 ; Search time 63.42 Seconds
(without alignments)
545.553 Million cell updates/sec

Title: US-09-383-551B-14
Perfect score: 1076
Sequence: 1 MKPYFCHVFCEFLRLTGT.....YMFMAAVNTNKKSLAGVTS 200

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 562222 seqs, 172994929 residues

Tc number of hits satisfying chosen parameters: 562222

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_19:**
1: sp_archaea:*
2: sp_bacteria:*
3: sp_fungi:*
4: sp_human:*
5: sp_invertebrate:*
6: sp_mammal:*
7: sp_mhc:*
8: sp_organelle:*
9: sp_phase:*
10: sp_plant:*
11: sp_rodent:*
12: sp_virus:*
13: sp_vertebrate:*
14: sp_unclassified:*
15: sp_virus:*
16: sp_bacteriap:*
17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	1063	98.8	200	11 Q9WVS0	Q9WVS0 mus musculus
2	1055	98.0	200	11 Q9JL17	Q9JL17 mus musculus
3	907	84.3	200	11 Q9R1T7	Q9R1T7 rattus norv
4	897	83.4	216	11 Q9WVR9	Q9WVR9 rattus norv
5	722.5	67.1	199	4 Q9Y6W8	Q9Y6W8 homo sapien
6	136.5	12.7	219	6 Q97630	Q97630 ovis aries
7	131	12.2	221	6 Q02757	Q02757 felis silve
8	129	12.0	220	6 Q9BDM8	Q9BDM8 macaca neme
9	129	12.0	221	6 Q9N214	Q9N214 felis silve
10	128	11.9	220	6 Q9BDN5	Q9BDN5 carcocubus
11	128	11.9	220	6 Q9BDM6	Q9BDM6 macaca mula
12	127.5	11.8	221	6 Q9N0N8	Q9N0N8 canis faml
13	125	11.6	221	6 Q9GKP3	Q9GKP3 canis faml
14	124	11.5	221	11 Q9JLV4	Q9JLV4 marmota mon
15	122	11.3	173	6 Q92829	Q92829 canis faml
16	120	11.2	220	6 Q9BDN8	Q9BDN8 papio anubi

17	108	10.0	220	6 Q9BDN2	Q9BDN2 callithrix
18	88	8.2	263	5 Q20288	Q20288 caenorhabdi
19	86	8.0	223	6 Q9BDP1	Q9BDP1 aotus trivi
20	86	8.0	612	10 Q9AUC3	Q9AUC3 lycopersico
21	85.5	7.9	658	3 Q94731	Q94731 schizosacch
22	83	7.7	271	10 Q94L31	Q94L31 lycopersico
23	82.5	7.7	223	4 Q96P43	Q96P43 homo sapien
24	80.5	7.5	223	6 Q9BDC4	Q9BDC4 macaca mula
25	80.5	7.5	223	6 Q9BDN7	Q9BDN7 papio anubi
26	80.5	7.5	303	5 Q94638	Q94638 onchocerca
27	80.5	7.5	336	5 Q18339	Q18339 caenorhabdi
28	80.5	7.5	336	6 Q9GJ73	Q9GJ73 saguinus oe
29	79.5	7.4	223	11 Q9JLV3	Q9JLV3 marmota mon
30	79	7.3	301	5 Q94634	Q94634 onchocerca
31	79	7.3	579	10 Q9MAG9	Q9MAG9 arabidopsis
32	79	7.3	719	2 Q9AJH1	Q9AJH1 ruminococcu
33	78.5	7.3	221	6 Q28090	Q28090 bos taurus
34	78.5	7.3	470	16 Q9PPA8	Q9PPA8 campylobact
35	78.5	7.3	779	5 Q9XYS8	Q9XYS8 dictyosteli
36	77.5	7.2	535	10 Q9FH36	Q9FH36 arabidopsis
37	77	7.2	323	6 Q9BDM9	Q9BDM9 macaca neme
38	77	7.2	323	6 Q9BDM2	Q9BDM2 cercopithe
39	77	7.2	676	16 Q97LI4	Q97LI4 clostridium
40	76.5	7.1	1312	5 Q9ULF4	Q9ULF4 leishmania
41	76	7.1	341	13 Q9IB06	Q9IB06 spherooides
42	76	7.1	379	10 Q94CH7	Q94CH7 arabidopsis
43	76	7.1	687	10 Q9LQ56	Q9LQ56 arabidopsis
44	75.5	7.0	221	6 Q97631	Q97631 ovis aries
45	75.5	7.0	2167	3 Q07348	Q07348 saccharomyc

ALIGNMENTS

RESULT 1

Q9WVS0	PRELIMINARY;	PRT;	200 AA.
ID Q9WVS0;			
AC Q9WVS0;			
DT 01-NOV-1999 (TRENBLrel. 12, Created)			
DT 01-NOV-1999 (TRENBLrel. 12, Last sequence update)			
DT 01-JUN-2001 (TRENBLrel. 17, Last annotation update)			
DE ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE AILIM			
DE PRECURSOR (CCLP PRECURSOR) (SURFACE PROTEIN).			
GN CCLP OR ICOS.			
OS Mus musculus (Mouse).			
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.			
OX NCBI_TaxID=10090;			
RN [1]			
RP SEQUENCE FROM N.A.			
RC TISSUE=SPLEEN;			
RA Tezuka K., Tamatani T.;			
RT "Cell surface molecule mediating cell adhesion and signal			
RT transmission."			
RL Submitted (FEB-1999) to the EMBL/GenBank/DBJ databases.			
RN [2]			
RP SEQUENCE FROM N.A.			
RC STRAIN=BAUB/C; TISSUE=SPLEEN;			
RA Wu D., Giannoni M.A., Kiesecker C.L., Faas S.J., Mickle A.P.,			
RA Matis L.A., Rother R.P.;			
RT "CCLP, A novel molecule that regulates T cell activation.;"			
RL Submitted (APR-2000) to the EMBL/GenBank/DBJ databases.			
RN [3]			
RP SEQUENCE FROM N.A.			
RC STRAIN=BAUB/C; TISSUE=SPLEEN;			
RX MEDLINE=20225659; PubMed=10760791;			
RA Mages H.W., Hutloff A., Heuck C., Buchner K., Himmelbauer H.,			
RA Oliveri F., Krocze R.A.;			
RT "Molecular cloning and characterization of murine ICOS and			
RT identification of B7h as ICOS ligand.;"			
RL Eur. J. Immunol. 30:1040-1047(2000).			
DR EMBL; AB023132; BAA82126.1; -			
DR EMBL; AF257230; AAF70099.1; -			

```
DR EMBL; AJ250559; CAB71153.1; -.
KW Signal.
FT SIGNAL.
SQ SEQUENCE 200 AA; 22690 MW; 9B2278E4CAB1DB47 CRC64;

Query Match
Best Local Similarity 98.8%; Score 1063; DB 11; Length 200;
Matches 198; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPETVOQLKMLFRERE 60
DB 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPETVOQLKMLFRERE 60

QY 61 VLCELTKTGSGNAVSIKPNMCLLYHLSNNSVSFFLNPPDSSQSGSYFCSLSIFDPPPFQ 120
DB 61 VLCELTKTGSGNAVSIKPNMCLLYHLSNNSVSFFLNPPDSSQSGSYFCSLSIFDPPPFQ 120

QY 121 ERNLSSGYLHIYESQLCCQLKWLVPGLPAFVVVLLFGCILIIWFSKKYKGSVHDNPSE 180
DB 121 ERNLSSGYLHIYESQLCCQLKWLVPGLPAFVVVLLFGCILIIWFSKKYKGSVHDNPSE 180

QY 181 YMFMAAVNTNKKSLAGVTS 200
DB 181 YMFMAAVNTNKKSLAGVTS 200

QY 181 YMFMAAVNTNKKSLAGVTS 200
DB 181 YMFMAAVNTNKKSLAGVTS 200

RESULT 2
QJUL17
ID Q9JUL17 PRELIMINARY; PRT; 200 AA.
AC Q9JUL17;
DT 01-OCT-2000 (TremBLrel. 15, Created)
DT 01-OCT-2000 (TremBLrel. 15, Last sequence update)
DT 01-MAR-2001 (TremBLrel. 16, Last annotation update)
DE CD28-RELATED PROTEIN 1 (INDUCIBLE COSTIMULATORY PROTEIN)
DE (FRAGMENT).
GN ICOS.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=INTESTINAL INTRA-EPITHELIUM;
RA Yoshinaga S.K., Whoriskey J.S., Khare S.D., Sarmiento U., Guo J.,
RA Horan T., Shih G., Zhang M., Coccia M.A., Kohno T., Tafuri-Bladt A.,
RA Campbell P., Chang D., Chiu L., Dai T., Duncan G., Elliott G.S.,
RA Hui A., McCabe S.M., Scully S., Shaklee C.L., Van G., Mak T.W.,
RA Senaldi G.;
RT "T-cell co-stimulation through B7RP-1 and ICOS.";
RL Nature 0:0-0(2000).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=129/Ola;
RA McAdam A.J., Greenwald R.J., Levin M.A., Chernova T., Malenkovich N.,
RA Ling V., Freeman G.J., Sharpe A.H.;
RT "The inducible costimulatory (ICOS) molecule is critical for CD40-
RT mediated antibody class switching.";
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF216748; AAF45150.1; -.
DR EMBL; AF327185; AAG48732.1; -.
DR EMBL; AF327184; AAG48732.1; JOINED.
FT NON_TER 200
SQ SEQUENCE 200 AA; 22709 MW; 87D97F0DC44ADCA7 CRC64;

Query Match
Best Local Similarity 98.0%; Score 1055; DB 11; Length 200;
Matches 197; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPETVOQLKMLFRERE 60
DB 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPETVOQLKMLFRERE 60
```

```
DB 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPETVOQLKMLFRERE 60
QY 61 VLCELTKTGSGNAVSIKPNMCLLYHLSNNSVSFFLNPPDSSQSGSYFCSLSIFDPPPFQ 120
DB 61 VLCELTKTGSGNAVSIKPNMCLLYHLSNNSVSFFLNPPDSSQSGSYFCSLSIFDPPPFQ 120
QY 121 ERNLSSGYLHIYESQLCCQLKWLVPGLPAFVVVLLFGCILIIWFSKKYKGSVHDNPSE 180
DB 121 ERNLSSGYLHIYESQLCCQLKWLVPGLPAFVVVLLFGCILIIWFSKKYKGSVHDNPSE 180
QY 181 YMFMAAVNTNKKSLAGVTS 200
DB 181 YMFMAAVNTNKKSLAGVTS 200

RESULT 3
Q9R1T7
ID Q9R1T7 PRELIMINARY; PRT; 200 AA.
AC Q9R1T7;
DT 01-MAY-2000 (TremBLrel. 13, Created)
DT 01-MAY-2000 (TremBLrel. 13, Last sequence update)
DT 01-DEC-2001 (TremBLrel. 19, Last annotation update)
DE ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE AILIM
DE PRECURSOR.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20462959; PubMed=11006126;
RA Tezuka K., Tsuji T., Hirano D., Tamatani T., Sakamaki K.,
RA Kobayashi Y., Kamada M.;
RT "Identification and characterization of rat AILIM/ICOS, a novel T-cell
RT costimulatory molecule, related to the CD28/CTLA4 family.";
RL Biochem. Biophys. Res. Commun. 276:335-345(2000).
DR EMBL; AB023134; BAA82128.1; -.
KW Signal.
FT SIGNAL.
SQ SEQUENCE 200 AA; 22529 MW; 0A74C35581F129D4 CRC64;

Query Match
Best Local Similarity 84.3%; Score 907; DB 11; Length 200;
Matches 168; Conservative 14; Mismatches 18; Indels 0; Gaps 0;

QY 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPETVOQLKMLFRERE 60
DB 1 MKPYCHVFVFCFLIRLLTGEINGSADHRMFSFHNGGVQISCKYPETVOQLKMLFRERE 60
QY 61 VLCELTKTGSGNAVSIKPNMCLLYHLSNNSVSFFLNPPDSSQSGSYFCSLSIFDPPPFQ 120
DB 61 VLCELTKTGSGNAVSIKPNMCLLYHLSNNSVSFFLNPPDSSQSGSYFCSLSIFDPPPFQ 120
QY 121 ERNLSSGYLHIYESQLCCQLKWLVPGLPAFVVVLLFGCILIIWFSKKYKGSVHDNPSE 180
DB 121 ERNLSSGYLHIYESQLCCQLKWLVPGLPAFVVVLLFGCILIIWFSKKYKGSVHDNPSE 180
QY 181 YMFMAAVNTNKKSLAGVTS 200
DB 181 YMFMAAVNTNKKSLAGVTS 200

RESULT 4
Q9WVR9
ID Q9WVR9 PRELIMINARY; PRT; 216 AA.
AC Q9WVR9;
DT 01-NOV-1999 (TremBLrel. 12, Created)
DT 01-NOV-1999 (TremBLrel. 12, Last sequence update)
DT 01-DEC-2001 (TremBLrel. 19, Last annotation update)
DE ACTIVATION-INDUCIBLE LYMPHOCYTE IMMUNOMEDIATORY MOLECULE AILIM
DE PRECURSOR.
OS Rattus norvegicus (Rat).
```


SQ SEQUENCE 221 AA; 25594 MW; B29D32E987CE51D1 CRC64;
 Query Match 11.5%; Score 124; DB 11; Length 221;
 Best Local Similarity 25.8%; Pred. No. 3.7e-05;
 Matches 39; Conservative 23; Mismatches 53; Indels 36; Gaps 6;

Db	33	YNEVNLSCKY-----TYNLF-SKEFRASLYKGVDSAVEVYVNGFNFSHQLOFYSHTG 84
QY	83	--CLYHLSSNNSVSFFLANPDSQSQSYFYCSLSIDPPFPQERNLSGG-YLHIYESQLCCQ 138
Db	85	FNCDGKLGNETVTETFLRLNLYNQDIFYCKIEVMYPPPYLDNEKSNGTIVHVKENNIC-- 141
QY	140	LKLWLPVGLPA-----FVVVLLFGCILI IW 164
Db	143	-----GVPSPPEPKPFWTLVVFSGVLGIY 167

```

Db      85  FNCDGKLGNETVTFTYRLNLYVNQTDYIFCKTEVMYPPPYLDNEKSNGTIVHVKENNIC-- 14
Qy     140  LKWLPLVCLPA-----FVVVLLFGCILIIV 164
Db     143  -----GVPSPEPPKPFWTLVWFSGLGIY 167

```

Q86289 PRELIMINARY; PRI; 1/5 AA.
AC
AD
AE
AF
AG
AH
AI
AJ
AK
AL
AM
AN
AO
AP
AQ
AR
AS
AT
AU
AV
AW
AX
AY
AZ
BA
BB
BC
BD
BE
BF
BG
BH
BI
BJ
BK
BL
BM
BN
BO
BP
BQ
BR
BS
BT
BU
BV
BW
BX
BY
BZ
CA
CB
CC
CD
CE
CF
CG
CH
CI
CJ
CK
CL
CM
CN
CO
CP
CQ
CR
CS
CT
CU
CV
CW
CX
CY
CZ
DA
DB
DC
DD
DE
DF
DG
DH
DI
DJ
DK
DL
DM
DN
DO
DP
DQ
DR
DS
DT
DU
DV
DW
DX
DY
EZ
FA
FB
FC
FD
FE
FF
FG
FH
FI
FJ
FK
FL
FM
FN
FO
FP
FQ
FR
FS
FT
FU
FV
FW
FX
FY
FZ
GA
GB
GC
GD
GE
GF
GG
GH
GI
GJ
GK
GL
GM
GN
GO
GP
GQ
GR
GS
GT
GU
GV
GW
GX
GY
GZ
HA
HB
HC
HD
HE
HF
HG
HH
HI
HJ
HK
HL
HM
HN
HO
HP
HQ
HR
HS
HT
HU
HV
HW
HX
HY
HZ
IA
IB
IC
ID
IE
IF
IG
IH
II
IJ
IK
IL
IM
IN
IO
IP
IQ
IR
IS
IT
IU
IV
IW
IX
IY
IZ
JA
JB
JC
JD
JE
JF
JG
JH
JI
JJ
JK
JL
JM
JN
JO
JP
JQ
JR
JS
JT
JU
JV
JW
JX
JY
JZ
KA
KB
KC
KD
KE
KF
KG
KH
KI
KJ
KK
KL
KM
KN
KO
KP
KQ
KR
KS
KT
KU
KV
KW
KX
KY
KZ
LA
LB
LC
LD
LE
LF
LG
LH
LI
LJ
LK
LL
LM
LN
LO
LP
LQ
LR
LS
LT
LU
LV
LW
LX
LY
LZ
MA
MB
MC
MD
ME
MF
MG
MH
MI
MJ
MK
ML
MM
MN
MO
MP
MQ
MR
MS
MT
MU
MV
MW
MX
MY
MZ
NA
NB
NC
ND
NE
NF
NG
NH
NI
NJ
NK
NL
NM
NN
NO
NP
NQ
NR
NS
NT
NU
NV
NW
NX
NY
NZ
OA
OB
OC
OD
OE
OF
OG
OH
OI
OJ
OK
OL
OM
ON
OO
OP
OQ
OR
OS
OT
OU
OV
OW
OX
OY
OZ
PA
PB
PC
PD
PE
PF
PG
PH
PI
PJ
PK
PL
PM
PN
PO
PP
PQ
PR
PS
PT
PU
PV
PW
PX
PY
PZ
QA
QB
QC
QD
QE
QF
QG
QH
QI
QJ
QK
QL
QM
QN
QO
QP
QQ
QR
QS
QT
QU
QV
QW
QX
QY
QZ
RA
RB
RC
RD
RE
RF
RG
RH
RI
RJ
RK
RL
RM
RN
RO
RP
RQ
RR
RS
RT
RU
RV
RW
RX
RY
RZ
SA
SB
SC
SD
SE
SF
SG
SH
SI
SJ
SK
SL
SM
SN
SO
SP
SQ
SR
SS
ST
SU
SV
SW
SX
SY
SZ
TA
TB
TC
TD
TE
TF
TG
TH
TI
TJ
TK
TL
TM
TN
TO
TP
TQ
TR
TS
TT
TU
TV
TW
TX
TY
TZ
UA
UB
UC
UD
UE
UF
UG
UH
UI
UJ
UK
UL
UM
UN
UO
UP
UQ
UR
US
UT
UU
UV
UW
UX
UY
UZ
VA
VB
VC
VD
VE
VF
VG
VH
VI
VJ
VK
VL
VM
VN
VO
VP
VQ
VR
VS
VT
VU
VV
VW
VX
VY
VZ
WA
WB
WC
WD
WE
WF
WG
WH
WI
WJ
WK
WL
WM
WN
WO
WP
WQ
WR
WS
WT
WU
WV
WW
WX
WY
WZ
XA
XB
XC
XD
XE
XF
XG
XH
XI
XJ
XK
XL
XM
XN
XO
XP
XQ
XR
XS
XT
XU
XV
XW
XX
XY
XZ
YA
YB
YC
YD
YE
YF
YG
YH
YI
YJ
YK
YL
YM
YN
YO
YP
YQ
YR
YS
YT
YU
YV
YW
YX
YY
YZ
ZA
ZB
ZC
ZD
ZE
ZF
ZG
ZH
ZI
ZJ
ZK
ZL
ZM
ZN
ZO
ZP
ZQ
ZR
ZS
ZT
ZU
ZV
ZW
ZX
ZY
ZZ

RN	[1]
RP	SEQUENCE FROM N.A.
RC	STRAIN=BEAGLE;
RX	MEDLINE=94222451; PubMed=8168859;

RA	Esteban R.L., Milne K.F., Alejandro R.;	
RT	"Molecular cloning of the lymphocyte antigen	
RT	CD28.";	
RL	Immunogenetics 39:373-373(1994).	
DR	EMBL; L22178; AAA51453.1; -.	
DR	InterPro; IPR003600; Ig-like.	
DR	SMART; SM00410; IG-like; 1.	
FT	NON_TER	1
FT	NON_TER	173
SQ	SEQUENCE	173 AA; 13770 MW; 7C265AE40931C1EA CRC64;

Qy	34	HNGVGQISCKYPTNV--QOLKMRFREREVLCELTKTGSGNAVSIRNPML-----CL 84
Db	14	YNNENVLSCKYTYNLFKSEPRASLYGDSAVEVCVVGNYFS-----HQPQYSSGTGDCD 69
Qy	85	YHLNNNSVFFLNPNPDSQGSYFCSLSIEDPPFPQBRNLSGG-YLHIYESQLCCQLKW 14
Db	70	GKLGNEIVTYLRLNFVYNQTDIYFCKIEVMYPPYIGNKSNNGTHIHKVKEHLCPD-ELF 12
Qy	144	LPVGLPAFVVVLLFGCILIIV 164
Db	129	-POSSKPFWALVVVVGAVLVFY 148

Search completed: September 18, 2002, 15:34:37
Job time: 485 sec

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)